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THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK
SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND
PROGRESSION BY MODULATING THE EXPRESSION OF PROTOONCOGENES, AXL AND CTNNAL1 (α-CATULIN)
Shhyam Moorthy, B.S.

Advisory Professor: Dr. Jeffrey N. Myers, M.D., Ph.D.

Background: Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most
common malignancy worldwide, with roughly 300,000 cancer related deaths occurring
globally each year. The survival of patients with HNSCC has not changed significa ntly
over the past decade, leading investigators to search for promising molecular targets. To
identify new treatment targets and biomarkers that could better guide therapy, we
previously characterized the genomic alterations from primary HNSCC patient samples.
We were among the first to discover that NOTCH1 is one of the most frequently mutated
genes in this cancer type. The spectrum of inactivating NOTCH1 mutations in HNSCC
suggested a tumor suppressive role for this protein; however, the mechanism of its functio n
is currently unknown.

Procedure: We used Sanger sequencing and immunoblotting to characterize 50 wellestablished HNSCC cell lines as being wild-type or mutant for NOTCH1. We cloned the
full length NOTCH1 receptor to restore the NOTCH signaling function in mutant cell lines
and activated this pathway by culturing cells on immobilized NOTCH ligand, Jagged1,
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coated plates. Clonogenic assays and competitive cell proliferation assays was used to
evaluate cell growth and proliferation. CRISPR-Cas9 system was used to knock out
NOTCH1 and/or NOTCH2 in wild-type cells. Tumor growth was evaluated in vivo in a
mice orthotopic model of oral cancer. An unbiased gene expression analysis was performed
to identify potential downstream targets of the NOTCH pathway. RNA-Seq data was
obtained from HNSCC TCGA data and was correlated with the 120 gene expression
signature obtained from cell lines. Flag-tagged constructs were used to overexpress HES2
and HES5, while shRNA’s was used to knock down AXL and catulin in mutant cell lines
to evaluate tumor growth.

Results: We show here that restoration of full length NOTCH1 in mutant HNSCC cell
lines and activation of NOTCH signaling in wild-type cell lines significantly decreases cell
growth in vitro and tumor growth in vivo. CRISPR-Cas9 knock out of NOTCH1 and
NOTCH2 in wild-type HNSCC cells accelerated cell growth that was reversed by
restoration of NOTCH1 in the same cell line. To evaluate the mechanism of NOTCH
induced growth inhibition, we performed an unbiased microarray analysis and observed
suppression of two proto-oncogenes, AXL and CTNNAL1 (α-catulin) after NOTCH1
activation, but not in its absence. In addition, genes modulated by NOTCH activation in
cell lines correlated with RNA-Seq data from 498 TCGA patient tumors. Restoration of
NOTCH1 in mutant cell lines significantly decreased protein expression levels of AXL and
α-catulin, while CRISPR-Cas9 knock out of NOTCH1 and NOTCH2 in wild-type cells
increased expression of these proto-oncogenes. Knock down of AXL and α-catulin using
shRNA’s abrogated tumor growth. Lastly, we show that HES2 and HES5, transcriptio na l
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regulatory proteins induced by NOTCH signaling might be sufficient to inhibit protein
expression levels of AXL and α-catulin and suppress growth.

Conclusions: For the first time, we are attributing a tumor suppressive function of NOTCH
in HNSCC. We conclude that reactivation of NOTCH signaling in HNSCC inhibits tumor
growth and progression. In addition, we are also providing a possible mechanism linking
NOTCH1 to the decreased expression of proto-oncogenes, AXL and CTNNAL1 (αcatulin) that potentially abrogates tumor growth. This underscores the need to understand
the clinical significance of the NOTCH pathway and its downstream targets, which could
then be exploited for potential therapeutic strategies.
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CHAPTER 1: HEAD AND NECK
SQUAMOUS CELL CARCINOMA
(HNSCC)

1

Chapter 1: Head and Neck Squamous Cell Carcinoma (HNSCC)

Anatomy and incidence
Head and Neck cancers is a broad term encompassing cancers that arise in the
upper aerodigestive tract and are usually localized to the oral cavity, oropharynx, larynx,
hypopharynx, nasopharynx, paranasal sinuses and nasal cavity (Argiris, Karamouzis,
Raben, & Ferris, 2008) (Figure 1). These cancers usually arise from the squamous
epithelial cells that reside in the moist surfaces of the mucosal areas of the head and neck
region. Thus, most head and neck cancers are squamous in nature giving it the term Head
and Neck Squamous Cell Carcinomas (HNSCC). Head and neck cancers can also arise
from different cell types, 90% of head and neck cancers are squamous cell carcinomas.
Approximately 650,000 new cases and 350,000 HNSCC related deaths occur each year
(Torre et al., 2015). HNSCC’s in the oral cavity is very common worldwide. Regions of
high prevalence of oral cancers include Melanesia, South-central Asia, Eastern and
Western Europe, and Southern Africa (F. Bray, Sankila, Ferlay, & Parkin, 2002). In the
United States alone, 45,780 new cases and 8,650 head and neck cancer-related deaths
occurred this year (Argiris et al., 2008). The approximate age for diagnosis is in a
patient’s early 60’s. These cancers are predominant in the male population. According to
the Surveillance Epidemiology and End Results (SEER) database, the 5-year survival for
all stages combined in about 60%.
Tobacco and alcohol consumption have been attributed as the major risk factors
of HNSCC that is exacerbated when combined (Blot et al., 1988; Hashibe et al., 2006;
Tuyns et al., 1988). Increased risk of HNSCC has been associated with polymorphisms in
certain enzymes that have the ability to metabolize alcohol and tobacco (Hashibe et al.,
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2006). In parts of Southeast Asia, there is high incidence of oral cancers associated with
chewing of betel quid (Proia, Paszkiewicz, Nasca, Franke, & Pauly, 2006).
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Figure 1: Anatomy of Head and Neck Squamous Cell Carcinoma (HNSCC). Permission
obtained from Algiris, A., Karamouzis, M.V., Raben, D., and Ferris, R.L. (2008). Lancet.
371 (9625): 1695-709. (Argiris et al., 2008)
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The risk of HNSCC in individuals with certain cancer susceptibility has shown to
be increased. These include hereditary non-polyposis colorectal cancer, Li-Fraumeni
syndrome, Fanconi’s anaemia, and ataxia telangiectasia (Foulkes et al., 1996; Trizna &
Schantz, 1992) . Besides tobacco and alcohol, recently, the Human Papilloma Virus
(HPV)- HPV16 and HPV18 has been identified as causal factor for HNSCC (G. D'Souza
et al., 2007). It has been reported that approximately 25% of HNSCC’s contain HPV
genomic DNA (Kreimer, Clifford, Boyle, & Franceschi, 2005). In terms of anatomic
regions HPV causes HNSCC predominantly in the tonsils and base of tongue within the
oropharynx and much less in the oral cavity and larynx (Hobbs et al., 2006). Although
not completely mutually exclusive, HPV related HNSCC has been observed frequently in
individuals without exposure to tobacco or alcohol and individuals who are
immunosuppressed. HNSCC of this type is poorly differentiated and have the tendency to
exhibit a basal cell histology (G. D'Souza et al., 2007). E6 and E7 viral oncoproteins have
the ability to inactivate tumor suppressor genes such as p53 and pRb thus mediating their
carcinogenic effects (Munger & Howley, 2002). HPV positive and negative tumors show
differences in their gene expression patterns (Slebos et al., 2006). HPV status can be an
important biomarker for prevention, treatment and prognosis. HPV positive tumors have
better response to therapy than HPV negative tumors (Califano et al., 1996). Furthermore,
they are more susceptible to immune surveillance than HPV negative tumors. Lastly,
vaccination against HPV has shown efficacy in preventing cervical cancer. This might
also prove useful for HPV positive HNSCC (G. D'Souza & Dempsey, 2011).
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Pathogenesis
HNSCC is a heterogeneous disease whose development is governed by diverse
genetic events leading to inactivation of tumor-suppressor genes and/or activation of
proto-oncogenes (Figure 2).

Figure 2: Molecular pathogenesis of HNSCC. Permission obtained from Califano, J., van
der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D.,
Greenberg, B., Koch, W., and Sidransky, D. (1996). Cancer Research. 56(11): 2488-92.
(Califano et al., 1996)
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HNSCC’s arise from a premalignant progenitor after which certain clonal
populations accumulate genetic alterations that progress to invasive malignancy (Califano
et al., 1996; Califano et al., 2000). These genetic alterations include somatic mutations,
insertions, deletions, promoter methylation and gene amplifications that result in loss of
tumor suppressor genes and/or activation of oncogenes. Califano et al. (Califano et al.,
2000) used PCR based microsatellite analysis to identify genetic alterations at different
histopathological stages of progression of the lesion. The most common genetic alteration
seen in HNSCC is the loss of 9p21, which is found in 70-80% of the cases seen in
squamous dysplasia and HNSCC (Califano et al., 2000; van der Riet et al., 1994). Loss of
Heterzygozity (LOH) of 9p21 is an early event in squamous neoplasia and has also been
in pre-neoplastic lesions (van der Riet et al., 1994). The CDKN2A gene located at 9p21
encodes p16 and p14ARF, which are responsible for G1 cell cycle regulation and MDM2mediated degradation of p53. Promoter methylation and homozygous deletions often
inactivate p16 (Reed et al., 1996). Although the highest LOH frequency in benign
squamous neoplastic lesions is 9p21, there is also LOH at 3p21 and 17p13 to a lesser
extent (Califano et al., 1996). The loss of 3p is considered another major event that
allows the benign hyperplasia to progress towards dysplasia (Hogg et al., 2002). For
example, in the region 3p14, the exomic deletion of the FHIT gene (fragile histidine triad
gene), a tumor suppressor gene, has been shown in HNSCC and other tumor types (Boyle
et al., 1993; Hogg et al., 2002; Mao, Fan, Lotan, & Hong, 1996). The most frequently
mutated gene TP53, located on 17p is mutated in over 80% of HNSCC ("TCGA Releases
Head and Neck Cancer Data," 2015) . These mutations begin to appear during the
progression of hyperplasia to dysplasia but most of these mutations occur late in the
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progression towards invasive carcinoma (Boyle et al., 1993). Overexpression of cyclin
D1 is often due to amplification of 11q13 has been seen in 30-60% of HNSCC and has
been associated with lymph node metastasis and poor overall survival (Meredith et al.,
1995; Michalides et al., 1995). Most transcriptional alterations in head and neck cancer
pathogenesis occur during the transition from normal mucosa to premalignant lesions
rather than premalignant lesions to invasive carcinomas (Ha et al., 2003). Amplification
of the epidermal growth factor receptor (EGFR) is seen 90% of cases of HNSCC
(Grandis & Tweardy, 1993). The EGFR, a receptor tyrosine kinase, binds to its ligand
EGF and activates a molecular cascade that involves modulation of molecules involved
with cell proliferation, growth, angiogenesis, apoptosis and metastatic potential (Rubin
Grandis et al., 1998). Many studies have shown poor prognosis of cases with
overexpression of EGFR. Targeting this receptor has been exploited and been successful
for therapeutic purposes (Karamouzis, Grandis, & Argiris, 2007).
Treatment
Surgery is used as a conventional treatment strategy for HNSCC. This, however,
is limited by tumor volume and cosmetic and functional concerns. For small tumors
located in the oral cavity or pharynx, surgical excision is preferred with preservation of
the functionality of the organ and good overall prognosis. Techniques such as
microsurgical treatment or robotic techniques have shown significant progress. These
techniques integrated with high-resolution magnified optics will likely have significant
benefit (Ambrosch, 2007; Lefebvre, 2006).
In addition to surgery, radiotherapy is an integral part of primary or adjuvant
HNSCC treatment. Radiation therapy for HNSCC is typically administered daily at a 2.0
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Gy dose for 5 days for a total of 70 Gy over a 7-week period. Post-operatively, radiation
doses varying from 60-65 Gy are typically prescribed (Argiris et al., 2008). Clinical
results from radiation therapy are very promising, and this is a major standard of care for
tumors of the oropharynx, hypopharynx, and larynx. Nevertheless,but it’s use is
associated with significant sequelae and occasional complications in the peri-treatment
period and many years later due to the progressive effects on tissue vasculature and
fibrosis.(Konski et al., 2006).
Chemotherapy plays an important role in HNSCC treatment. Platinum
compounds, anti-metabolites, and taxanes have shown effectiveness in treating HNSCC.
Cisplatin, a platinum based compound is regarded as the standard chemotherapeutic agent
in combination with surgery and/or radiation. Like cisplatin, carboplatin is also used but
is less effective as a combination regimen (Colevas, 2006). Taxane based combinations
have been tested successfully in induction and/or concomitant treatment of locally
advanced HNSCC. Cetuximab, an antibody against EGFR, was the first targeted agent
introduced in chemotherapy (Grandis & Tweardy, 1993). The combination of EGFR
inhibitors and other target agents (such as angiogenesis inhibitors) has surfaced as novel
treatment strategies and their effectiveness in combination with surgery and/or
radiotherapy is under investigation.
Field cancerization
Slaughter and colleagues first described the concept of field cancerization when
they observed multiple independent tumors surrounding the mucosa adjacent to the
HNSCC (Slaughter, Southwick, & Smejkal, 1953). Slaughter suggested that there are
large areas in the aerodigestive tract mucosa affected by long term exposure to
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carcinogens that results in genetic events independent of the primary tumor site resulting
in genetically altered fields. Techniques such as chromosome X inactivation,
microsatellite analysis and p53 mutational status have confirmed the presence of these
alterations neighboring the primary HNSCC site, confirming Slaughter’s concept of field
cancerization (Califano et al., 1996). Although these independent genetic lesions result in
satellite tumor sites, there is evidence that tumors arising in these fields are clonally
related and arise from a common neoplastic progenitor. It is possible that these
transformed cells might have micro-metastasized across the aerodigestive tract. The
clinical implication of a field is that it may be a potential source of local recurrence and
second primary tumors after surgical resection of the primary tumor. The genetic
constitution of the field is currently not completely understood but in recent studies that
stained for p53, genetic changes at chromosome 9p, decreased Keratin 4 expression and
decreased cornulin expression are potential biomarkers with this regard (Karamouzis et
al., 2007).
Sequencing studies in HNSCC
Cancer, in general, arises through accumulation of genetic and epi-genetic
changes often caused due to carcinogen exposure. This induces alterations in signaling
pathways that result in cancer related phenotypes such as unlimited replicative potential,
self-sufficiency in growth signals, insensitivity to anti-growth signals, ability to evade
apoptosis, invasion and metastasis, and angiogenesis which has been well summarized by
Hanahan and Weinberg (Hanahan & Weinberg, 2011). The accumulation of these
aberrant pathways is often secondary to a lifetime of environmental exposure to
carcinogens such as tobacco and alcohol that results in enhanced proliferation,
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dedifferentiation, immortalization and loss of cell death of epithelial cells in the mucosa.
Therefore, a deeper understanding of the molecular biology of HNSCC is needed to
enhance the development of therapeutic approaches. Investigators have identified several
critical genes important in HNSCC progression. These include TP53(Poeta et al., 2009),
CDKN2A(Demokan et al., 2012), Cyclin D1(Papadimitrakopoulou et al., 2001),
PIK3CA(Murugan, Hong, Fukui, Munirajan, & Tsuchida, 2008), HRAS and
EGFR(Bonner et al., 2010). The approaches used for the identification of these genes
involved fluorescence in situ hybridization (FISH), immunohistochemistry (IHC),
promoter methylation studies, histone modification analysis and copy number variations
from extracted tumors compared to the surrounding normal tissues. Despite efforts to
identify biomarkers in HNSCC, no prognostic marker has been able to predict the
response to treatments. On the contrary, other tumor types have drug-able targets and
specific genetic alterations predictive of treatment outcomes (Rothenberg & Ellisen,
2012). These imclude HER2 amplifications in breast cancers, BRAF mutations in
melanoma, and JAK2 in hematopoietic malignances. In breast cancers, PIK3CA is
mutated at a frequency of 30%, while FGFR2, which is mutated in 20% of endometrial
and lung cancers, has been investigated as a target in clinical trials (Thariat et al., 2015).
Until 2011, the mutational status in HNSCC was not completely understood.
Identification of targetable genes by next generation sequencing (NGS) opened new
avenues for personalized cancer therapy.
In order to gain a better understanding of the genetic alterations in HSNCC,
Aggarwal and colleagues (Agrawal et al., 2011) (Figure 3) and Stransky and colleagues
(Stransky et al., 2011) (Figure 4) used high throughput next generation sequencing to
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analyze the genomic alterations found in HNSCC. Both groups performed whole exome
sequencing from 32 and 74 primary tumors, respectively and compared the sequence to
the corresponding normal DNA of the same patient (Figures 3 and 4). Agarwal and
colleagues (Agrawal et al., 2011) used the Illumina or SOLiD platform to sequence the
DNA with coverage of 77 or 40-fold respectively and approximately 90% of the targeted
bases were represented by at least 10 reads in these platforms. They identified 911
somatic mutations in 725 genes among the 32 tumors. Furthermore, Sanger and/or 454
sequencing was used to validate these findings.
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Figure 3: Frequent somatic mutations in HNSCC by whole exome sequencing.
Permission obtained from Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda,
C., Chang, K., Li, R. J., Myers, J. N. (2011). Science, 333(6046), 1154-1157. (Agrawal et
al., 2011).
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Figure 4: Frequent somatic mutations in HNSCC. Permission obtained from Stransky,
N., et al., (2011) Science.. 333(6046): p. 1157-60 (Stransky et al., 2011)
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Mutations identified from these studies confirmed previous reports of alterations
in TP53, CDKN2A, PIK3CA, PTEN and HRAS. In both studies, novel inactivating
mutations in NOTCH1 were found. This was the first time mutations in NOTCH1 in
solid tumors were reported. NOTCH signaling is involved in the development of
multicellular organisms. Maintenance of stem cells and differentiation are two processes
by which NOTCH signaling regulates development. NOTCH signaling in cancer was first
highlighted in T-cell Acute Lymphoblastic Leukemia (T-ALL) in which constitutive
activation of NOTCH signaling promotes tumorigenesis. The role of NOTCH1 in T-ALL
was found as a result of translocation of the NOTCH1 gene from chromosome 7 to
chromosome 9 adjacent to the T-cell Receptor β enchancer/promoter (Reynolds, Smith,
& Sklar, 1987). However such translocations was found in less than 1% of all human TALL. Weng et al. (Weng et al., 2004) published that more than 50% of all T-ALL have
activating mutations in NOTCH1, revealing an oncogenic function of this protein in TALL. Pear et al. (W. Pear et al., 1999) showed that mice when reconstituted with
hematopoietic progenitor cells expressing the human intracellular NOTCH1 (ICN1)
develop T-cell leukemia.
NOTCH1 acts as a tumor suppressor or oncogene (Egloff & Grandis, 2012)
depending on cancer type. In HNSCC, both Agarwal et al. (Agrawal et al., 2011), and
Stransky et al. (Stransky et al., 2011) have shown loss of function mutations consistent
with a tumor suppressor role. Targeting NOTCH signaling with gamma secretase
inhibitors in T-ALL has shown pre-clinical activity in inhibiting tumorigenesis and
currently being evaluated clinically. In contrast, the role of NOTCH signaling as a tumor
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suppressor has been difficult to target in certain cancers due to loss of this pathway and a
lack of NOTCH agonists.
Evidence of NOTCH as a tumor suppressor comes from studies in keratinocytes.
NOTCH1 signaling in murine keratinocytes upregulates early differentiation markers
such as keratin 1 and involucrin as well as WAF1 allowing terminal differentiation in the
suprabasal layers of the skin (Nicolas et al., 2003). Recently Pickering et al. (Pickering et
al., 2013) performed whole exome sequencing from primary cutaneous cell carcinoma
that identified the tumor suppressive role of NOTCH1 as a potential driver in this cancer
type. The mutational landscape of cutaneous squamous cell carcinoma is similar to
HNSCC. In both cancers, alterations in NOTCH1 appear to be inactivating. The missense
mutations cluster in the EGF-like repeats and truncating mutation are distributed
throughout the gene except the PEST domain, which in contrast is found in T-ALL. More
than 30% to 50% tumors with NOTCH1 mutations in cSCC have inactivating NOTCH1
mutations, further supporting the role of this gene as a tumor suppressor. Recently, Mao
et al. (Song et al., 2014) sequenced 52 Chinese patients with HNSCC and detected
NOTCH1 mutations in 43% of the tumors. Although, this group confirmed previous
reports of inactivating mutations in the EGF domain, interestingly, 29% of the mutations
were localized to the NOTCH1 the LNR domain. This is a domain is located close to the
heterodimerization domain that harbors activating mutations in hematologic
malignancies, however, the functional impact of these mutations remains unclear.
Califano et al. (Sun et al., 2014) evaluated copy number variations, gene expression,
methylation and mutations from 44 HNSCC primary tumors. They found a bimodal
pattern of NOTCH signaling pathway expression in which a smaller set of mutants
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exhibited inactivating NOTCH1 mutations, whereas a larger subset exhibited
overexpression or increased gene copy number of the NOTCH receptor, ligands or
downstream pathway activations. Although this group found significant upregulation of
the NOTCH ligands, JAG1 and JAG2, it is unclear whether their overexpression within
the same tumors would contribute to cis-inhibition or activation of the pathway.
Moreover, copy number gains in NUMB, an inhibitor of the NOTCH pathway, were also
found with JAG1 gains. This might argue that both cis-inhibition and inhibition by
NUMB might downregulate the NOTCH signaling pathway in tumors. Whether
overexpression of ligands in the same tumor contributes to cis-inhibition should be
further investigated. Over the past 4 years, several efforts have been made to identify
frequent somatic mutations in HNSCC, however few have offered insights into the
mechanistic role of NOTCH as an oncogene or tumor suppressor. Recent TCGA data
showed that inactivating mutations in FAT1 and NOTCH1 are not mutually exclusive.
FAT sequesters β-catenin and inhibits the Wnt signaling cascade. These findings touch
upon the mechanistic insights into the essential interplay between NOTCH signaling and
the Wnt pathway. So far, we know that in a subset of HNSCC tumors, NOTCH might act
as a tumor-suppressor and in the others it might play the role of an oncogene. This might
depend on tumor type, stage, extracellular factors or the microenvironment, but is not
completely understood. The main objective of this thesis is to provide data that support a
tumor suppressor role for NOTCH1 in a subset of HNSCC through functional and
mechanistic studies. In addition, we offer insights into how these tumors might be
targeted by identification of the association of NOTCH signaling with two potential
proto-oncogenes AXL and α-catulin that are suppressed after NOTCH activation.
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CHAPTER 2: NOTCH SIGNALING
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Chapter 2: NOTCH signaling
Structure of NOTCH receptor
NOTCH is family of transmembrane receptors that are involved in cell-cell
interaction. Mammals have four NOTCH (NOTCH 1-4) paralogs that have both unique
and redundant functions. The NOTCH receptor can be broadly structured into 4 regions:
extracellular domain, transmembrane domain, intracellular domain and PEST domain
(Figure 5) (Kopan & Ilagan, 2009).
The extracellular domain of all NOTCH receptors contain 29-36 tandem
epidermal growth factor (EGF) – like repeats which are involved in binding to the
NOTCH receptor of the adjacent cell. Interactions between the receptor of one cell and
the ligand of a neighboring cell are called trans activation. This occurs by the binding of
the EGF repeats 11-12 on the NOTCH receptor. On the contrary, binding of the NOTCH
receptor and ligand on the same cell results in inhibition of the pathway called cisinhibition. This includes EGF repeats 24-29 on the NOTCH receptors that bind to the
ligand expressed by the same cell. Calcium ions play an important role in ligand-receptor
binding. The EGF repeats binding to calcium ions can determine structure and affinity of
binding. The extracellular region is composed of a Negative Regulatory Region (NRR)
which has three cysteine-rich Lin12-NOTCH repeats (LNR) in addition to a
heterodimerization domain (Figure 3). This NRR is important as it prevents activation of
the NOTCH pathway without ligand binding. The region below the heterodimerization
(HD) domain contains a cleavage site called S1, which is the site for furin- like
convertases.
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Figure 5: Structure of NOTCH family receptors in drosophila and mammalian systems.
Permission obtained from Kopan, R. and M.X. Ilagan. (2009). Cell. 137(2): p. 216-33.
(Kopan & Ilagan, 2009)
Figure legend: EGF: Extracellular Growth Factor, NRR: Negative Regulatory Region,
LNR: Lin12 NOTCH Repeats (LNR A, B and C), HD: Heterodimerization Domain,
TMD: TransMembrane Domain, RAM: RBP-Jκ Association Module, ANK: ANKyrin
Repeats, NLS: Nuclear Localization Sequence, TAD: TransActivation Domain, OPA:
glutamine rich repeat, QQ: Glutamine repeats, PEST: Proline/Glutamic
acid/Serine/Threonine rich motif, Ofut: fucosylation motifs (green: common, light blue:
unique), Rumi: glycosylation motifs (dark blue: common, magenta: unique), NECD:
NOTCH ExtraCellular Domain, NTMIC: NOTCH TransMembrane and Intracellular
Domain.
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Cleavage at S1 converts full length NOTCH into a NECD-NTMIC (NOTCH
extracellular domain- NOTCH transmembrane Intracellular domain) that is bound by
covalent interactions between the N and C- terminus of the HD domain. The furin-like
cleavage at S1 is part of the secretory pathway that occurs in the golgi before NOTCH
receptor gets translocated to the plasma membrane. The transmembrane domain (TMD)
contains a “stop translocation” signal that has 3-4 Arg/Lys residues that regulates
translocation of the receptor. After the TMD, begins the intracellular domain. The
domain near the N-terminus of the intracellular region contains a RAM domain (RBPj
association module), with 12-20 amino acids centered around a conserved WxP motif
(Lubman, Korolev, & Kopan, 2004). RAM is linked to several ankyrin repeats (ANK) by
one nuclear localization sequence (NLS). Following the ANK, are more NLS and a
transactivation domain (TAD). The end C-terminus contains proline/glutamic
acid/serine/threonine (PEST) motifs that governs the stability of NICD.
Structure of NOTCH ligands
NOTCH ligands may be present in the same cell or adjacent cells that bind to the
extracellular domains of the NOTCH receptor. Most NOTCH ligands are also type 1
transmembrane proteins and are membrane bound like the receptors. Cordle and
colleagues (Cordle et al., 2008) employed X-ray and NMR techniques to study the
structure of the NOTCH receptor. These receptors are characterized by three related
structural motifs: N-terminal DSL (Delta/Serrate/LAG-2), EGF repeats called the DOS
domain (Delta and OSM-11 like proteins) and EGF like repeats (Figure 6). The DSL and
DOS domains are both involved in binding to the NOTCH receptor. Mammals have two
types of NOTCH ligands, Jagged1/Jagged2 and Delta like ligand 1, 3 and 4 (DLL1, 3, 4).
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Both Jagged ligands have a cysteine rich domain, which is absent from DLL1. Additional
proteins that lack DSL or DOS domains have been reported as non-canonical ligands for
the NOTCH receptor. For example, F3/Contactin1, NB-3/Contactin6 DNER and MAGP1
have been reported in the central nervous system and in cultured cells (B. D'Souza,
Miyamoto, & Weinmaster, 2008). These non-canonical receptors have been unexplored
and their physiological functions in the NOTCH signaling pathway hasn’t been
elucidated. After binding of the ligand to the receptor, endocytosis of the ligand is
triggered by the cell expressing the ligand. E3 ubiquitin ligases like Neuralized and
Mindbomb monoubiquitinate the ligand that is followed by degradation of the ligand.
After endocytosis, in a process that is not completely understood, cells produce more
active surface ligands (Le Borgne, 2006).
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Figure 6: Structure of NOTCH ligands in drosophila and mammalian systems.
Permission obtained from Kopan, R. and M.X. Ilagan. (2009). Cell. 137(2): p. 216-33.
(Kopan & Ilagan, 2009)
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NOTCH activation and regulation
The binding of the NOTCH ligand to its receptor results in a sequence of
proteolytic events. The first proteolytic cleavage occurs at site S2 (located just before the
TMD and in the NRR) by ADAM metalloproteases (Figure 7). S2 cleavage is one of two
key proteolytic cleavages that is often mediated by ADAM17/TACE. After S2 cleavage,
an intermediate receptor called NOTCH Extracellular Truncation (NEXT) is formed that
is still tethered to the plasma membrane. The S2 cleavage exposes the receptor to another
key cleavage site called site 3, S3 that is located within the transmembrane domain. The
enzyme that cleaves the NOTCH receptor at S3 is called -secretase. This enzyme
belongs to a class of intermembrane cleaving proteases (i-CLiPs) (Wolfe & Kopan,
2004). Only after cleavage by -secretase, the NOTCH intracellular domain (NICD) (also
called Intracellular NOTCH (ICN) or activated NOTCH) is released from the plasma
membrane and translocates to the nucleus. In the nucleus, it interacts with DNA binding
proteins CSL (CBF1/RBPj) via its RAM domain. The ANK domain associates with
CSL, which then recruits a co-activator called Mastermind- like 1(MAML1). This
complex then binds to the promoter regions of their targets and regulate diverse
phenotypes. Canonically, these targets belong to the HES and HEY family of genes that
are known transcriptional repressors.
The NOTCH ligand, meanwhile, is endocytosed by E3 Ubiquitin ligase in the
neighboring cell. Mindbomb and Neuralized are E3 Ubiquitin ligases that recognize
Jagged and Delta ligands respectively. After endocytosis, the process by which NOTCH
ligands re-surface to the plasma membrane is not completely understood. Ligand
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clustering, post-translational modifications and/or recycling ligands to specific membrane
microdomains are some potential explanations (Pfister et al., 2003).
Just like the NOTCH ligand, several processes also regulate the NOTCH receptor.
E3 ubiquitin ligases such as Deltex, Nedd4, and Cbl1either recycle the receptors or target
them for lysosomal degradation (S. J. Bray, 2006; Le Borgne, 2006). Another key
molecule involved in regulation of the NOTCH receptor is NUMB, which in association
with the AP2 component α-adaptin promotes NOTCH degradation. NUMB is a
membrane-associated phosphotyrosine binding (PTB) protein that was first discovered as
a cell fate determinant in Drospophila melanogaster (M. Park, Yaich, & Bodmer, 1998;
Uemura, Shepherd, Ackerman, Jan, & Jan, 1989). The antagonistic effect on NUMB on
NOTCH signaling has drawn attention to the role of NUMB in several cancers (Flores,
McDermott, Meunier, & Marignol, 2014). The exact mechanism of NUMB inhibiting
NOTCH signaling is not completely understood, but two models have been suggested for
such inhibition. Endosomal trafficking of NOTCH is essential for its activation,
regulation and degradation (Yamamoto, Charng, & Bellen, 2010). NUMB associates with
AP2 adapter complex via α-adaptin in clathrin coated pits and is involved in endocytic
trafficking (Santolini et al., 2000). This model suggests the possibility of NOTCH being
endocytosed and thus inhibited by NUMB. On the other hand, NUMB can also directly
bind to ICN and prevent its translocation to the nucleus. This was shown by Frise et al.,
(Frise, Knoblich, Younger-Shepherd, Jan, & Jan, 1996) by co-expressing NOTCH and
NUMB that prevented translocation of ICN. Both these models suggest an inhibitory role
of NUMB in regulating NOTCH signaling.
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Besides E3 ubiquitin ligases and NUMB, post-translational modifications,
particularly glycosylation (the process of adding glycans to proteins), at the EGF repeats
of the NOTCH receptor is another mechanism of regulation. The NOTCH receptors have
been thought of as large glycoproteins. Two forms of O-glycosylation; O-glucose and Ofucose modify the EGF repeats of the receptor (Haines & Irvine, 2003; Rampal, Luther,
& Haltiwanger, 2007; Stanley, 2007). Post-translation, NOTCH receptor is fucosylated
by O-fucosyltransferase. O-fucosylation facilitates proper folding of the receptor in the
endoplasmic reticulum. The addition of O-fucose and/or O-glucose determines specificity
of ligand binding. For example, fringe mediated addition of N-glucosamine on EGF
repeat 12 enhances binding of the receptor to Delta but reduces its binding to Serrate in
Drospophila melanogaster (Wu & Bresnick, 2007). In mammals, multiple fringe proteins
(Lunatic, Manic and Radical fringes) regulate fucosylation of NOTCH receptors and their
ligands. For example, luatic fringe modifies NOTCH signaling in T-cells such that it
enhances binding to Delta like ligand but not Jagged1 (Tsukumo, Hirose, Maekawa,
Kishihara, & Yasutomo, 2006; Visan et al., 2006). Although the mechanistic contribution
of these saccharides to NOTCH biology is not completely understood, the development
of improved methods to detect glycosylation and the generation o-glycosylation deficient
NOTCH alleles will be important contributors to NOTCH biology. Table 1 summarizes
the core components of the NOTCH signaling pathway in Drosophila and mammalian
systems.
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Figure 7: NOTCH signaling pathway. Permission obtained from Kopan, R. and M.X.
Ilagan. (2009). Cell. 137(2): p. 216-33. (Kopan & Ilagan, 2009)
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Table 1: Core components of the NOTCH signaling pathway in Drosophila and
mammals.
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NOTCH signaling in differentiation
The NOTCH signaling pathway is an evolutionarily conserved pathway from
invertebrates to vertebrates. NOTCH signaling is critical to the maintenance and renewal
of several organs that include skin, blood, intestine, liver and muscle. NOTCH plays an
important role in stem cells, in that it determines whether stem cell continue to proliferate
and maintain their stemness or promote the differentiation of stem cells to progenitors or
terminally differentiated cells. Embryonic stem (ES) cells are derived from the early
embryonic stages and are pluripotent (Thomson et al., 1998). These cells express
NOTCH1, however the progenitor cells from which these ES cells are derived do not
express NOTCH1 (Hadland et al., 2001). The activation of NOTCH signaling at different
stages of ES cell differentiation has been shown to enhance the generation of particular
precursor cells (P. M. Chen et al., 2008; Kobayashi et al., 2009). Schroeder et al.
(Schroeder & Just, 2000) have shown that activation of NOTCH signaling in mesodermal
cells blocks the generation of endothelia, cardiac muscle, and hematopoietic cells while
inhibition of NOTCH signaling in ES cells (by deletion of RBP-Jκ) directs differentiation
of the cardiomyocyte lineage. On the other hand, NOTCH signaling also plays an
important role in the differentiation of a variety of progenitor cells. In the hematopoietic
system, Delta1 ligand mediated NOTCH1 activation has shown to stimulate
megakaryocytic development from hematopoietic stem cells (Mercher et al., 2009). In Tcell progenitors, it has been shown that NOTCH gain of function induced by
overexpression of NOTCH1 or stimulation with DLL1 and DLL4 ligands led to aberrant
proliferation and differentiation (de La Coste et al., 2005; Hozumi, Abe, Chiba, Hirai, &
Habu, 2003; Jaleco et al., 2001; Pui et al., 1999). On the contrary, loss of function studies
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using inactivated NOTCH1, mutant RBP-Jκ or using the γ-secretase inhibitor produced a
similar phenotype in B-cell progenitor cells (Hadland et al., 2001; H. Han et al., 2002).
Put together, NOTCH signaling instructs differentiation along the T-cell rather than the
B-cell lineage during lymphopoiesis.
In addition to hematopoiesis, NOTCH signaling also plays an important role in
skin differentiation. The epidermis has four layers: basal, spinous, granular and cornified.
Each layer expresses different markers. Adult stem cells reside either in the basal layer or
in the bulge of the hair follicle. Stem cells at the basal layer are unipotent and these cells
commit to terminal differentiation (Blanpain & Fuchs, 2006; Fuchs & Raghavan, 2002)
while the stem cells at the follicle bulge are usually quiescent and enter the proliferative
stage in response to injury (Blanpain & Fuchs, 2009; L. Li & Clevers, 2010). NOTCH
signaling modulates differentiation and proliferation of epidermal stem cells (Ambler &
Maatta, 2009; Okuyama, Tagami, & Aiba, 2008; Watt, Estrach, & Ambler, 2008).
Condition gain of function (NICD overexpression) and loss of function studies
(NOTCH1 -/-) have shown that NOTCH signaling promotes basal to spinous
differentiation (Blanpain, Lowry, Pasolli, & Fuchs, 2006; Rangarajan et al., 2001). Dotto
et al. (Dotto, 2008) and others (Demehri, Turkoz, & Kopan, 2009; Nicolas et al., 2003)
have shown that embryonic ablation of RBP-Jκ in the epidermis causes epidermal
hyperplasia. After birth, loss of NOTCH results in hyperplasia, creating a tumorpromoting microenvironment. NOTCH as a tumor suppressor in skin highlights the
complex role played by NOTCH signaling in controlling epidermal differentiation and
regulating exit from the proliferative stem cell niche. In the follicular bulge stem cell
population, NOTCH signaling functions as a gate-keeper. In the absence of NOTCH,
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stem cells can select either epidermal or follicular differentiation (Demehri & Kopan,
2009). The differences observed in the specific activities of NOTCH signaling in
different stem cell populations plays a complex, context dependent role in stem cell
biology.

NOTCH in cancer
NOTCH signaling plays diverse roles during the development and maintenance of
normal tissues. This effect is recapitulated in several forms of cancer. NOTCH may act as
a tumor suppressor or and oncogene depending on the context and exerting its effect on
differentiation, growth, migration, angiogenesis and self-renewal. In this chapter, the role
of NOTCH as an oncogene and tumor suppressor will be elucidated.
NOTCH as an oncogene
The best-known example of oncogenic NOTCH signaling is in T-cell acute
lymphoblastic leukemia (T-ALL) that is a neoplasm of immature T-cells. The first known
role of NOTCH1 in T-ALL was known because of its translocation from chromosome 7
to chromosome 9 (Ellisen et al., 1991). This translocation was found only in 1% of all TALL’s. A much broader role of NOTCH1 was revealed after the discovery of activating
mutations in this cancer type. Activating mutation in NOTCH1 was found at frequency of
60% (Weng et al., 2004). There are two types of activating mutations in T-ALL. The
first occurs at the heterdimerization domain that results in ligand independent
metalloprotease cleavage at the S2 site. The second consists of frame shift mutations or
stop codons at the PEST degradation domain. Such mutations prevent degradation of
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NOTCH and stabilize the NICD (Malecki et al., 2006). In the murine system, NOTCH1
plays a role in the early stages of T-cell development, including commitment to T-cell
fate and subsequent progression to the DN3 stage of development. This suggests that the
leukemogenic activity stems from exaggerated normal development function (Radtke,
Wilson, Mancini, & MacDonald, 2004). Besides, T-ALL, NOTCH signaling also has
oncogenic functions in other contexts, especially breast cancer, medulloblastoma,
colorectal cancer, non-small cell lung carcinoma and melanoma (Ranganathan, Weaver,
& Capobianco, 2011). The oncogenic function of NOTCH in solid tumors was first
discovered in breast cancers, which was driven by mouse mammary tumor virus
(MMTV). Integration of MMTV in the host genome resulted in the constitutively active
form of NOTCH4 (Gallahan, Kozak, & Callahan, 1987). The expression of NOTCH
receptors is elevated in breast cancers and the expression of NOTCH ligands such as
Jagged1 correlates with more aggressive disease (Reedijk et al., 2005; Weijzen et al.,
2002). Recently, activating mutations in chronic lumphocytic leukemia (CLL) has been
identified. NOTCH1 activating mutations in this cancer type predicts to impair FBW7
degradation of NOTCH1 (Fabbri et al., 2011). NOTCH receptor expression and its
downstream targets are up regulated in primary human melanomas (Balint et al., 2005).
Forced expression of intracellular NOTCH (NICD) promotes melanoma progression.
Increased NOTCH activity has been correlated with PI3K-Akt activity in melanoma cells
(Z. J. Liu et al., 2006). To date, no gain of function mutations have been discovered in
solid tumors suggesting the ligand activation of the receptor dominates the role of
NOTCH as an oncogene (Lobry, Oh, & Aifantis, 2011). Recently, other work has implied
the role of NOTCH as an oncogene in other solid tumors such as medulloblastoma
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(Hallahan et al., 2004) and ovarian cancer (J. T. Park et al., 2006). It is likely that there
might be other neoplasms in which the oncogenic function of NOTCH will be uncovered
in the future.
NOTCH as a tumor suppressor
Although activation of NOTCH can be oncogenic, there is also sufficient
evidence to show that NOTCH can be tumor suppressive. This has been shown in skin,
pancreatic epithelium, hepatocyte and other hematopoietic cells. In skin keratinocytes,
activation of NOTCH in the suprabasal layers results in differentiation and cell cycle
arrest (Rangarajan et al., 2001). Conditional knock out of NOTCH1 in the skin resulted in
increase of the basal epidermis. Loss of NOTCH1 in the skin causes spontaneous basal
cell carcinoma and increased sensitization to chemically induced skin carcinogenesis
(Nicolas et al., 2003). Viatour and colleagues (Viatour et al., 2011) showed that NOTCH
acts a tumor suppressor in hepatocellular carcinoma (HCC). They found that inhibition of
NOTCH signaling using the γ-secretase inhibitor accelerated HCC development.
Furthermore, using intracellular NOTCH1 (ICN1) resulted in cell cycle arrest and
apoptosis. In order to evaluate the clinical relevance, the authors looked at patient
survival and its correlation with NOTCH. They found better patient survival in cohorts
that had increased NOTCH related genes. Taken together, their results suggest a tumor
suppressive role of NOTCH in HCC. Zweidler-McKay et al. showed that in B-cell
malignancies, NOTCH is known to arrest cell growth and induce apoptosis suggesting a
tumor suppressor role (Zweidler-McKay et al., 2005). This role of NOTCH has also been
elucidated in neruoblastoma using the activated intracellular form of NOTCH (ICN) or
activation by recombinant NOTCH ligand (Zage et al., 2012). The recently published
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work in HNSCC sheds light on inactivating mutation seen in NOTCH1 which renders
this protein an oncogene in this tumor type (Agrawal et al., 2011; Stransky et al., 2011;
"TCGA Releases Head and Neck Cancer Data," 2015). These were initial sequencing
studies that identified NOTCH as a tumor suppressor based on the mutational landscape.
The functional significance of these inactivating mutations is currently unknown and is
the main focus of this thesis.
The role of NOTCH as an oncogene in breast, T-ALL, and ovarian cancer versus
tumor suppressor in skin, HNSCC, and HCC highlights an intriguing dual role of
NOTCH that is context dependent. NOTCH either promotes stem cell maintenance of
terminal differentiation. It is possible that these fundamental roles of NOTCH may
contribute to its role as an oncogene or tumors suppressor. By affecting differentiation,
for example, NOTCH could set the stage for accumulation of additional mutations. In
myeloid- leukeima, defective NOTCH signaling promotes differentiation of stem cells to
granulocytic/monocytic progenitor cells (GMP). This expands the pool of putative
leukemia initiating cells driving the accumulation of oncogenic mutations in TET that
then results in graulocytic/monocytic leukemia (Moran-Crusio et al., 2011). Activating
mutations in NOTCH could potentially promote T-cell progenitors population, resulting
in T-ALL while NOTCH could also stimulate terminal differentiation of progenitor cells
preventing further accumulation of cancer initiating populations, which might be the case
in HCC (Lobry et al., 2011).
NOTCH in HNSCC
Currently, very little is known about the functional role of NOTCH in HNSCC.
Following whole exome sequencing studies that identified inactivating mutations in
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NOTCH1, there has been growing interest in the potential role of NOTCH signaling in
the development of head and neck cancers. Besides TP53, NOTCH mutations commonly
occur in head and neck cancers, skin and NSCLC. NOTCH signaling is still being
assessed as a tumor suppressor in squamous cell carcinomas. Prior to the sequencing
studies, there have been very little studies elucidating the role of NOTCH in HNSCC
most of which was in relation to aberrations in other molecules. The purpose of this thesis
is to attribute a tumor suppressive role of NOTCH in HNSCC and elucidate the
functional relevance of NOTCH signaling in inhibiting growth in vitro and in vivo. Here,
we show for the first time, that NOTCH1 inhibits two proto-oncogenes AXL and
CTNNAL1 and make a novel connection of these molecules with NOTCH1 in abrogating
cell growth. Elucidating how NOTCH inactivation promotes tumorigenicity could
identify new therapeutic targets that are upregulated because NOTCH signaling is lost in
HNSCC. We propose that AXL and CTNNAL1 may be novel targets downstream of
NOTCH that can be exploited for therapeutic intervention in tumors that have an inactive
NOTCH pathway.
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CHAPTER 3: AXL AND α-CATULIN
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Chapter 3: AXL and α-CATULIN
AXL
AXL is a receptor tyrosine kinase (RTK) that belongs to the TAM family of
transmembrane receptors (Axelrod & Pienta, 2014). This receptor gets its name from the
first letter of each member of its family: Tyro3, AXL and Mer (Prasad et al., 2006).
These are a structurally distinct family of orphan RTK’s that was discovered after
isolation of their full length cDNA’s (Graham, Dawson, Mullaney, Snodgrass, & Earp,
1994; Lai & Lemke, 1991; O'Bryan et al., 1991). The TAM receptors have two ligands;
growth arrest specific 6 (Gas6) and Protein S. While Gas6 can bind to all TAM receptors,
Protein S can only bind to Tyro3 and Mer (Hafizi & Dahlback, 2006). The AXL gene is
harbored on chromosome 19. It has 20 exonsspread over a 44 kb region. The 5’ upstream
region of AXL is GC rich. This region does not have TATA and CAAT boxes. Using
cloning and 5’ deletion techniques Mudduluru and Allgayer characterized the promoter
region of AXL (Mudduluru & Allgayer, 2008). In their publication, they show that a
minimalistic GC-region alone is sufficient to activate the AXL promoter. In addition,
there are also several binding sites for transcription factors upstream of the AXL start
codon. These binding sites include five Sp binding sites (SP a- Sp e), one MZF1 and one
AP1 binding site (Mudduluru & Allgayer, 2008; Mudduluru, Leupold, Stroebel, &
Allgayer, 2010; Mudduluru, Vajkoczy, & Allgayer, 2010). Another feature of this
promoter shown by Sayan et al. is how CpG islands control promoter activation of AXL.
CpG islands are critical in gene expression and consequently the control of cell cycle,
tumor differentiation and development (Bartolomei, Webber, Brunkow, & Tilghman,
1993; Carlone et al., 2005). In the CpG islands, promoter methylations is a common
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epigenetic modification that is used to repress gene expression. There are 19 CpG islands
within the promoter region as putative methylation sites (Mudduluru & Allgayer, 2008).
The transactivation potential of Sp1 and Sp3 transcription factors is affected by
methylation of these CpG sites within the Sp transcription factor binding motifs (Zhu et
al., 2003). Using cell lines with varying expression levels of AXL, Mudduluru and
Allgayer elucidated that CpG islands located in proximity to the Sp family binding motifs
were methylated in low AXL expressing cell lines. On the contrary, cell lines which had
high AXL expression that showed no methylation (Mudduluru & Allgayer, 2008).
Mouse loss of function mutants demonstrated the biological role of the TAM
receptors after identification of the structure of TAM receptor and ligands (Camenisch,
Koller, Earp, & Matsushima, 1999). Tyor 3 -/-, AXL -/-, and Mer -/- mice are all viable
and fertile. Liu and colleagues (E. Liu, Hjelle, & Bishop, 1988) first discovered AXL
from patients with Chronic Myelogenous Leukemia (CML). When this discovery was
made, AXL was shown to be necessary but not sufficient for transformation. AXL is
located in the “p” arm of chromosome 19 with a molecular weight of about 140 kDa.
The extracellular domain of the TAM receptors have two structural modules that
are repeated in other RTK ectodomains, defining two plus two configuration. In the
ectodomains, the amino terminal regions have immunoglobulin domains that facilitate
binding of the ligsnd (Sasaki et al., 2006) that is followed by type 3 fibronectin
sequences. The transmembrane domain of most TAM receptors have a protein tyrosine
kinase catalytic domain. Activation of this domain results in downstream activation of the
phosphoinositide 3 kinase (PI3K)/ Akt pathway. The PI3K signaling is associated
through a TAM-autophosphorylated Grb2-binding site, which is located approximately
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18 residues at the carboxy terminal of the kinase domain. This region is conserved across
all the TAM’s (Fridell et al., 1996; Ling, Templeton, & Kung, 1996). Activation of
phospholipase C, ERK1/2, Ras and MAP kinase activation has also been shown before
(Keating et al., 2010). The TAM ligands are large (80kDa) proteins that share the same
multidomain arrangement. The carboxy terminal has an SHBG domain composed of two
laminin G domains. The SHBG domain is responsible for binding to the Ig domains of
the receptors. This binding induces their dimerization and kinase activation. The second
domain is called Gla domain. This domain is located at the amino terminus of both
ligands (Stitt et al., 1995). The Gla domain is known to be rich in glutamic acid residues.
The hydroxyl groups of these residues are carboxylated post-translationally (Huang et al.,
2003).
Like other RTK’s, AXL can also function independent of the ligand depending
upon the context. For example, in vascular smooth muscle cells (VSMC) and lens
epithelial cells, ligand independent AXL activation occurs in response to hydrogen
peroxide. The binding of the receptor to the ligand activates the AXL signaling cascade,
which results in diverse phenotypic functions such as cell proliferation, migration,
invasion, differentiation and EMT (Figure 6). Which signaling pathways are activated are
regulated spatially and temporally determined by extracellular environment, cell and
tissue type. When AXL was discovered in CML, PI3K signaling was the first discovered
downstream cascade through which it regulates cell migration, growth, and apoptosis
(Nielsen-Preiss et al., 2007; Ruan & Kazlauskas, 2013). Over the years, AXL has been
shown to have diverse signaling capabilities through the PI3K, Akt, mTOR, NFκB and
MAPK pathways.
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Like other RTK’s binding of Gas6 to AXL down regulates its expression through
degradation via c-Cbl ubiquitin ligase (Valverde, 2005). AXL is also regulated posttranscriptionally by micro RNA’s miR-34a and miR-199a/b. This was shown in a
bioinformatics screen in NSCLC, breast and colorectal cancer cell lines (Mudduluru et
al., 2011). HIF1-, MZF1, AP1, sp1 and sp3 transcriptional factors can also regulate
AXL expression transcriptionally.

AXL in cancers
AXL is overexpressed in several cancer types. Correlation studies have shown the
association of AXL with motility and invasion and that the treatment with R428, an AXL
inhibitor reverses this phenotype. Increased AXL expression has been evaluated as a poor
prognostic factor for overall survival in colon cancer, osteosarcoma, and pancreatic
cancer (Dunne et al., 2014; J. Han et al., 2013; Song et al., 2011). AXL expression is also
a prognostic for increased lymph node metastasis and clinical stage in lung
adenocarcinoma, breast and ovarian cancer (D'Alfonso et al., 2014; Rankin et al., 2010;
Shieh et al., 2005)
AXL in Non-small cell lung carcinoma (NSCLC)
AXL overexpression has been observed in 60% of NSCLC cell lines and also in a
significant fraction of primary tumors (Shieh et al., 2005; Wimmel, Glitz, Kraus, Roeder,
& Schuermann, 2001). In H1299 lung cancer cell lines, it has been shown that AXL is
upregulated upon loss of p53 and in part gain of function activities of mutant p53 was
mediated through AXL overexpression (Vaughan et al., 2012). Zhang et al. had shown
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high AXL activation in NSCLC and demonstrated evidence for epithelial-tomesenchymal transition (EMT) in lung cancer models that were resistant to erlotinib in
vitro and in vivo (Z. Zhang et al., 2012). After AXL inhibition, the sensitivity to
erolotinib was restored showing that inhibition of AXL can overcome chemo resistance.
They also showed low AXL expression levels in cells that have vimentin blocked. This
suggests that AXL expression is higher during the process of EMT and that AXL
confersresistance occurs in the process of EMT. Evaluation of AXL expression in
patients before and after EGFR inhibitor treatment demonstrated that increased
expression of AXL is essential for resistance to EGFR inhibitors. Around the same time,
Byers et al. confirmed a 75-gene EMT signature by employing gene expression profiles
(Byers et al., 2013). This was done in NSCLC cell lines and tumors from lung cancer
patients, usingthree different arrays. This defined signature could predict resistance to
EGFR and PI3K/Akt inhibitors. They suggested that AXL is a mediator of resistance to
EGFR inhibitors further implicating that such resistance could be associated with a
mesenchymal phenotype. Their signature strongly correlates with the mesenchymal group
in which they observed upregulation of AXL but this was not seen in the epithelial group.
Furthermore, they observed that inhibition of AXL in mesenchymal cells reversed
resistance to the drug treatments. Taken together, AXL has two possible roles in cancer;
association with an EMT phenotype and resistance to targeted agents.

AXL in breast cancer
AXL is overexpressed in highly invasive breast cancer cell lines. On the contrary,
weakly invasive breast cancer cell lines express AXL at very low levels. It has also been
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shown that AXL expression correlates with motility and invasiveness of breast cancer
cell lines (Y. X. Zhang et al., 2008). Estrogen receptor has also been shown to induce
AXL expression and this could important in proliferation, differentiation and apoptosis of
human breast epithelium (Berclaz et al., 2001). The progesterone receptor B (PRB)
upregulates the AXL ligand, Gas6 (Richer et al., 2002) and Her2 is also reported to
trigger AXL activation suggesting crosstalk in clinically important pathways (Bose et al.,
2006). Berclaz et al. immunostained AXL and estrogen receptor (ER) in a panel of 23
normal and 111 malignant breast cancer samples (Berclaz et al., 2001). They found was a
high correlation between AXL and ER expression in malignant breast tissue. In addition,
there was also a correlation between AXL expression and the stage of the tumor.
Gjerdrum et al. had investigated AXL expression levels in 190 breast cancer patients and
showed that high AXL expression negatively correlates with breast cancer survival
(Gjerdrum et al., 2010). Holland et al. used RNAi to inhibit AXL and showed decreased
growth of MDA-MB-231 cells in a xenograft model (Holland et al., 2005). In addition,
AXL knockdown in MDA-MB-231 demonstrated that AXL was necessary for
invasiveness in metastatic breast cancer cells (Gjerdrum et al., 2010). In the same cell
lines, decreased AXL mRNA and protein levels correlates with cell invasion potential
and decreases phosphorylation of AKT (Mackiewicz et al., 2011). Similar to NSCLC in
which AXL expression was reduced when vimentin was blocked (Z. Zhang et al., 2012),
Vuoriluoto et al. found that vimentin promotes EMT activation and is also necessary for
AXL upregulation (Vuoriluoto et al., 2011).
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AXL in Acute Myeloid Leukemia (AML)
AXL was found as a prognostic marker and therapeutic target in acute myeloid
leukemia (AML). AML cells can induce expression of Gas6 from bone marrow derived
stromal cells. Gas6 mediates proliferation, survival and chemo resistance of AXL
expressing AML cells. This creates a chemo protective tumor cell niche. The small
molecule AXL inhibitor BGB324 (R428), is able to overcome this mechanism and
synergize with chemotherapy (Ben-Batalla et al., 2013). AXL overexpression also
promotes migration and invasion of prostate cancer cells in vitro (Paccez et al., 2013;
Shiozawa et al., 2010). It is also associated with higher frequency of distant metastasis in
patients with pancreatic adenocarcinoma (Linger et al., 2013; Song et al., 2011). Recently
performed work has shown that AXL can mediate resistance to anti-EGFR inhibitors
(Byers et al., 2013; Giles et al., 2013; Ye et al., 2010; Z. Zhang et al., 2012). Patients with
AML had high AXL mRNA levels and worse progression free survival (Rochlitz et al.,
1999). AXL expression in drug resistance was shown by Hong et al. wherein they
observed high expression of AXL in AML patients refractory to doxorubicin treatment
(Hong et al., 2008). In the same study, expression of endogenous AXL was shown to be
induced by chemotherapeutic drugs in a dose-dependent manner in AML cell lines.
AXL in HNSCC
Brand and colleagues evaluated if AXL is a functional molecular target in
HNSCC and whether targeting AXL could enhance the efficacy of standard treatments
used to treat these patients (Brand et al., 2015). They show that AXL inhibition (using
siRNA’s and a pharmacological inhibitor- R428) effectively reduced HNSCC cell
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growth, migration and invasion. The pharmacological inhibitor of AXL, R428, has shown
specificity for AXL (Holland et al., 2010) and is now being evaluated clinically in Phase
1 trials (Fleuren et al., 2014). Brand et al. (Brand et al., 2015) showed that using
increasing doses of R428, all AXL expressing HNSCC cell lines were significantly
growth inhibited. Furthermore, they also used patient derived xenografts (PDX) that were
resistant to radiation therapy and showed higher AXL expression in these PDX models.
Their study concluded that AXL is highly expressed in HNSCC and is associated with
worse clinical outcomes.
AXL inhibitors
As described earlier, overexpression of AXL has been implicated in a variety of
cancer types. Genetic and possibly epigenetic mechanisms potentially regulate the
activation of AXL in cancers. Like other RTK’s that have inhibitors such as imatinib
mesylate (Gleevec), Herceptin, Tarceva and Iressa (Gschwind, Fischer, & Ullrich, 2004),
AXL has also been the subject of study for therapeutic intervention. The development of
AXL inhibitors could potentially improve the treatment of different cancer types in which
AXL is deregulated. Recently, RNA interference (RNAi) and therapeutic agents have
been used to validate the efficacy of AXL inhibition. In 2010, Ye and colleagues
developed a monoclonal antibody (YW327.6S2) against AXL which has high affinity for
this receptor (Ye et al., 2010). This antibody has been shown to decrease xenograft
tumor growth and potentiates the effect of anti-VEGF treatment. It also enhances the
effect of erlotinib in decreasing NSCLC tumor growth as well as breast cancer metastasis.
The identification of 3-quinolinecarbonitrile (Keri et al., 2005) compounds demonstrated
potent inhibitory activity against AXL as well as inhibition of motility and invasiveness
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especially in breast cancer cell lines (Y. X. Zhang et al., 2008). NA80x1 is a compound
that directly inhibits AXL phosphorylation. This compound was previously reported to
display inhibitory activity against Src kinase (Boschelli, Barrios Sosa, Golas, &
Boschelli, 2007; Boschelli et al., 2001). SKI-606 is a Src/Abl inhibitor that also is a
potent AXL inhibitor. SKI-606 can inhibit AXL 20 times lower than NA80x1. In their
publication, it was suggested that both SKI-606 and NA80x1 might be potential
therapeutic targets against breast cancer growth and metastasis. However, both these
compounds have many off target effects and show effects in the micro-molar range,
which is clinically not a viable option.
In 2010, a small molecule AXL inhibitor called R428 ((1-(6,7-dihydro-5Hbenzo[6,7]cyclohepta[1,2-c] pyridazin-3-yl)-N3-((7-pyrrolidin-1-yl)-6,7,8, 9-tetrahydro5Hbenzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5- diamine) was identified by Holland and
colleagues (Holland et al., 2010) that had effects in the nanomolar range. This small
molecule inhibits AXL activity and blocks downstream events of AXL such as Akt
phosphorylation, cell invasion and cytokine production. Dose dependent reduction in
Snail, an EMT transcriptional regulator, inhibition of angiogenesis and tumor formation
was also seen. Holland et al. also translated this in vivo and observed an increase in
survival. Breast cancer and lung cancer models in animals after receiving R428 had a
median survival of over 80 days compared to non-treated animals that had a survival of
52 days. Furthermore, R428 had a synergistic effect with cisplatin treated mice resulting
in suppression of liver metastasis.
Using an in silico approach, Mollard et al. developed a series of compounds that
potentially inhibits AXL and identified 2,4,5-trisubstituted pyrimidines as potent AXL
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inhibtior in the nanomolar range (Mollard et al., 2011). Cerchia et al. employed the
concept of RNA Aptamers to develop GL21.T, a potential AXL inhibitor (Cerchia et al.,
2012). DNA or RNA aptamers are molecules that bind to targets with high specificity and
affinity. GL21.T binds to the extracellular regions of AXL and Tyro3. The authors used a
xenograft fluorescent model and demonstrated that this aptamer specifically accumulates
in the tumor region and mice treated with this aptamer had close to 70% smaller tumors
compared to non-treated controls.
Thus, the identification of molecules with different structures (antibodies, small
molecules, and aptamers) reveals the versatility that can be exploited in the development
of inhibitors against AXL. In this context, identification and development of therapies
involving the inhibition of AXL as well as targeting its downstream effectors may
represent novel targeted therapeutics.
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CTNNAL1: α-catulin
CTNNAL1 is a gene encoding the protein α-catulin, an 82kDa vinculin/α-catenin
family protein. This gene was oringinally identified as a down-regulated transcript in
sodium butyrate treated pancreatic cancer cells which were undergoing differentiation
and apoptosis (J. S. Zhang et al., 1998). The N-terminal region of α-catulin has structural
similarities to human vinculin and α-catenin thus giving it the name α-catulin (αCATenin and vinCULIN). It contains binding sites for β-catenin, α-actinin and talin
suggesting that α-catulin may be a cytoskeletal linker protein (Janssens, Staes, & van
Roy, 1999). Vinculins and α-catenins are functionally and structurally related proteins.
Both have analogous functions despite their low sequence similarity. Both these
molecules are important for the formation of adhesion complexes since they can both
bind to actin. During cell-cell contacts, α-catenin binds to either β-catenin or plakoglobin
(γ-catenin) linking the transmembrane to the actin cytoskeleton (Aberle, Schwartz, &
Kemler, 1996). During cell-substrate contacts, vinculin in linked to integrins via talins
(transmembrane receptors for binding to the extracellular matrix) (Burridge,
Chrzanowska-Wodnicka, & Zhong, 1997). The formation of adhesion complexes and its
association to the actin cytoskeleton is necessary for proper differentiation and
homeostasis and also for cell growth, motility, gene expression and apoptosis (Rudiger,
1998). Notwithstanding the sequence similarities of α-catulin with α-catenin and vinculin,
α-catulin does not inhibit the Wnt/β-catenin signaling pathway (Merdek, Nguyen, &
Toksoz, 2004). The CTNNAL1 gene is located on chromosome 9q31-32. This is a region
that is frequently lost and is a tumor suppressor marker that has been reported in many
cancers (Schultz et al., 1995). This suggests that α-catulin might have a tumor
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suppressive function. There are, however, conflicting reports that show evidence of αcatulin binding directly to IKK-β and Lbc (a Rho GEF) which promotes cell migration
and is resistant to apoptosis (B. Park et al., 2002; Wiesner et al., 2008). This evidence
suggests an oncogenic potential of α-catulin. In their publication, Wiesner et al.
performed a genetic screen using the regulatory C-terminal HLH domain of IKK-β as bait
and identified α-catulin as an IKK-interacting protein. α-catulin augments activation of
NF-κB after stimulation with TNF-α or IL1. Thus, α-catulin serves as a scaffold protein
linking the IKK-β and Rho signaling pathways. Consequently, the biological functions
are promotion of cell migration and protection of cells from undergoing apoptosis. These
are the hallmarks of a gene with tumorigenic potential suggesting an oncogenic role of αcatulin. Recently, Kreisede and colleagues have shown that α-catulin is highly expressed
in melanoma cells compared to melanocytes and that α-catulin is a key driver of tumor
formation, growth, invasion and metastasis by upregulating E-cadherin and
downsregulating Snail/Snug and MMP2/MMP9 . Cao et al. reported that α-catulin was
highly expressed in squamous cell carcinoma and its knockdown increased migratory and
invasive behavior in vitro and in vivo (Cao, Chen, Masood, Sinha, & Kobielak, 2012).
Furthermore, the increase of NF-κB expression by α-catulin elevates fibronectin and
αvβ3 expression and promotes cell migration, invasion and metastasis in lung cancer cells
(Liang et al., 2013). More recently, Kreisede et al. have shown that downregulation of αcatulin using shRNA’s diminished NF-κB, MAPK and AP-1 activation in melanoma
cells and sensitized these cells to cisplatin treatment (Kreiseder et al., 2015) . Although
recent studies have underscored the importance of α-catulin in tumor growth,
progression, invasion and metastasis, currently there are no inhibitors targeting this
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protein. Investigating the modulation of α-catulin might shed light into exploiting other
molecules regulating α-catulin which may be further extended to targeted therapy.

CHAPTER 4: MATERIALS AND METHODS
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Chapter 4: Materials and Methods
Cell lines
HNSCC cell lines were obtained from sources outlined in (Zhao et al., 2011) and
were Short Tandem Repeat (STR) profiled for authenticity. Zhao and colleagues have
described the assembly, characterization and STR profile of all these cell lines which is
outlined in Table 2 .All cells were cultured in DMEM complete media containing 10%
FBS, Penicillin/Streptomycin, glutamate, non-essential amino acids, vitamins, pyruvate
and Myco-Zap ®. Cells were incubated in a 37 0 C, 5% Carbon Dioxide incubator.
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Cell line

Primary site

HN31
PJA34
UMSCC 47
(UM47)
UMSCC 22A
(UM22A)

LN
OC

Age Sex TNM Stage

Primary Source
Dr. John Ensley, Wayne State
University

50

M

OC

53

M

T3N1M0

HP

58

F

T2N1M0

183

OP

54

M

T3N0M0

HN4
CAL27
PCI15B

REC(L)
LN

57
54
69

M
F
M

T2N0M0
T2N1M0
T2N0M0

UMSCC1

REC (OC)

73

M

T2N0M0

JHU022

LN

M

T3N2B

Dr. Thomas E. Carey, University of
Michigan
Dr. Thomas E. Carey, University of
Michigan
Dr. Peter G. Sacks, New York
University
Dr. D.M. Easty, Ludwig Institute of
Cancer Research, London
Dr. Theresa Whiteside, UPMC
Dr. Thomas E. Carey, University of
Michigan
Dr. David Sidransky, Johns Hopkins
University

Table 2: HNSCC cell lines. LN: Lymph Node, OC: Oral Cancer, HP: Hypopharyngeal,
OP: Oropharyngeal, L: Lungs

Western Blots
HNSCC cells were lysed with Radio Immune Precipitation Assay (RIPA) lysis
buffer (Tris: 50mmol/L, NaCl: 150mmol/L, EDTA: 1mmol/L, NP-40: 1%, SDS: 1%,
deoxycholate: 0.5%, glycerol: 10%, mercaptoethanol: 10%, NaF: 10mmol/L,
orthovanadate: 1mmol/L, pyrophosphate: 2.5 mmol/L and protein inhibitors). After
lysing, cells were subjected to sonification and then allowed to solubilize in the buffer for
30 min. The lysates were then centrifuged at 14,000 rpm at 4 0 C for 30 min after which
the supernatant was collected. Protein quantitation was performed using the Pierce ™
BCA protein assay kit (ThermoFisher Scientific). The protein lysate after the protein
assay was mixed with 5% β-mercptoethanol and SDS and loaded onto either 7.5% or 4-
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20% gradient gels (Mini-PROTEAN ® TGX Pre-Cast protein gels) based on the size of
the protein blotted. Gels were run using 10X premixed electrophoresis buffer containing
25mM Tris, 192 mM glycine and 0.1%SDS at pH 8.3 mixed with double distilled water
at 80-110 V for 2-2.5h. Gels were then transferred on nitrocellulose membranes using
10X premixed transfer buffer containing 25mM Tris, 192 mM glycine and 20% methanol
at pH 8.3 either for 2h or overnight at 4 0 C at 100 V. After transfer, the membrane was
blocked using 5% milk-TBST for 2 hours with constant movement. The membrane was
then incubated with the primary antibody at concentrations ranging from 1:100- 1:1000
depending on the antibody overnight at 4 0 C with constant movement. After incubation,
the membrane was washed for 5 min. with TSB buffer containing 0.1% Tween-20 about
5 times. Secondary antibody containing species-specific Horseradish peroxidaseconjugated antibody for 1h at room temperature with constant movement. Protein signals
were developed using SuperSignal West chemiluminescent system (Pierce ®
Biotechnology) on an X-ray film.
Plasmids
Intracellular NOTCH1 (ICN1)
Plasmids encoding the activated forms of NOTCH1 and NOTCH2 were obtained
from Dr. Patrick Zweidler-McKay’s lab. ICN1-MigR1 was constructed by sub cloning
the ICN1 region (codons 1770-2555) of the human total NOTCH1 (W. S. Pear et al.,
1996) into the BgIII site of MigR1 (W. S. Pear et al., 1998). This is a bicistronic vector
that co-expresses GFP after the Internal Ribosome Entry Site (IRES) providing a
surrogate marker for gene expression.
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CRISPR-Cas9 plasmids
CRISPR-Cas9 NOTCH1 and NOTCH2 plasmids were obtained from Santa Cruz
Biotechnology (sc400167). Each plasmid contained a pool of three plasmids, encoding
the Cas9 nuclease and a target specific 20 nucleotide guide RNA (gRNA) for maximum
knockout efficiency. CRISPR-Cas9 plasmids for NOTCH1 and NOTCH2 were
transfected into PJA34 cells and sorted to obtain a pure population of GFP positive cells.
Knockout was confirmed by western blotting for total NOTCH1, Cleaved-NOTCH1 and
total NOTCH2.
NOTCH1 Full Length (NFL1)
The full length NOTCH1 cDNA was obtained from Origene that was initially
untagged and cloned into a pCMV6-XL6 vector. We obtained the MigR1 empty vector
(6.5 kb) from Dr. Patrick Zweidler-McKay’s lab. We cloned NFL1 (7.3 kb) into the
MigR1 vector. The MigR1 vector was first digested with BglII and EcoR1 restriction
sites to insert a Multiple Cloning Site (MCS) containing the restriction sites for Mfe1 and
Xho1. This is because NFL1 lacked a BglII restriction site but had an Mfe1 site. Since
Mfe1 and EcoR1 contain compatible cohesive ends, we swapped the MCS on MigR1
with another one that contains Mfe1 and Xho1 restriction sites. We then cleaved the
MigR1 construct with Mfe1 and Xho1 and cleaved the NFL1 with EcoR1 and Xho1 and
ligated the two constructs to engineer a MigR1-NFL1 (13.8 kb) construct.
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Short Hairpin RNA’s for AXL and α-catulin
Several of the shRNA’s were obtained from Dharmacon (GE Life Sciences) through
the shRNA and ORFeome core facility at M.D. Anderson Cancer Center. We obtained
four shRNA’s for each gene: AXL and CTNNAL1. The mature antisense sequences for
AXL are:
1) AACTTAGATGCTTAGGATC
2) TGATAGCTAAGAAGGAGAG
3) TGAGGATGGAGTCGTCCTG
4) TCTTTGAAACCTAGAACCT
The mature antisense sequences for CTNNAL1 are
1) ATCTTTATGATTAATAAGC
2) TCAATGACCTTATCCAATG
3) TATTTCCAGAGGTTCTGTC
4) TCCAATGCCACTTTCATAC
Each shRNA was cloned into pGIPZ lentiviral vector driven by a human CMV promoter
that also harbors a GFP construct before the IRES sequence. In addition, these lentiviral
vectors carry a gene encoding N-acetyl transferase mediating puromycin resistance.
HES2 and HES5
HES2 and HES5 gene constructs were obtained from Dr. Patrick ZweidlerMckay’s lab and subcloned into a MigR1 vector.
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Transfections
Retroviral transfections were performed in HEK-293GP2 cells. Cells were plated
at a density of 6 million cells on the day before transfectio n. On the day of transfection,
10.8 μg plasmid was used with 1.2 μg of packaging plasmid, VSV-G (Dr. ZwedilerMcKay’s lab) suspended in Serum free DMEM media. In a separate tube, Genjet was
suspended in serum free DMEM media and later mixed with the tube containing the
plasmid and VSVG. The Genjet-plasmid complex was incubated at room temperature for
20 min. before addition to HEK 293-GP2 cells. After adding the complex to the cells,
they were incubated at 370 C, 5% CO 2 incubator for 45 min. after which complete media
was added. About 8h after incubation, the media was replaced with complete media and
incubated in a 330 C 5% CO 2 incubator for 48-72h. Viral supernatants were collected at
48h and 72h time points.
Lentiviral transfections were performed using HEK 293 F17 cells. Cells were
plates at a density of 6 million cells the day before transfection. On the day of
transfection, 10 μg of DNA, 5ug of envelope plasmid, pMD2.G (addgene) and 5 μg of
packaging plasmid pCMV-dr8.2 dvpr (addgene) were mixed in Opti-Mem Reduced
Serum Media (gibco, Life technologies). In a separate tube, Lipofectamine 2000
(ThermoFischer Scientific) was mixed with Opti-Mem Reduced Serum Media and
incubated at room temperature for 10 min. Plasmid-lipofectamine complex was then
allowed to form for 45 min. at room temperature after which this complex was added to
cells. About 8h after transfection, media was replaced with complete media with serum
and incubated in a 370 C 5% CO 2 incubator for 48-72h. Viral supernatants were collected
at 48h and 72h time points
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Retroviral infections
Retroviral infections were performed on adherent cells plated a day before
infection. Briefly, 300,000 cells were plated in each well of a six well plate before
infections. On the day of the infection, 2 ml of the viral supernatant was added to the
cells after removing the media. This was considered a 100% viral titer. Similar titers were
made at 50%, 25%, and 12.5% by adjusting the amount of viral titer and media such that
the total volume is 2ml in each well. To each well, 2 μl of polybrene (1 mg/ml. Santa
Cruz Biotechnology) was then added. The six well plates were then centrifuged at
12,000g for 1.5 hr at room temperature and incubated at 37 0 C for 48-72h.
Lentiviral infections
Lentiviral infections were performed on non-adherent cells on the day of infection
on 10 cm tissue culture plates. Briefly, 1.5 million cells were suspended in 1ml of
complete media after which 5 ml of viral supernatant was added and plated on 10 cm
dishes. This was considered a 100% viral titer. Similar titers were made at 50%, 25%,
and 12.5% by adjusting the amount of viral titer and media such that the total volume is 6
ml in each 10 cm plate. Each well also had 2.4 μl of polybrene. After transduction, plates
were incubated at 370 C for 12-14h before media was changed to complete media and
incubated for an additional 48-72h.
Clonogenic assays
Clonogenic assays were conducted on 6-well plates. The plating efficiency was
determined for each HNSCC cell line by seeding the cells at different densities in the
wells and allowing them to form colonies over a 10-14 day period. Roughly, 1000-2000
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cells per well were found to be good plating numbers for cell lines used in this assay.
After transduction, cells were sorted for GFP positive cells by flow cytometery and
allowed to recover for 48h. Post recovery, cells were plated at a density of 1000 cells per
well and incubated in a 370 C, 5% CO 2 incubator. About 10-14 days after plating, cells
were washed with PBS twice after removing the growth media and stained with crystal
violet (0.5% w/v) for 5 min. Cells were washed again with water and colonies were
observed under a microscope. A colony was marked if it contained at least 50 cells. By
visual observation, we recorded one colony per well containing 50 cells and set that
colony as the threshold for colony number and size. Later, using the Image J software
(NIH), we measured the size of the marked colony and excluded any colonies that were
smaller than the threshold. Such an analysis allowed us to measure both colony number
and colony size at the same time.
Quantitative Real Time PCR (qRT-PCR)
Total RNA was extracted using RNAqueous ® - 4PCR DNA-free RNA isolation
kit (Ambion, Life technologies). Briefly, cells were scrapped using a scraper after adding
the guanidinium lysis buffer solution. The sample lysate was then mixed with ethanol and
applied to a silica-based filter. This filter selectively and quantitatively binds mRNA and
larger rRNA. Small RNA’s such as tRNA and 5S rRNA are not bound. The filter is
washed to remove residual DNA, protein and other contaminants and the RNA is eluted
in nuclease-free water containing EDTA. Post elution from the filter, the RNA was
treated with ultra-pure DNase 1 to remove any trace amounts of DNA. Finally, using the
DNase Inactivation agent, Dnase and divalent cations are removed. RNA concentration
was measured using NANODROP 2000 spectrophotometer (Thermo Scientific). cDNA
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was prepared by reverse transcription using SuperScript ® First-Strand synthesis
(Invitrogen, Life Technologies) in a Veriti Dx 96-well thermal cycler (Applied
Biosystems, Life technologies) according to the manufacturer’s instructions that included
temperature cycles ranging from 4 0 C to 700 C. FAM-MGB TaqMan PCR primers and
probes specific for HES1, HES2, HES3, HES4, HES5, HEY1, HEY2 and GAPDH were
purchased commercially (ThermoFisher Scientific). A total of 100ng of cDNA was used
per reaction and each reaction was measured in quadruplets using a c1000 Bio-Rad
Thermal Cycler (Bio-Rad). The expression of each target gene was normalized against
GAPDH that was calculated by the ΔCT method (ΔΔCT = [ΔCT of target gene]-[ΔCT of
internal control gene (GAPDH)]) and the fold change of expression was calculated using
the comparative CT method, 2(-ΔΔCT )
Jagged1 and Fc immobilization
Recombinant human Jagged1-Fc chimera was bought from R&D Biosystems.
Recombinant Jagged1 was dissolved in PBS and sterile filtered using 0.22 μm syringe
driven filters (Millex ®- GV). Before coating six well plates with Jagged1 or human IgGFc (control), 1 mg/ml of protein G, (PROSPEC) was added to 1.5 ml of PBS in each well
and incubated at room temperature overnight. Next day, plates were washed with 2ml of
PBS and blocked with 1% Bovine Serum Albumin (Rockland Immunochemicals)
dissolved in PBS for 2h. Plates were then washed with PBS and coated with 10 μg/ml of
recombinant Jagged1 or Fc and incubated either at room temperature for 3.5h or
overnight at 40 C to allow immobilization of Jagged1 or Fc onto the surface after which
cells were cultured on Jagged1 or Fc coated plates. Cells were plated at a density of
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300,000 cells/well for western blot and harvested 72h later or 1000-2000 cells/well for a
clonogenic assay.

Competitive Cell Proliferation Assay
ICN1 and MigR1: Cells were plated at a density of 300,000 cells/ well in six well
plates a day before transduction with ICN1 or MigR1. Retroviral infections were
performed at a low Multiplicity Of Infection (MOI) such that only 30-50% of the cells
are infected with either ICN1 or MigR1. After transduction, cells were allowed to grow
for 72h after which cells were trypsinized. Post trypsinizations, a fraction of the cells
were analyzed for GFP by flow cytometry (100,000 cells with the use of FL1; BD FACS
Calibur) while the rest were plated at a density such that they can be sequentially
passaged every three days for two weeks. FlowJo Software (TreeStar Inc) was used to
calculate the percentage of GFP positive cells in the mixed population.
NFL1: Cells were plated at a density of 300,000 cells per well in six well plates
before transduction with NFL1. Similar to ICN1 and MigR1, cells were infected at a low
multiplicity of infection such that only 30-50% of the cells are infected with NFL1. Three
days post infection, cells were plated on immobilized Jagged1, Fc or uncoated plates.
Seventy two hours after culturing on immobilized ligand coated plates, cells were
trypsinized and a fraction of cells was analyzed by flow cytometry (100,000 cells) while
the rest were replated on Jagged1, Fc or uncoated plates for another three days. FlowJo
Software (TreeStar Inc) was used to calculate the percentage of GFP positive cells in the
mixed population.
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Cell Cycle Analysis
Cell cycle assessment was performed on XL flow cytometer or FACS Calibur or
FACS Fortessa analyzer. The cell cycle data was analyzed on FlowJo software.
Senescence
After transduction and flow sorting, cells were plates at a density of 2000 cells per
well in a 6-well plate and allowed to attach overnight. At day 4 or 6, cells were exposed
to a fixative for 10 minutes, washed again with PBS and incubated with 1ml senescence
staining solution overnight at 370 C.
Orthotopic Mice injections
The Institutional Animal Care and use Committee (IACUC) of the University of
Texas MD Anderson Cancer Center approved all animal experimentation. Our orthotopic
nude mouse tongue model has been previously described in the literature. Nude mice
were obtained from Jackson Laboratories and acclimatized for 2 weeks prior to
injections. HNSCC cell lines HN31, UM47 and PJA34 were transduced with ICN1,
NFL1, MigR1 or dnMAML1 and sorted for GFP positive cells by flow cytometry. Prior
to sorting, cells were optimized using variable titers for the intensity of GFP and
percentage of viable cells such that all viral titers were matched equally. Cells were
allowed to recover for 48h prior to mice injections. 50,000 cells were then injected in the
dorsal tongue of mice in a volume of 30 ul of Serum free DMEM media. Mice were
examined twice a week for 4 weeks where tumor size and weight loss were assessed and
recorded. Tongue tumors were measured with microcalipers, and tumor volume
calculated as (A)(B2 )π/6, where A is the longest dimension of the tumor and B is the
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dimension of the tumor perpendicular to A. At the end of study, mice were euthanized by
CO 2 asphyxiation when they lost more than 20% of their preinjection body weight or 30
days following the initiation of treatment. For immunohistochemical analysis, mice were
sacrificed and tongue tumors were collected. Tissues were then fixed in 4%
paraformaldehyde, paraffin-embedded, sectioned and stained with hematoxylin and eosin
(H&E). Tumor growth and overall survival was measured until mice were sacrificed and
plotted using Graphpad Prism.
Unbiased gene expression analysis
Three biological replicates of two HN cell lines, PJ34 and 183, were treated with
Jagged ligand or control, Fc for 5 days. Table 3 contains detailed sample information.
Gene expression was measured by Affymetrix HuGene 2.0 ST array.
Sample
PJA 34 on Jagged1 (A)
PJA 34 on Jagged1 (B)
PJA 34 on Jagged1 (C)
PJA34 on Fc (A)
PJA34 on Fc (B)
PJA34 on Fc (C)

Cell line
PJA34
PJA34
PJA34
PJA34
PJA34
PJA34

Comment
Treated
Treated
Treated
Control
Control
Control

183 on Jagged1 (A)
183 on Jagged1 (B)
183 on Jagged1 (C)
183 on Fc (A)
183 on Fc (B)
183 on Fc (C)

183
183
183
183
183
183

Treated
Treated
Treated
Control
Control
Control

Table 3: Sample description
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All the data pre-processing steps have been done by the Department of
Bioinformatics at M.D. Anderson Cancer Center by Dr. Jing Wang’s team. A linear
model was fit to each probeset with both treatment and cell line as fixed effects.
Therefore, we started with their preliminary result. Based on these raw p-values, we
modeled them using a beta-uniform mixture (BUM) mode to generate different p-value
cut offs based on selected false discovery rates (FDR). Based on the identified significant
deferentially expressed probesets using the FDR of 0.05, we assessed concordance
correlation of multiple probesets that map to the same gene, and selected only one
probeset for each gene if their expression is inconsistent, and averaged the expression of
those probesets if their expression is consistent. Therefore, we generated one record for
each gene. The RNA-seq data include 279 TCGA Head and Neck cancer patient samples.
The 131 genes of interest were originated from the significant gene list from the
comparison of JAG treated and control HN cells based on Affyymetrix HuGene 2.0 ST
array data. The TCGA RNA-seq data were downloaded from Broad firehose and have
already been processed with RSEM and normalized. We read in the TCGA RNA-seq data
and the genes of interest. We added 1 to the data and did log2 transformation. Then, we
accumulated the data into the one with the expression of the interested genes. There were
131 genes of interest, but we can only find 118 genes that matched in the TCGA data. We
then produced heat maps with Pearson distance and ward linkage based on the data with
279 samples and 118 genes.

62

Antibodies
The antibodies used in this project is outlined in Table 4:
Antibody
Total-NOTCH1
Total-NOTCH2
Cleaved-NOTCH1
P21
ΔNP63
AXL
Phospho-AXL
Gas6
Α-catulin
Flag
HES5
Actin

Source
Santa Cruz
Santa Cruz
Cell Signaling
CalBioChem
Santa Cruz
Cell Signaling
Cell Signaling
Santa Cruz
Santa Cruz
Cell Signaling
AbCam
Sigma

Catalog number
sc 6014
sc 5545
D3E8
OP64
Sc 8431
C89E7
D12B2
sc 1936
sc 390584
2368S
Ab25374
A1978

Concentration
1 to 750
1 to 750
1 to 750
1 to 1000
1 to 1000
1 to 1000
1 to 1000
1 to 1000
1 to 1000
1 to 1000
1 to 100
1 to 2000

Diluent
2.5% Milk-TBST
2.5% Milk-TBST
2.5% Milk-TBST
5% BSA-TBST
2.5% Milk-TBST
2.5% Milk-TBST
2.5% Milk-TBST
5% BSA-TBST
2.5% Milk-TBST
2.5% Milk-TBST
5% BSA-TBST
5% BSA-TBST

Table 4: Antibodies description

Statistical Analysis
The Student t and a one-way ANOVA tests were carried out to analyze in vitro data. For
mouse studies, a 2-way ANOVA test was used to compare tumor volumes between
control and treatment groups. All data were expressed as mean ± standard error, and P <
0.05 was considered significant
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CHAPTER 5: ACTIVATION OF NOTCH
SIGNALING INHIBITS GROWTH
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Chapter 5: Activation of NOTCH signaling inhibits growth
Parts of this chapter are adapted from my previous co-author publication in
Cancer Discovery in 2013 (Pickering et al., 2013). According to the journal: “Authors of
articles published in AACR journals are permitted to use their article or parts of their
article in the following ways without requesting permission from the AACR. All such
uses must include appropriate attribution to the original AACR publication.
Authors may do the following as applicable: Submit a copy of the article to a doctoral
candidate's university in support of a doctoral thesis or dissertation”
Chapter 5.1: NOTCH1 mutational status in HNSCC cell lines
Rationale: NOTCH1 is mutated at a frequency of 15-19% (Agrawal et al., 2011;
Stransky et al., 2011; "TCGA Releases Head and Neck Cancer Data," 2015). To explore
the mutation rate of NOTCH1 in cells, our lab had previously sequenced a panel of 44
HNSCC cell lines that had previously been characterized for TP53 mutations and
tumorigenicity (Sano et al., 2011; Zhao et al., 2011). The spectrum of homozygous
mutations found in NOTCH1 closely mirrored previously sequenced tumors (Agrawal et
al., 2011). Table 5 lists sequencing results for some HNSCC cell lines that included
nonsense mutations (UMSCC47, UMSCC22A, PCI15B), a frame shift (HN4), and a
C478F missense mutation (HN31), which corresponds to an amino acid critical for ligand
binding. However, expression of NOTCH1 at the translational level was not established.
In order to validate the sequencing studies, we evaluated total-NOTCH1 protein
expression levels
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Results: We performed a western blot to evaluate the NOTCH1 protein
expression levels in wild-type and mutant cell lines based on Sanger sequencing (Figure
8). Cell lines that were wild-type for NOTCH1 (PJA34, 183, CAL27, UMSCC1 and
JHU022) expressed the total-NOTCH1 protein, while cell lines mutant for NOTCH1
(HN4, UMSCC22A, UM47 and PCI15B) did not express the protein. HN31 has a C478F
missense mutation and expresses total NOTCH1 but the mutation prevents NOTCH1
from being activated. The results from the western blot corroborate with sequencing
studies and provided us an in vitro model system to manipulate the phenotypic effect of
NOTCH1.
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Cell Line

NOTCH1

UM47

G192X

HN4

A343Fs

HN31

C478F ms

UM22A

E1679X

PCI15B

Q1957X

PJ34

Wt

CAL27

Wt

183

Wt

UMSCC1

Wt

JHU022

Wt

NOM9

Wt

Table 5: NOTCH1 status in HNSCC cell lines

Total-NOTCH1

Figure 8: NOTCH1 protein expression levels in HNSCC cell lines
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Chapter 5.2: Activation of NOTCH1 in mutant HNSCC cell lines is detrimental to cell
growth
Rationale: NOTCH1 is mutated in about 15-19% of HNSCC (Agrawal et al.,
2011; Stransky et al., 2011; "TCGA Releases Head and Neck Cancer Data," 2015).
HNSCC cell lines were previously classified as being mutant or wild-type from Sanger
sequencing and protein expression levels. Based on the spectrum of mutations from
sequencing studies, we know that a subset of HNSCC have an inactive NOTCH pathway.
The functional relevance of these mutations has not been explored. Since mutant HNSCC
cell lines have inactive NOTCH1, we sought to determine the phenotypic effects of
restoring a functional NOTCH signaling pathway in these cells.
Results: Retroviral constructs of the intracellular forms of NOTCH1 (ICN1) that
was cloned into a Murine Stem Cell Driven Vector (MSCV) IRES driven GFP vector
called MigR1 (kindly provided to us by Dr. Zweidler-McKay) was engineered to
overexpress the protein. Additionally, the full- length, wild type NOTCH1 receptor
(NFL1) was cloned into the same parental retroviral vector (MigR1) (Figure 9). Mutant
NOTCH1 bearing HNSCC cell lines HN31, HN4, PCI15B and UMSCC47 were infected
with ICN1 or MigR1 at low multiplicity of infection such that only a small fraction of the
infected population (20-50%) expressed the vector. Using this method, a mixed
population of green and non-green cells was obtained and a competitive cell proliferation
assay (also known as “horserace” assay) was performed. The fraction of green cells in the
mixed population was monitored by flow cytometry and recorded every 3 days. The cells
were sequentially passaged such that some cells were evaluated for GFP by flow analysis
and the rest were cultured for another three days. By doing so, the modulation in GFP
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positive population could be monitored over a 15-day period. The population of cells
expressing GFP was normalized to day three after infection. The fraction of cells having
ICN1 (green cells) progressively declined after infection (Figure 10). At day 15, the
relative fraction of ICN1 cells had been reduced to 40% of its initial value. This
suggested that the population of cells having ICN1 was selected against those cells that
do not express the protein, implying that the activation of NOTCH1 in mutant HNSCC
cells could be disadvantageous to their growth and proliferation. Moreover, the
morphology of cells infected with ICN1 was vastly different from cells infected with
MigR1. Some of these cells were smaller, circular and had a flattened morphology
reminiscent of senescent cells, while others were rounded and spheroid in shape that
eventually detached from the substrate (Figure 11).

69

Figure 9: Retroviral constructs of ICN1, ICN2 and NFL1
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Figure 10: Intracellular NOTCH1 is disadvantageous to the growth of mutant HNSCC
cells.
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Figure 11: ICN1 infected mutant HN31 cells are smaller and rounder and some have a
flattened package-like morphology compared to cells infected with the empty vector
MigR1.
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Chapter 5.3: NOTCH1 activation appears to induce senescence and G1 growth arrest
Rationale: Inhibition of cell growth can be attributed to various factors such as
cell death (apoptosis/necrosis), senescence, cell cycle arrest or mitotic catastrophe. Since
growth inhibition was found in mutant cells after restoration and activation of NOTCH1,
the phenomenon governing the growth arrest was evaluated in these cells. In esophageal
squamous cell carcinoma (ESCC), Kagawa et al. demonstrated that the activated form of
NOTCH1 (ICN1) induced cellular senescence corroborated by G0/G1 cell cycle arrest,
flat and enlarged morphology and senescence associated β-galactosidase activity
(Kagawa et al., 2015). Based on morphology, some cells appeared to have an enlarged,
flat, and pancake-like structure, while some cells exhibited a spheroid apoptotic-like
morphology after restoring ICN1 in mutant HNSCC cell lines.
Results: To evaluate senescence, mutant cells expressing ICN1 and/or MigR1 were
evaluated for β-galactosidase using immunohistochemistry. Nearly 30% of the HN31
ICN1 cells stained positively, indicating that some of these cells do undergo senescence
(Figure 12). Furthermore, western blotting performed three days and five days after
infection with ICN1 or MigR1 revealed increased expression of p21 (marker for
senescence) only in the NOTCH1 mutant cells infected with ICN1 (Figure 13). Cell cycle
analysis demonstrated that the ICN1 infected cells were arrested in the G1 phase of the
cell cycle relative to the MigR1 infected cells (Table 6). In addition, a small percentage
(15%) of the cells were also present at the sub-G0 phase indicating that some of these
cells undergo apoptosis. Taken together, senescence, cell cycle arrest and apoptosis
appear to contribute to the delayed growth in NOTCH1 infected cells.
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10X

10X

Figure 12: Mutant HNSCC cells HN31 undergoes senescence after restoring the
activated form of NOTCH1 (ICN1).
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p21

Actin

Figure 13: Induction of p21 (a marker for senescence and cell cycle arrest) in HN31 cells
infected with ICN1 but not MigR1 at two different time points (D3= Day 3 post infection
and D5=Day 5 post infection)

75

Table 6: ICN1 cells are arrested in the G1 phase of the cell cycle.
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Chapter 5.4: NOTCH1 or NOTCH2 is possibly sufficient to inhibit cell growth
Rationale: NOTCH has four family members; NOTCH 1-4. Among the NOTCH
family members, NOTCH1 is the most frequently mutated in HNSCC (15-19%),
followed by NOTCH2 (2-5%) (Agrawal et al., 2011). NOTCH1 and NOTCH2 mutations
are not mutually exclusive in HNSCC cells. Li et al. demonstrated deletions in the
NOTCH2 genes in HNSCC cell lines and tumors (H. Li et al., 2014). Whether NOTCH1
and NOTCH2 contribute to similar phenotypes is currently unknown. To investigate if
NOTCH2 had any effect on cell growth, the NOTCH1 mutant (HN31) and NOTCH wildtype cell lines (PJA34) were infected either with the empty vector-MigR1, activated form
of NOTCH1 (ICN1) or activated form of NOTCH2 (ICN2).
Results: Cells were transduced and sorted for GFP positive cells such that the
percentage and intensity of GFP was similar in all conditions. Forty-eight hours after
sorting, cells were seeded at 1000 cells per well in 6-well plates for a colony forming
clonogenic assay. After seeding, cells were evaluated for change in morphology every
two days and stained with crystal violet after colony sizes reached about 50 cells in the
control MigR1 plates (12 days after seeding). ICN1 and ICN2 alone were sufficient to
inhibit cell growth compared to the empty vector (MigR1) and parental controls (Figure
13). Parental and MigR1 transduced cells had similar colony number 10 days after
plating, but the colony number and size in cells transduced with ICN1 or ICN2
significantly declined by more than 90%. This suggests that ICN2 may also be sufficient
to inhibit cell growth.
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Figure 14: Activated NOTCH1 or NOTCH2 is sufficient to inhibit growth of HNSCC cell
lines
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Chapter 5.5: Restoration of full-length NOTCH1 is sufficient to inhibit cell growth
Rationale: Transducing cells with activated NOTCH1 is often not ideal since cells
are subjected to non-physiological amounts of the protein. In other cancer types such as
hepatocellular carcinoma (Qi et al., 2003), neuroblastoma (Zage et al., 2012) and B-ALL
(Kannan et al., 2011), the activated form of NOTCH has been used to elucidate growth
inhibitory phenotypes. Although such studies have demonstrated how NOTCH inhibits
growth, to date, the impact of expression of the full-length NOTCH receptor on mutant
NOTCH1 bearing cells has not been evaluated. To test this, the full- length NOTCH1
receptor was cloned in the retroviral system, and the impact of NOTCH1 signaling was
evaluated by growing the cells on plates coated with the NOTCH ligand, recombinant
Jagged1.
Results: NOTCH1 mutant cells HN31 and UMSCC 47 were infected at a low
multiplicity of infection (MOI of 20% to 50%) with retrovirus bearing either full length
NOTCH1 (NFL1-GFP) or the empty vector (MigR1-GFP) such that there was a mixed
population of green and non-green cells. These cells were then cultured on the
recombinant NOTCH ligand, Jagged1 that is fused to an Fc chimera and coated onto
plastic cell culture plates. Jagged1 and Fc were coated on plates the day before seeding
cells. As a control, cells were cultured on the Fc chimera coated plates that is not fused to
Jagged1. Additionally, cells were also plated on plates without Jagged1 or Fc (Uncoated
plates). A competitive cell proliferation assay was then performed by sequentially
passaging these cells every three days on Jagged1, Fc or uncoated (UC) plates and
analyzing GFP positive cell fraction by flow cytometry. The population of NFL1-GFP
positive cells cultured on Jagged1 was suppressed by at least 50% relative to NFL1-GFP
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cells cultured on Fc and uncoated plates (Figure 15Figure 16Figure 17). In sharp contrast,
the fraction of cells infected with MigR1 remained relatively steady through the time
course. Compared to MigR1 infected cells, all cells infected with NFL1 were selected
against the mixed population of cells. This, in part, implies that signaling between NOTH
receptors and endogenous NOTCH ligands contributes to growth inhibition in NFL1
infected cells plated on Fc or uncoated plates. Taken together, these results suggest that
restoration on NFL1 and possible activation of the NOTCH pathway by culturing these
cells on Jagged1 is disadvantageous to the growth of these mutant cells. In order to
investigate long-term growth of these cells, a colony forming clonogenic assay was
performed in which HNSCC cells UM47, HN31 and HN4 were infected with NFL1 or
MigR1 and sorted by flow cytometry to obtain a pure population of green cells. After
sorting, these cells were cultured at a low density (1000 cells/well in 6-well plates) on
Jagged1 or Fc coated plates for a 10-day period. The cells were then stained with crystal
violet after 10 days and the number of colonies (a colony was defined as one having at
least 50 cells) were counted. Mutant cells infected with NFL1 and cultured on Jagged1
were significantly growth inhibited compared to those cultured on Fc and the MigR1
infected controls (

Figure 18). Based on these findings, it was hypothesized that this inhibition in cell
growth is mediated by the activation of NOTCH signaling. To test this, a western blot
was performed on these mutant cell lines after infection with NFL1 or MigR1 and
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culturing on Jagged1 or Fc. Mutant cell lines infected with NFL1 cultured on Jagged1
expressed high levels of cleaved (activated) NOTCH1, while cells infected with the
empty vector did not induce cleavage of NOTCH1 (Figure 19). The presence of cleaved
NOTCH1 only in mutant cell lines infected with NFL1 suggests that activation of the
NOTCH signaling pathway contributes to the growth inhibitory phenotype. Maximal
induction of cleaved NOTCH1 was observed in NFL1 infected mutant cells cultured on
Jagged1, however, we also observed cleaved NOTCH1 induction in NFL1 infected cells
cultured on Fc and uncoated plates as well. This confirms the phenotype previously seen
in the competitive cell proliferation assays (Figure 15Figure 16Figure 17) that activation
of the NOTCH pathway through endogenous ligand contributes to inhibition of growth.
Previously, while using ICN1, we observed that mutant cells underwent senescence
(Figure 12). We examined if a similar phenomenon also occurs after restoring the fulllength NOTCH1 protein. Similar to our previous results, we observed that mutant cells
with NFL1 cultured on Jagged1 stained positive for β-galactosidase indicating that
restoration of NFL1 and activation of the pathway by Jagged1in mutant cells possibly
contributes to senescence mediated growth arrest. On the contrary, Jagged1 mediated
senescence was not observed in MigR1 infected cells. Mutant cells infected with NFL1
cultured on Fc also did not exhibit a senescent morphology. Although these cells express
modest cleaved NOTCH1 levels and are growth inhibited compared to MigR1 infected
cells, it is possible that the expression levels of NOTCH1 was not strong enough to
induce senescence.
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Figure 15: The fraction of mutant cells restored with NFL1 decreases progressively
compared to cells infected with the empty vector. UM47 mutant cells infected with NFL1
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while
cells infected with MigR1 remains steady through the 23 day time period.
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Figure 16: The fraction of mutant cells restored with NFL1 decreases progressively
compared to cells infected with the empty vector. HN4 mutant cells infected with NFL1 is
selected against a mixed population of NFL1 and non-NFL1 expressing cells while cells
infected with MigR1 remains steady through the 23 day time period.
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Figure 17: The fraction of mutant cells restored with NFL1 decreases progressively
compared to cells infected with the empty vector. HN31 mutant cells infected with NFL1
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while
cells infected with MigR1 remains steady through the 23 day time period.
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Figure 18: Restoration of NOTCH1 inhibits cell growth. Inhibition in the number of
colonies of mutant cells after restoration with NFL1 and culture on Jagged1. (a:
quantitation of clonogenic assay, b: crystal violet staining of colonies)
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Figure 19: NOTCH1 is activated only in mutant cells infected with NFL1 but not MigR1.
Restoration of NFL1 in mutant cell lines induces cleavage of NOTCH1 when cultured on
Jagged1 but not on Fc or uncoated plates.
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Figure 20: HN31, HN4 and UMSCC22A mutant HNSCC cells undergo senescence after
restoring NFL1 and culturing on Jagged1
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Chapter 5.5: Activation of the NOTCH signaling pathway in wild-type cell lines
inhibits cell growth

Rationale: We previously demonstrated that restoration of NOTCH signaling in
mutant HNSCC cells inhibits cell growth. NOTCH1 is mutated in about 15-19% of
HNSCC (Agrawal et al., 2011; Stransky et al., 2011; "TCGA Releases Head and Neck
Cancer Data," 2015), however, majority of the tumors have wild-type NOTCH1.
Although these tumors express the wild-type receptor, the NOTCH pathway may not be
activated due to alterations is Jagged1, overexpression of NUMB, improper
glycosylation, or proteosomal degradation. Thus, we wanted to investigate the functional
relevance of activating the NOTCH pathway in a wild-type setting. To activate the
NOTCH pathway, wild-type cells were cultured on Jagged1 and hypothesized that
Jagged1 would induce growth inhibition in wild-type cells similar to the mutant cells.
Results: PJA34 and CAL27 NOTCH1 wild-type cells were cultured on
recombinant Jagged1 or Fc coated plates. Jagged1 and Fc were coated on cell culture
plates the day before seeding. Both wild-type cell lines were plated at a low density to
observe morphology change and colony formation. Cells cultured on Jagged1 appeared to
be slower in growth, small, and spherical (Figure 21). Similar to the mutant cells, a small
fraction of wild-type cells when cultured on Jagged1 appeared flattened and exhibited a
pancake-like morphology. These cells stained positive for β-galactosidase indicating that
NOTCH activation may result in some cells undergoing senescence (Figure 21).
Moreover, when protein expression levels for cleaved NOTCH was evaluated by western
blotting, activation of NOTCH signaling was observed only in cells cultured on Jagged1
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but not on Fc (Figure 22). These results imply that activation of the NOTCH signaling
pathway in wild-type cells might be responsible for aberrations in cell morphology. To
measure the long term effects of activating NOTCH signaling in these cells, a colony
forming clonogenic assay was performed in which wild-type cell lines (PJA34, 183,
CAL27 and UMSCC1) were cultured on Jagged1 or Fc for a 10-day period. All wild-type
cell lines were significantly growth inhibited when cultured on Jagged1 (Figure 23).
Furthermore, cleaved NOTCH1 expression was observed only in cells cultured on
Jagged1 but not Fc. Taken together, the change in morphology, growth inhibition and
expression of cleaved NOTCH1 was evident only in wild-type cells cultured on Jagged1
suggesting that NOTCH activity induces these changes. To confirm that NOTCH
signaling does indeed play a role in modulating cell growth, NOTCH activation was
inhibited using the γ-secretase inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl)-Lalanyl]-S-phenylglycine t-butyl ester) at two different concentrations (2μM and 10μM) in
CAL27 and PJA34 wild-type cell lines after culturing them on Jagged1 or Fc. After
addition of DAPT, a reversal in growth inhibition was observed when cell were cultured
on Jagged1 (Figure 24). This result suggests that NOTCH activation might be necessary
for growth inhibition. Since inhibition of γ-secretase may exert a dose dependent effect,
the wild-type cell lines PJA34 was infected with the dominant negative form of
Mastermind- like 1 (MAML1) that has a mutation that prevents MAML1 from binding to
ICN, thus physiologically blocking the NOTCH pathway. After sorting infected cells to
obtain a pure population of dnMAML1-GFP cells, PJA 34 dnMAML1 cells were
cultured on Jagged1 or Fc using parental PJA34 cells as controls. PJA34 parental cells as
observed before had suppressed levels of cell growth when cultured on Jagged1

89

compared to Fc. However, dnMAML1 was able to reverse the Jagged1 mediated growth
inhibition (Figure 25). Both approaches to inhibit NOTCH signaling (GSI and
dnMAML1) showed a reversal of Jagged1 mediated cell growth inhibition. In addition to
these approaches, we also employed the CRISPR-Cas9 system to knock out NOTCH1
and NOTCH2 in PJA34 cell lines. This system was used not only to knockout both
NOTCH isoforms, but also to determine which specific NOTCH member (NOTCH 1 or
NOTCH 2) mediates growth inhibition. Using this technique, stable knockouts of either
or both NOTCH receptors was achieved (Figure 26). To determine cell growth potential,
PJA 34 parental cells, NOTCH1 knockout cells (NOTCH1 KO), NOTCH2 knockout
(NOTCH2 KO) cells and NOTCH1/NOTCH2 double knockout cells (dKO) were
cultuted on Jagged1 or Fc in a colony forming assay. Knocking out either NOTCH1
(NOTCH1 KO) or NOTCH2 (NOTCH2 KO) in PJA34 cells did not relieve the growth
inhibition relative to parental cells on Jagged1. However, knocking out both NOTCH1
and NOTCH2 (double knockout- dKO) significantly reversed Jagged1 mediated growth
inhibition (Figure 27). The CRISPR-Cas9 knockout studies suggested that both NOTCH1
and NOTCH2 are required for inhibiting cell growth. To show that NOTCH signaling is
sufficient to inhibit cell growth, full length NOTCH1 (NFL1) was infected in the double
knockout (dKO) PJA34 cell line to evaluate cell growth in a colony forming clonogenic
assay. Abrogation in protein expression levels of total NOTCH1 and cleaved NOTCH1
was observed in PJA34 dKO cells cultured on Jagged1 or Fc (Figure 28). However, after
restoration of NFL1 in PJA34 dKO cells, the abrogation in protein expression levels of
total-NOTCH1 and cleaved NOTCH1 was rescued (Figure 28) suggesting restoration of
the pathway. Next, PJA34 parental cells, dKO cells and dKO cells after restoration of
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NFL1 (dKO+NFL1) were subjected to a clonogenic assay on Jagged1 or Fc. As expected,
PJA34 parental cells on Jagged1 was growth suppressed that was abrogated by PJA34
dKO cells cultured on Jagged1 and Fc. However, restoration of NFL1 in the double
knockout (dKO+NFL1) cell lines suppressed growth similar to the parental cells when
cultured on Jagged1 and rescued the PJA34 dKO phenotype (Figure 29). Taken together,
we have shown that NOTCH activation in wild-type cells inhibits cell growth and that
NOTCH1 is necessary and sufficient to inhibit cell growth in vitro.
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Figure 21: Morphology change and senescence when NOTCH1 wild-type are cultured on
Jagged1. Culture of wild-type cell lines on Jagged1 shows small, rounded and growth
inhibited colonies, some of which undergo senescence compared to cells cultured on Fc.
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Figure 22: Protein expression of Total-NOTCH1 and cleaved NOTCH1: Western blot
depicting total NOTCH1 (Tm-NOTCH1) in wild-type and mutant cell lines and cleaved
NOTCH1 (cl-NOTCH1) expression in wild-type cell lines cultured on Jagged1
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Figure 23: Wild-type cell lines cultured on Jagged1 are significantly growth inhibited
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Figure 24: Inhibition of NOTCH signaling using γ-secretase inhibitor reverses NOTCH
mediated growth suppression.
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Figure 25: dnMAML1 reversed Jagged1 mediated growth inhibition
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Figure 26: CRISPR-Cas9 knockout of NOTCH1 (NOTCH1 KO), NOTCH2 (NOTCH2
KO) or both
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Figure 27: Knocking out both NOTCH and NOTCH2 relieves Jagged1 mediated growth
suppression. KO: Knockout
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Figure 28: Restoration of NFL1 in the double knock out cell line activates NOTCH
signaling: CRISPR-Cas9 double knockout cell line PJA34 shows activation of NOTCH
signaling after restoration with NFL1 and culturing cells on Jagged. KO: Knockout
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Figure 29: NOTCH signaling is necessary and sufficient to modulate cell growth.
CRISPR-Cas9 NOTCH1 and NOTCH2 double knockout cell line PJA 34 promotes
growth on Jagged1 and Fc that is inhibited after restoration with NFL1.
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Chapter 5.6: Restoration of NOTCH signaling in mutant HNSCC cell lines inhibits in
vivo tumorigenecity

Rationale: We have demonstrated that activation of the NOTCH signaling
pathway in mutant and wild-type HNSCC cell lines inhibits in vitro cell growth abilities.
To evaluate in vivo tumor growth of mutant cell lines after restoration with NOTCH1, we
infected mutant cell lines HN31 and UM47 with ICN1 or NFL1 and hypothesized that
restoration of NOTCH signaling would inhibit in vivo tumor forming ability. Tumor
forming ability was evaluated in an orthotopic tongue model of oral cancer.
Results: NOTCH signaling was restored in mutant cell lines HN31 and
UMSCC47 using full- length NOTCH1 (NFL1) or the intracellular form of NOTCH1
(ICN1). The empty vector MigR1 and parental cells were used as controls. After
retroviral infections with ICN1, NFL1 and MigR1, cells were sorted for GFP by flow
cytometry. Forty-eight hours after sorting later, 50,000 cells were injected per mouse
cells into the dorsal right region of the tongue in nude mice. Ten mice were injected in
each condition. We then monitored tumor formation for a 25 day period measuring tumor
size every 3 days. Mutant cells infected with NFL1 or ICN1 when injected in mice had
significantly lower tumor volumes and an increase in overall survival was observed
(Figure 30a and b). At the end of the 25 day period, the tumor volume in NFL1 and ICN1
injected mice was less than 50% compared to the parental and empty vector (MigR1)
controls. The effect was even pronounced in cells having ICN1 (blue dashed line in the
graph of Figure 30a) compared to NFL1 cells (although there was no significant
difference between ICN1 and NFL1) and these mice began to form tumors only 20 days
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post injection. The slow-growing in vivo tongue tumors derived from mutant UM47
infected with NFL1 expressed NOTCH1 (Figure 31a), grew in a more organized fashion
than control MigR1 infected cells lacking NOTCH1 protein (Figure 30b), and had
frequent keratin pearls (Figure 30c) suggesting increased differentiation compared to
MigR1 infected tumors which had higher tumor cellularity (Figure 30d). These results
suggested that in addition to inhibiting in vivo tumor forming ability, NOTCH activation
in vivo can also induce differentiation, in part, explaining the reduction in cell growth.
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Figure 30: Restoration of NOTCH signaling in mutant HNSCC cell lines inhibits tumor
growth (a) and increases overall survival (b) in a xenograft orthotopic model of oral
cancer
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Figure 31: NFL1 infected UM47 tumor xenografts appear more differentiated. Mutant
UM47 infected with NFL1 (a, c) grew slowly in mouse tongues compared to UM47
infected with control MigR1. (b, d). Anti-total NOTCH 1 staining (brown) of NFL1infected (a) or MigR1 infected (b) tumors. Growth of NFL1-infected tumors was more
organized (c) and had keratin pearls (arrows) compared to MigR1 infected tumors,
apparent after H&E stain
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Chapter 5.7: Inhibition of NOTCH signaling enhances tumor growth in vivo
Rationale: I previously showed that NOTCH1 is sufficient to inhibit tumor
growth. Proweller et al. demonstrated that in mouse keratinocytes, expression of the panNOTCH inhibitor dominant negative Mastermind like-1 (dnMAML1) resulted in a
hyperplastic epidermis and spontaneous development of cutaneous squamous cell
carcinoma (cSCC) (Proweller et al., 2006). Their results imply that in tumor types
wherein NOTCH acts as a tumor suppressor (such as skin cancer in this case),
transcriptional inhibition of this pathway accelerates tumor growth. On the contrary, in
pancreatic cancer, NOTCH acts as an oncogene. In this cancer type, it was shown that
dnMAML1 delays the formation of pancreatic intraepithelial neoplasia (Thomas et al.,
2014). Taken together, dnMAML1 appears accelerate or inhibit tumorigenesis in cancers
in which NOTCH acts as a tumor suppressor and oncogene respectively. In HNSCC,
since NOTCH1 has inactivating mutations similar to cSCC (Pickering et al., 2014), I
hypothesized that abrogation of all NOTCH signaling would exacerbate tumor formation.
To determine the comprehensive function of NOTCH mediated growth suppression and
overcome potential redundancies between receptors, I proposed to abrogate some of
canonical (LAG1-CSL- dependent) NOTCH signaling using dnMAML1 in a NOTCH
wild-type cell line that is non-tumorigenic in mice.
Results: I infected PJA34 cells with dnMAML1 (MigR1-GFP-tagged) or with the
empty vector MigR1 and sorted these cells to obtain a pure population GFP positive cell
by flow cytometery. The transductions were performed such the percentage and intensity
of GFP cells were equal in all conditions. In addition, I also transduced Jagged1, the
ligand for the NOTCH receptor in the same cell line before mice injections. Twelve days

105

post injection in the dorsal tongue of mice, tumors in the dnMAML1 and Jag1 group
began to develop. By end of 20 days, tumor volumes in the Jag1 and dnMAML1 mice
were significantly larger than the control groups (Figure 26). Although only 5/10
dnMAML1 formed tumors, the growth of these tumors was significantly larger than the
parental and MigR1 group. Jagged1 and NOTCH receptor in the same cell can potentially
result in cis-inhibition (Cordle et al., 2008). It might be possible that cis-inhibition rather
than trans activation in PJA34 cells overexpressing Jagged1 contributes to accelerated
tumor growth. To address the issue of cis-inhibition, we co-cultured wild-type parental
cells with wild-type Jagged1 overexpressing cells. We performed a western blot to
evaluate expression levels of cleaved NOTCH1. Parental cells expressed very little
cleaved NOTCH1, while parental cells mixed with Jagged1 overexpressing cells had
higher amounts of cleaved NOTCH1 (Figure 27). Interestingly, levels of cleaved
NOTCH1 was lower in Jagged1 overexpressing cells. This suggests that although there
might have been some cis-inhibition in parental-Jagged1 mixed cells, there was more
transactivation resulting in cleaved NOTCH1. In Jagged1 overexpressing cells, cis
inhibition might have possibly resulted in lower levels of cleaved NOTCH1. In mice,
when Jagged1 cells were injected, there might have been greater cis-inhibition than transactivation resulting in increased tumor volumes. Since MAML1 exerts its effects in the
nucleus, it might be possible that there was no little or nuclear localization of dnMAML1
after transduction in these cells. I did not determine the nuclear presence of dnMAML1 in
these cells, thus, in 50% mice that did not form tumors in the dnMAML1 group,
dnMAML1 may have not have translocated to the nucleus.
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Figure 32: NOTCH signaling may be necessary for inhibiting tumor growth.
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Figure 33: Possibility of cis-inhibition when PJA34 and 183 cells are overexpressed
with Jagged1
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Discussion
In this chapter, for the first time the growth inhibitory effects after restoration of
NOTCH signaling in mutant and wild-type NOTCH1 expressing HNSCC cell lines has
been demonstrated. In addition, we found that NOTCH1 is sufficient to inhibit
tumorigenicity and might also be necessary for mediating inhibitory growth signals.
Using the activated form of NOTCH (ICN1) and the full- length NOTCH1 (NFL1), it has
been shown that NOTCH1 is sufficient to inhibit in vitro growth by competitive cell
proliferation assays and clonogenic assays. In Acute Myeloid Leukemia (AML), Kannan
et al. have shown that ICN1 induces growth arrest through a competitive cell proliferation
assay (Kannan et al., 2013). Moreover they have shown arrest of cells in the G1 phase of
the cell cycle, which is also consistent with our data. Since NOTCH1 acts as a tumor
suppressor in AML, our results corroborate with previously reported findings. The
reason for growth inhibition is not completely understood. As we have shown,
senescence in part contributes to growth arrest, while a small fraction of cells also under
cell death. Devgan et al. have shown that in keratinocytes, p21 is downstream of
NOTCH1 signaling and regulates keratinocyte growth (Devgan, Mammucari, Millar,
Brisken, & Dotto, 2005). Although we have also shown an induction in p21 when
NOTCH1 is activated, it doesn’t completely account for growth inhibition since only
30% of the cells undergo senescence. More than 60% of the cells were arrested in the G1
phase of the cell cycle and about 15% in the sub-G0 phase after transduction with
activated NOTCH1 (ICN1). Kannan et al. have shown that in B-ALL, NOTCH signaling
induces PARP mediates apoptosis (Kannan et al., 2011). Since only 15% of cells were
arrested in the sub-G0 phase, the apoptotic mechanism was not further investigated.
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When using a more physiological full- length NOTCH1 (NFL1), the growth inhibitory
effects mirrored ICN1. Even in this case the percentage of senescent cells was lower
suggesting that there might be other mechanisms besides senescence and cell death
contributing to growth arrest. Indeed, the role of NOTCH in differentiation cannot be
discounted because in mice that were injected with mutant cells having NFL1 or ICN1,
the formation of keratin pearls representative of a differentiated phenotype were
observed. Thus, it is possible that such induction in differentiation may contribute to
growth arrest. Rangarajan and colleagues (Rangarajan et al., 2001) used a tamoxifen
inducible system to delete the NOTCH1 gene in the keratinocytes of mice. They show
that NOTCH1 promotes differentiation, transcriptionally up regulates p21 and inhibits
keratinocyte growth (Rangarajan et al., 2001). Their results confirm our findings of
NOTCH1 inducing p21, inhibiting tumor growth and possibly activating a differentiation
program. Furthermore, we have shown that either the intracellular form of NOTCH1 or
NOTCH2 (ICN1 or ICN2) may be sufficient to inhibit cell growth. NOTCH2 is mutated
at a lower frequency compared to NOTCH1 and these mutations are not mutually
exclusive. Thus, there is a possibility that in tumors that have an intact NOTCH1,
mutations in NOTCH2 may contribute to tumor progression. Our findings indicate that
both ICN1 and ICN2 can contribute to growth inhibition. To represent a more
physiological condition, the full-length NOTCH2 needs to be cloned and experiments
similar to NFL1 must be performed which is part of our future directions. NOTCH1 and
NOTCH2 may be required for growth inhibition. To prove that both these isoforms may
be necessary, the NOTCH signaling pathway was inhibited by expression of the panNOTCH inhibitor, dnMAML1. In a weakly tumorigenic NOTCH1 wild-type cell line,
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inhibiting the NOTCH signaling pathway increased tumor growth but this effect was seen
only in 50% of the mice injected. dnMAML1 has been shown to induce basal hyperplasia
impairing squamous differentiation in mouse esophageal epithelium (Ohashi et al., 2010).
In our system, we might have to evaluate the nuclear localization of dnMAML1. Since
dnMAML1 suppresses the transcriptional activity of NOTCH in the nucleus, it is possible
that the lack of nuclear localization after transduction in cells prevents NOTCH pathway
inhibition. In light of this caveat; to better inhibit the pathway we have stably knocking
out NOTCH1, NOTCH2 or both using the CRISPR-Cas9 approach. For the first time, we
demonstrate the use of CRISPR technology to knock out the NOTCH gene in HNSCC
cell lines and show that knocking out both NOTCH1 and NOTCH2 relieves growth
suppression in vitro. Furthermore, we have also demonstrated that restoring NOTCH1 in
double knock out cells rescues abrogation of growth inhibition, implying that NOTCH1
is necessary and sufficient to modulate cell growth. In future studies, we will examine
the in vivo tumorgienecity after injected these cells in mice and hypothesize that
knocking out both NOTCH1 and NOTCH2 would exacerbate tumor growth.
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CHAPTER 6: DOWSNTREAM EFFECTORS
OF NOTCH MEDIATED GROWTH
INHIBITION
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Chapter 6: Downstream effectors of NOTCH mediated growth inhibition
Chapter 6.1: AXL and CTNNAL1 (α-catulin) are downstream of NOTCH signaling
Rationale: In Chapter 5, the effects of activating the NOTCH signaling pathway
in wild-type and mutant cell lines was elucidated and its growth suppressive effect was
demonstrated. There are several mediators of cell growth and diverse signaling cascades
involved in regulating cell growth and proliferation. Previous publications have
extensively detailed the oncogenic role NOTCH in breast, pancreatic cancer and T-ALL.
Others have characterized NOTCH as a tumor suppressor in skin, esophageal cancer, BALL and hepatocellular carcinoma. For example, in B-ALL, Kannan et al. examined the
role of NOTCH inducing HES1 and PARP mediated apoptosis (Kannan et al., 2011).
Rangarajan and colleagues have described the role of p21 in contributing to NOTCH
induced differentiation and growth arrest (Rangarajan et al., 2001). In esophageal cancer,
Kagawa et al. attributed a p16 –Rb pathway or a p14-p53 pathway to senescence
(Kagawa et al., 2015). To date, the mechanism of NOTCH acting as a tumor suppressor
in HNSCC has not been explored. Identifying modulators downstream of the NOTCH
pathway would help in targeting certain molecules that are upregulated in the absence of
NOTCH signaling, and could potentially lead to better-targeted therapeutics. We had
previously shown the induction of p21 as a possible potential downstream target of
NOTCH1 based on the senescent morphology observed after activation with ICN1 in one
mutant cell line (HN31). To identify the downstream modulators of the NOTCH
signaling pathway in an unbiased fashion, we performed a microarray after activating the
NOTCH pathway in two wild-type cell lines PJA34 and 183 by culturing them on
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Jagged1 for 5 days. Subsequently, the Affymetrix 2.0 gene array was used to evaluate
gene expression.
Results: Each condition was performed in biological triplicates and normalized
before analyzing differences for expression between genes when these wild-type cells
were cultured on Jagged1 compared to Fc. We used the BRB-ArrayTools in a univariate
test. All the data pre-processing steps were performed by the Department of
Bioinformatics (M.D. Anderson Cancer Center). Linear model was fit to each probeset
using both treatment (culture on Jagged1 or Fc) and cell lines (PJA34 and 183) as fixed
effects. Based on the raw p-values, they generated a model using beta-uniform mixture
(BUM) to generate different p-value cut-offs based on a False Discovery Rate (FDR) of
0.05. Using this FDR, based on the identified significantly modulated probesets,
concordance correlation of multiple probesets that map to the same gene was evaluated.
Only one probeset for each gene was selected if their expression was inconsistent. If their
expression was consistent, an average of the expression of those probesets was reported.
We found 1808 genes to be differentially regulated when comparing both
treatment and cell line conditions (Appendix 1). There are 277 differentially expressed
genes that have treatment effects (Jagged1 versus Fc) without cell line difference (PJA34
versus 183). Appendix 1 contains the average expression of 1808 differentially expressed
genes including the p-value and the relative fold change of the treated group to the
control group (relative to Fc). Out of these 1808 genes, we filtered genes that had more
than a 1.4 fold difference in gene expression when these cells were cultured on Jagged1
versus Fc. Based on this filter, we narrowed the number of genes to 120 of which 50
genes were upregulated and 70 genes were downregulated by Jagged1 induced NOTCH
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activation (Table 7). Some of the genes that were upregulated when NOTCH was
activated are tumor suppressor genes like EPHA4, TP53INP1, PDCD 4, KRT4, KRT13
while genes that were downregulated when NOTCH was activated include AXL, MMP9,
INTGA3, LAMC2 and CTNNAL1 among others. The set of 120 altered genes was then
subjected to an unbiased core analysis using the Ingenuity Pathway software (IPA) to
identify the most significantly altered cellular functions and pathways (Table 8). Based
on the Ingenuity Pathway analysis, the three most significantly altered pathways when
NOTCH is activated is cell movement (P= 2.7 e-12) followed by cell growth and
proliferation (P=3.95 e-11) that was followed by cell adhesion/interaction (P=8.05e-10).
Our finding that cell growth and proliferation was one of the significantly altered
phenotypes validated our previous report (Chapter 5) of NOTCH significantly affecting
cell growth and tumor progression. The current microarray analysis extends our earlier
report to identify potential candidate genes that might be involved in modulating cell
growth. Based on the significance of change (P-values), intensity of change (1.4 fold
threshold) and novelty of these candidate targets with NOTCH1 (based on literature
published), we identified two proto-oncogenes that were down modulated when NOTCH
was activated. AXL was the most significantly altered gene in both cell lines (6.41e-9)
and had approximately 3-fold downregulation when NOTCH was activated by Jagged1.
CTNNAL1 (α-catulin) had the highest downregulation among all genes in the 183 wildtype cell line (24 fold). We were interested in genes suppressed by NOTCH signaling
since these genes may be potentially targeted therapeutically and thus investigated the
modulation of AXL and α-catulin after NOTCH activation.
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Official Gene
Symbol

Gene Symbol
used in TCGA
TCGA

Regulation
by
NOTCH
activation

P-value

Fold
change
in
PJ34

Fold
change
in 183

CAV1

CAV1

3.59E-09

-1.88

-2.21

AXL

AXL

6.41E-09

-2.74

-3.55

FHL2

FHL2

1.15E-07

-1.79

-2.05

CMTM8

CMTM8

1.64E-07

-1.47

-1.62

SERPINE1

SERPINE1

2.07E-07

-2.74

-2.22

PTRF

PTRF

3.53E-07

-2.02

-2.16

NAV3

NAV3

4.33E-07

-2.02

-1.84

LAMC2

LAMC2

5.09E-07

-2.60

-4.66

DRAM1

DRAM1

5.62E-07

-1.88

-2.08

AFAP1L2

AFAP1L2

6.00E-07

-1.49

-1.60

NETO2

NETO2

1.31E-06

-1.79

-1.59

TMCC3

TMCC3

2.29E-06

-1.72

-1.88

SEMA7A

SEMA7A

2.29E-06

-1.57

-1.59

ITGA5

ITGA5

2.34E-06

-1.55

-1.67

HOMER3

HOMER3

2.38E-06

-1.61

-1.46

ZBED2

ZBED2

2.55E-06

-1.89

-1.70

SYT16

SYT16

2.68E-06

-1.76

-1.62

SLC16A2

SLC16A2

3.34E-06

-1.80

-2.57

FGFBP1

FGFBP1

Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated

3.66E-06

-1.84

-2.19
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FHOD1

FHOD1

ITGA3

ITGA3

PXN

PXN

PKP2

PKP2

THSD4

THSD4

KLK6

KLK6

SOX15

SOX15

PLEK2

PLEK2

MOBKL2B

MOBKL2B

LOXL2

LOXL2

PLAUR

PLAUR

MMP9

MMP9

UPP1

UPP1

LOXL4

LOXL4

SLC7A2

SLC7A2

TMEM27

TMEM27

ANKRD2

ANKRD2

AP2B1

AP2B1

LEPREL1

LEPREL1

SLC39A14

SLC39A14

CD55

CD55

HEG1

HEG1

PI4K2A

PI4K2A

Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated

3.75E-06

-1.44

-1.47

5.03E-06

-1.56

-1.88

5.48E-06

-1.51

-1.83

5.73E-06

-1.51

-1.54

6.42E-06

-1.50

-1.54

1.11E-05

-1.83

-1.76

1.34E-05

-1.76

-1.40

1.86E-05

-1.79

-1.61

1.94E-05

-1.58

-1.52

2.16E-05

-2.49

-1.63

2.35E-05

-1.91

-1.74

2.35E-05

-1.60

-2.53

2.80E-05

-1.43

-1.55

2.94E-05

-3.12

-1.80

3.00E-05

-1.50

-2.24

3.16E-05

-1.63

-1.48

3.72E-05

-1.67

-1.56

4.28E-05

-1.43

-2.22

6.37E-05

-1.63

-1.51

6.56E-05

-1.46

-2.26

8.36E-05

-1.42

-1.73

8.76E-05

-1.49

-1.87

9.68E-05

-1.49

-1.40
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FST

FST
FAM55C

NXPE3
VEGFC

VEGFC

SIRPA

SIRPA

KIRREL

KIRREL

OLR1

OLR1

KIAA0040

KIAA0040

CYR61

CYR61

VLDLR

VLDLR

RAB32

RAB32

TIMP4

TIMP4

ABCG2

ABCG2

FAM101B

FAM101B

MFAP5

MFAP5

NT5E

NT5E

COL17A1

COL17A1

CPA4

CPA4

EMP3

EMP3

CTNNAL1

CTNNAL1

TIMP3

TIMP3

CDH13

CDH13

FAM46B

FAM46B

IL6R

IL6R

Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated

0.00010061

-1.99

-5.32

0.000109425 -1.52

-1.69

0.000109475 -2.01

-1.50

0.000121239 -1.80

-1.42

0.000126131 -1.77

-1.46

0.00013061

-6.59

-2.08

0.000150652 -1.55

-1.46

0.000154488 -1.92

-1.70

0.00018433

-1.58

-2.03

0.000209603 -1.48

-1.80

0.000261133 -1.40

-1.46

0.000307053 -1.84

-6.60

0.000374899 -2.28

-1.45

0.000455964 -1.48

-3.14

0.000464717 -1.48

-2.34

0.000479488 -1.43

-3.37

0.000582963 -1.45

-1.56

0.000688038 -2.13

-1.53

0.0009852

-24.86

-2.12

0.001204042 -1.54

-1.41

0.001276195 -1.61

-1.45

0.001472671 -1.41

-1.65

0.002073781 -1.61

-1.63
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HBEGF

HBEGF

EREG

EREG

EPHA2

EPHA2

FOSL1

FOSL1

B4GALT6

B4GALT6

BCL6

BCL6

TNKS

TNKS

HLA-DRA

HLA-DRA

SCARNA9

SCARNA9

LONP2

LONP2

SCARNA17

SCARNA17

GUSBP3

GUSBP3

AKR1C3

AKR1C3

ZNF117

ZNF117

MUC16

MUC16

PGLYRP4

PGLYRP4

IKZF2

IKZF2

DLX5

DLX5

KRT4

KRT4

PRODH

PRODH

MYH14

MYH14

TXNIP

TXNIP

KLHL24

KLHL24

Down
regulated
Down
regulated
Down
regulated
Down
regulated
Down
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated

0.002619748 -1.44

-1.72

0.003182918 -1.93

-1.46

0.003589923 -1.49

-1.62

0.004399443 -2.54

-1.82

0.004750404 -1.46

-1.50

0.002698801 1.61

1.49

0.002485846 1.77

1.41

0.001875278 3.39

1.50

0.001560804 2.16

1.53

0.001107504 1.45

1.41

0.00090611

1.47

1.67

0.000559537 1.50

1.46

0.00054151

1.52

1.76

0.000509494 1.63

2.63

0.000431455 2.03

1.47

0.000373443 1.44

2.23

0.00033363

1.41

1.45

0.000332635 1.77

1.64

0.000263173 2.00

7.95

0.00016933

1.83

1.59

0.000141238 1.57

1.73

0.000124053 2.63

1.67

0.00010392

1.55

1.74
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KRT13

KRT13

GOLGA8A

GOLGA8A

GLUL

GLUL

TMEM45B

TMEM45B

GOLGA8B

GOLGA8B

MANSC1

MANSC1

FAM102B

FAM102B

DSP

DSP

PRKX

PRKX

PCMTD2

PCMTD2

CNKSR3

CNKSR3

GCLC

GCLC

RNF138P1

RNF138P1
KIAA1370

FAM214A
HES5

HES5

ST6GALNAC2

ST6GALNAC2

ACPP

ACPP

SLC12A2

SLC12A2

PBX1

PBX1

CYP1A1

CYP1A1

PPAP2A

PPAP2A

TNFSF10

TNFSF10

KIAA1147

KIAA1147

Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated

9.57E-05

1.77

3.60

7.85E-05

1.70

1.40

6.63E-05

1.67

1.43

6.02E-05

1.43

2.06

4.87E-05

1.76

1.43

4.58E-05

1.56

1.73

2.85E-05

1.66

1.41

2.46E-05

1.47

1.65

2.37E-05

1.56

1.66

2.07E-05

1.41

1.48

1.67E-05

1.41

1.92

1.57E-05

1.77

1.41

1.42E-05

2.98

2.43

1.28E-05

1.41

1.46

1.15E-05

1.46

1.64

1.15E-05

1.46

1.57

9.76E-06

1.62

1.44

8.22E-06

1.57

2.29

7.54E-06

1.64

1.82

6.40E-06

1.65

2.25

4.43E-06

1.83

3.05

3.47E-06

1.41

1.63

3.24E-06

1.47

1.71
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PDCD4

PDCD4

PLD1

PLD1
C9orf150

LURAP1L
SLPI

SLPI

TP53INP1

TP53INP1

EPHA4

EPHA4

VTCN1

VTCN1

KRT15

KRT15

RAB40B

RAB40B

Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated
Up
regulated

2.01E-06

1.72

2.08

8.95E-07

1.66

2.02

7.13E-07

1.74

2.03

1.58E-07

1.44

1.56

1.21E-07

2.99

2.27

8.73E-08

1.65

1.94

2.24E-08

3.08

2.96

2.22E-08

1.90

1.69

1.78E-08

1.70

1.98

Table 7: Top 120 genes modulates when NOTCH signaling is activated. (Red=
upregulates, Green= Downregulated when treated with Jagged1)
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Table 8: Ingenuity Pathway Analysis of significantly modulated pathways when NOTCH
is activated in wild-type cell lines PJA34 and 183. (Red= Genes Upregulated by NOTCH,
Green= Genes Downregulated by NOTCH).
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Figure 34: Heat-map of 277 differentially expressed genes having treatment effects but
not cell lines effects. Top green bar: control samples. Top orange bar: Jagged1 treated
samples.
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Figure 35: Heat map of 1571 differentially expressed genes that have both treatment and
cell line effects. Top green bar: control samples. Top orange bar: Jagged1 treated
samples
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Chapter 6.2: NOTCH1 modulates AXL and CTNNAL1 (α-catulin) at the protein level
Rationale: We had previously observed induction of AXL and CTNNAL1 (αcatulin) at the gene expression level after activating NOTCH signaling in wild-type cell
lines. AXL and α-catulin are overexpressed in many cancers (Dunne et al., 2014; Schultz
et al., 1995). Elevated protein expression of AXL has been evaluated as a poor prognostic
factor for overall survival in colon cancer, osteosarcoma, and pancreatic cancer (Dunne et
al., 2014; J. Han et al., 2013; Song et al., 2011). Furthermore, AXL expression is also a
prognostic for increased lymph node metastasis and clinical stage in lung
adenocarcinoma, breast and ovarian cancer (D'Alfonso et al., 2014; Rankin et al., 2010;
Shieh et al., 2005). Recently, Kreisede and colleagues have shown that α-catulin is highly
expressed in melanoma cells and that α-catulin is a key driver of melanoma tumor
formation, growth, invasion and metastasis (Kreiseder et al., 2013). In order to validate
that the transcriptional modulation of AXL and α-catulin by NOTCH1, we performed a
western blot to evaluate the expression of these two proto-oncogenes at the protein level.
Results: We first overexpressed the activated form of NOTCH1 (ICN1) in a
NOTCH1 wild-type and mutant cell line (PJA34 and HN31 respectively) and evaluated
protein expression of AXL and α-catulin 3 days and 5 days after infection. At both time
points, there was significant suppression of both AXL and α-catulin in ICN1 infected
cells compared to MigR1 (empty vector) infected cells suggesting that the activated form
of NOTCH1 might be sufficient to modulate these two proto-oncogenes (Figure 36).
Next, the full length NOTCH1 receptor (NFL1) was expressed in the mutant cell lines
HN31, UM22A and UM47 and these cells were then cultured on Jagged1 for 3 days to
evaluate AXL and α-catulin levels in a more physiological setting. Expression levels of

125

both the proto-oncogenes was diminished by at least 50% when NOTCH signaling was
activated by Jagged1 compared to cells cultured on Fc and empty vector infected cells
(Figure 37). To prove that the down modulation of AXL and α-catulin was indeed due to
NOTCH signaling, the wild-type cells PJA34 were infected with dnMAML1 (to inhibit
NOTCH signaling) before culturing these infected cells on Jagged1 or Fc for 3 days.
Inhibiting the NOTCH signaling pathway using dnMAML1 reversed the Jagged1
mediated suppression of both these proto-oncogenes (Figure 38). In addition to using
dnMAML1, we also knocked out NOTCH1 and NOTCH2 using the CRISPR-Cas9
system in the wild-type cell lines PJA34 and found that knocking out both NOTCH
isoforms induces expression of AXL and α-catulin (Figure 39). The wild type cell line
when cultured on Jagged1 suppresses AXL and α-catulin, however double knockout of
NOTCH1 and NOTCH2 (dKO) reverses this suppression suggesting that NOTCH1 and
NOTCH2 might be necessary to suppress these proto-oncogenes. Interestingly,
restoration of NFL1 in the dKO PJA 34 cell line relieves the induction of these molecules
when cultured on Jagged1. Furthermore, even restoration of NFL1 in the NOTCH1 KO
PJA 34 inhibited AXL and α-catulin when cultured on Jagged1. This suggests that
NOTCH signaling may be necessary and sufficient to inhibit AXL and α-catulin.
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Figure 36: Activated NOTCH1 (ICN1) is sufficient to suppress AXL and α-catulin.
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Figure 37: Restoration of full length NOTCH1 (NFL1) in the mutant cell lines: HN31,
UM22A and UMSCC47 after activation with Jagged1 suppress AXL and α-catulin
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Figure 38: Inhibition of NOTCH signaling using dnMAML1 reverses Jagged1 induced
suppression of AXL and α-catulin.
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Figure 39: NOTCH signaling is necessary and sufficient to inhibit AXL and catulin:
Knocking out NOTCH signaling using the CRISPR-Cas9 system induces AXL and αcatulin which is reversed when the same cell line is restored with NFL1.
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Chapter 6.3: HES2 and HES5 may be sufficient to modulate AXL and α-catulin
Rationale: Canonically, the activation of the NOTCH pathway induces expression
of the HES and HEY family of genes which are known transcriptional modulators
(mostly repressors) of target genes involved with cell proliferation, differentiation,
migration, and angiogenesis. We initially identified AXL and α-catulin suppression from
gene expression arrays and since HES and HEY are direct downstream targets of the
NOTCH signaling pathway, we hypothesized that HES or HEY members might be
involved in regulating the expression of these proto-oncogenes.
Results: First, the mRNA expression levels of the HES and HEY family members
after activating NOTCH signaling was evaluated in a NOTCH1-mutant cell line (HN31)
expressing NFL1 and culturing cells on Jagged1 or Fc for 20h since hEs and HEY are
early expression genes. Shown in Figure 40 is qRT-PCR analysis showing significantly
altered members of HES and HEY after NOTCH activation. There was a 3-5 fold
increase in HES2, HES5 and HEY2, but no significant change in HES1, HES3, HES4
and HEY1 (Figure 40). Among the selected candidate targets, HES2 and HES5 had the
highest increase (3.5 and 5 fold respectively) compared to HEY2 (2.5 fold).
Following the identification of these downstream targets, we evaluated if these
molecules are sufficient to inhibit AXL and α-catulin expression. For this, MigR1-flag
tagged- GFP constructs of HES2 and HES5 were expressed in the NOTCH1 mutant cell
line HN31. Forty-eight hours after infection, these cells were purified for GFP by flow
cytometry, and were harvested for western blotting. Both HES2 and HES5 were
sufficient to suppress protein levels of AXL by at least 55% and α-catulin by at least 33%
compared to the parental and empty vector controls (Figure 42: Relative expression levels
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of Flag-Tag, HES5, AXL, p-AXL, α-catulin and Gas6 from the western blot shown in
Figure 41). Furthermore, there was also a decrease in phopho-AXL and Gas6 (a ligand
for AXL) suggesting that AXL activity is also abrogated when HES2 and HES5 are
overexpressed. Taken together, NOTCH1 can inhibit HES2 and HES5, which might be
sufficient to modulate AXL and α-catulin protein expression.
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Figure 40: Modulation of HES and HEY members after restoration of NOTCH signaling
in HN31 cells and culturing on Jagged1 for 20h
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Figure 41: HES2 and HES5 might be sufficient to modular protein expression of AXL, pAXL, Gad6 and α-catulin. Overexpressing HES2 and HES5 using Flag tagged constructs
in the mutant cell line HN31 inhibits protein expression of proto-oncogenes AXL and αcatulin.
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Figure 42: Relative expression levels of Flag-Tag, HES5, AXL, p-AXL, α-catulin and
Gas6 from the western blot shown in Figure 41
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Chapter 6.4: The 120 in vitro gene signature corresponds with NOTCH activation status
in patients
Rationale: Previously, we identified 120 differentially regulated genes when the
NOTCH signaling pathway was activated in wild-type cell lines PJA34 and 183. Some of
these genes, such as AXL (Brand et al., 2015), CTNNAL1 (Cao et al., 2012), INTGA3
(Nakada et al., 2013), INTGA5 (Janes & Watt, 2006), VEGFC (Wang, Chen, Fang, &
Yang, 2013), and keratins (Rangarajan et al., 2001) have shown to be overexpressed in
different cancers. The correlation between NOTCH mutational status in HNSCC patients
and expression of the identified genes is not known. Since the gene expression array was
performed in vitro after activating NOTCH signaling, we evaluated the correlation
between the 120 identified genes in vitro to NOTCH mutational status in HNSCC
patients. We hypothesized that genes modulated by NOTCH signaling in vitro would
correlate with HNSCC patients having an active NOTCH gene signature.
Results: We evaluated RNA-seq data from 498 TCGA HNSCC patient samples
based on the in vitro gene signature. The 120 genes of interest originated from the
significant gene list based on Affymetrix HuGene 2.0 ST array data. There are more than
20,000 genes for the expression data and the whole data set was divided into two parts
according to tumor sites: Oral Cavity (OC) and Laryngeal/Hypopharyngeal (LH). The
TCGA RNA-Seq data was downloaded from Broad GDAC Firehose and was processed
and normalized by the Department of Bioinformatics (M.D. Anderson Cancer Center).
We read the TCGA RNA-Seq data and subsetted the data into one with the expression of
the interested genes. The NOTCH1 and NOTCH2 mutation status were overlaid and
patients were assigned two or three groups based on clustering. We then produced heat
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maps with pearson distance and ward linkage based on 498 patient samples, 120 genes
and two anatomical sites. We found two distinct clusters; genes upregulated after
NOTCH activation were grouped into cluster A (left red bar of Figure 43Figure 44) while
all genes that were downregulated by NOTCH activation formed cluster B (left green bar
of Figure 43 Figure 44). In cluster A of the Oral cavity subset, we found 49 genes
upregulated by Jagged1 and 17 genes downregulated, while in cluster B, only 1 gene was
upregulated by Jagged1 and 53 genes were downregulated (Table 9). Similarly, we
observed 44 Jagged1 upregulated genes and 24 downregulated genes in cluster A of the
Laryngeal/Hypopharyngeal subset, and 6 upregulated and 46 downregulated genes in
cluster B of the same subset (Table 12). Since we performed an unsupervised clustering
analysis, we observed similar clustering of the 120 genes to the cell lines in vitro and thus
confirmed our previous in vitro microarray analysis. In the two anatomical sites, we
observed at least two clusters; patients having an inactive NOTCH gene signature (cluster
1) or an active NOTCH gene signature (cluster 2). Since patients in cluster 1 had gene
expression levels opposite of those in cell lines (i.e. genes upregulated in cell lines when
NOTCH was active was downregulated in cluster 1 in patients and vice versa), those
patients possibly have an inactive NOTCH pathway. Genes modulated in cluster 2
resemble cell lines with an activated NOTCH pathway. Thus, it is possible that these
patients might have an active NOTCH pathway. Moreover, patients in cluster 2 lack any
NOTCH1 or NOTCH2 mutations. In the Oral Cavity patient subset, 34 patients were
mutant for NOTCH1 and 113 patients harbored a wild-type receptor in Cluster 1, while in
cluster 2, only one patient had NOTCH1 mutations and 39 patients harbored the wildtype NOTCH1 (Table 10). In the Laryngeal/Hypopharyngeal cluster, cluster 1 had 15
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NOTCH1 mutant patients and 28 wild-type, while cluster 2 had 1 NOTCH1 mutant
patient and 29 wild-type NOTCH1 patients (Table 11). In cluster 3 of both sites, are
patients that might have the NOTCH pathway inactivated in ways besides somatic
mutation. Thus, these patients might be clustered under an active NOTCH gene signature
but might have an inactive NOTCH downstream pathways. Correlation heat maps, and a
histogram depicting the number of differentially expressed genes with various FDR cutoffs and p-values for the Oral Cavity group are shown in appendix 2 and 3 respectively.
Shown in Table 13 are the associations of the 120 differentially expressed genes with the
different clusters (in cell lines A versus B) in the TCGA patient samples in both
anatomical sites. We observe that in patients, clustering is similar to cell lines and
correlate with each other. In addition to subjecting the 120-gene signature to an unbiased
clustering analysis in patients, we were also interested in the most significantly
modulated genes among all the genes in patient tumors. We performed an unsupervised
clustering and generated a heat map of the significantly differentially expressed genes
from the t-test between group 1 and group 2 based on an FDR of 0.000001 at all
anatomical sites (Figure 45and Figure 46). When the differential expression of these
genes were analyzed, we were surprised to find that in addition to high mRNA levels of
keratins, integrins, AXL and modest increase in α-catulin, two of the top effectors were
aldehyde dehydrogenase ALDH1A1 and ALDH1A3. Both these are stem cell markers
whose mRNA levels was high in patients with an active NOTCH pathway. We observed
a 32-fold increase in ALDH1A1 in Oral Cancer patients with active NOTCH pathway
and 10 fold increase in ALDH1A3. Similarly, we found a 13 fold increase in ALD1A1 in
Laryngeal/hypopharyngeal cancers and 19 fold increase in ALDH1A3. ALDH1A1 and
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ALDH1A3 were two of the top stem cell makers that we didn’t observe from the
microarray in vitro. This finding is intriguing because it implies that activation of
NOTCH signaling can potentially turn on a stem cell program and increase maintenance
of stem cells. We had shown earlier that in mutant cells after restoring NOTCH1, and
injecting these cells in mice, we observed the formation of keratin pearls indicating
differentiation. While, we do observe differentiation markers from the TCGA data, we
now also have evidence of a possible increase in stem cell markers. We speculate that
NOTCH activation increases differentiation and thus inhibits cell growth, but the
upregulation of ALDH1A3 and ALDH1A5 opens up new avenues on how NOTCH may
regulate a stem cell phenotype that needs to be investigated in the future.
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Figure 43: Heat-map of the 120 in vitro gene signature in Oral Cavity
TCGA tumors
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Table 9: Total number of Oral Cavity (OC) patients in each cluster corresponding to
NOTCH1 mutational status. Shown in parenthesis are expected numbers based on ChiSquared test

Table 10: Total number of genes in each cluster of Oral Cavity (OC) patients
corresponding to modulation by Jagged1 in cell lines. Shown in parenthesis are expected
numbers based on Chi-Squared test.
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Figure 44: Heat-map of the 120 in vitro gene signature in
Laryngeal/Hyopharyngeal TCGA tumors
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Table 11: Total number of Laryngeal/Hypopharyngeal (LH) patients in each cluster
corresponding to NOTCH1 mutational status. Shown in parenthesis are expected
numbers based on Chi-Squared test

Table 12: Total number of Laryngeal/Hypopharyngeal (LH) patients in each cluster
corresponding to NOTCH1 mutational status. Shown in parenthesis are expected
numbers based on Chi-Squared test
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Figure 45: Unsupervised clustering of 498 TCGA Oral Cavity (OC) tumors based on
20,000 genes.
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Figure 46: Unsupervised clustering of 498 TCGA Laryngeal/Hypopharyngeal (LH)
tumors based on 20,000 genes
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Official Gene
Symbol

Gene Symbol
used in TCGA
TCGA

Regulated Oral
by
Cavity
NOTCH
Gene
Cluster
(A or B)

Larnyx
Hypopharynx
Gene Cluster
(A or B)

CAV1
AXL
FHL2
CMTM8
SERPINE1
PTRF
NAV3
LAMC2
DRAM1
AFAP1L2
NETO2
TMCC3
SEMA7A
ITGA5
HOMER3
ZBED2
SYT16
SLC16A2
FGFBP1
FHOD1
ITGA3
PXN
PKP2
THSD4
KLK6
SOX15
PLEK2

CAV1
AXL
FHL2
CMTM8
SERPINE1
PTRF
NAV3
LAMC2
DRAM1
AFAP1L2
NETO2
TMCC3
SEMA7A
ITGA5
HOMER3
ZBED2
SYT16
SLC16A2
FGFBP1
FHOD1
ITGA3
PXN
PKP2
THSD4
KLK6
SOX15
PLEK2
MOBKL2B

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
B
A
B
B
B
B
A
A
A
B
B

B
B
B
B
B
B
B
B
A
B
A
A
B
B
B
B
A
B
B
B
B
B
A
A
B
B
B
B

LOXL2
PLAUR
MMP9
UPP1
LOXL4

1
1
1
1
1

B
B
B
A
A

B
B
B
B
A

MOB3B
LOXL2
PLAUR
MMP9
UPP1
LOXL4
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SLC7A2
TMEM27
ANKRD2
AP2B1
LEPREL1
SLC39A14
CD55
HEG1
PI4K2A
FST
NXPE3
VEGFC
SIRPA
KIRREL
OLR1
KIAA0040
CYR61
VLDLR
RAB32
TIMP4
ABCG2
FAM101B
MFAP5
NT5E
COL17A1
CPA4
EMP3
CTNNAL1
TIMP3
CDH13
FAM46B
IL6R
HBEGF
EREG
EPHA2
FOSL1
B4GALT6
BCL6
TNKS

SLC7A2
TMEM27
ANKRD2
AP2B1
LEPREL1
SLC39A14
CD55
HEG1
PI4K2A
FST
FAM55C
VEGFC
SIRPA
KIRREL
OLR1
KIAA0040
CYR61
VLDLR
RAB32
TIMP4
ABCG2
FAM101B
MFAP5
NT5E
COL17A1
CPA4
EMP3
CTNNAL1
TIMP3
CDH13
FAM46B
IL6R
HBEGF
EREG
EPHA2
FOSL1
B4GALT6
BCL6
TNKS

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0

A
A
B
B
B
B
A
B
B
B
B
B
B
A
B
B
B
A
B
B
B
B
B
B
B
B
B
B
B
B
A
A
A
B
A
B
A
A
A

A
A
A
A
B
A
B
A
B
B
A
B
B
A
B
A
B
A
B
A
A
B
A
B
B
B
B
A
B
B
A
A
B
B
B
B
B
A
A
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HLA-DRA
SCARNA9
LONP2
SCARNA17
GUSBP3
AKR1C3
ZNF117
MUC16
PGLYRP4
IKZF2
DLX5
KRT4
PRODH
MYH14
TXNIP
KLHL24
KRT13
GOLGA8A
GLUL
TMEM45B
GOLGA8B
MANSC1
FAM102B
DSP
PRKX
PCMTD2
CNKSR3
GCLC
RNF138P1
FAM214A
HES5
ST6GALNAC2
ACPP
SLC12A2
PBX1
CYP1A1
PPAP2A
TNFSF10
KIAA1147

HLA-DRA
SCARNA9
LONP2
SCARNA17
GUSBP3
AKR1C3
ZNF117
MUC16
PGLYRP4
IKZF2
DLX5
KRT4
PRODH
MYH14
TXNIP
KLHL24
KRT13
GOLGA8A
GLUL
TMEM45B
GOLGA8B
MANSC1
FAM102B
DSP
PRKX
PCMTD2
CNKSR3
GCLC
RNF138P1
KIAA1370
HES5
ST6GALNAC2
ACPP
SLC12A2
PBX1
CYP1A1
PPAP2A
TNFSF10
KIAA1147

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A

A
A
A
A
A
A
A
A
B
A
A
A
A
A
A
A
A
A
A
B
A
A
A
B
A
A
A
A
A
A
B
A
A
A
A
A
A
A
A
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PDCD4
PLD1
LURAP1L
SLPI
TP53INP1
EPHA4
VTCN1
KRT15
RAB40B

PDCD4
PLD1
C9orf150
SLPI
TP53INP1
EPHA4
VTCN1
KRT15
RAB40B

0
0
0
0
0
0
0
0
0

A
A
A
A
A
A
A
A
A

B
A
A
B
A
A
A
A
A

Table 13: Clustering of genes modulated in both tumor sites corresponding to the genes
clustered in cell lines

149

Discussion
In chapter 6, the identification of several downstream molecules of the NOTCH
signaling pathway that may contribute to growth inhibition is elucidated. We have shown
that activating NOTCH signaling in the wild-type cell lines PJA34 and 183 by culturing
them on Jagged1 upregulates the expression of potential tumor suppressor genes and
inhibits proto-oncogene expression. From this unbiased gene expression analysis, we
were able to make associations of the NOTCH signaling pathway with effectors that were
not known before. Among key genes down regulated by growth on JAG1 are CTNNAL1
(α-catulin), AXL kinase, integrins α3 and α5, LAMC2 (i.e., a component of Laminin-5),
and several genes known to mediate invasion such as MMP9 and urokinase-type
plasminogen activator receptor (PLAUR). Among genes upregulated by JAG1 exposure
were keratins 4 and 13 (i.e., principal keratins produced by squamous epithelial cells
during differentiation). Tumor suppressor genes upregulated by JAG1 included TRAIL
(i.e., TNFSF10) as well as PDCD4, which is a negative regulator of the TRAIL inhibitor
FLIP, and is also an established target of oncogenic microRNA 21 (miR-21). In both
PJA34 and 183 cells, AXL, α-catulin, LAMC2, and keratin 4 (KRT4) were among the
top 15 most significantly altered genes following growth on JAG1, based upon P-value.
KRT4 and α-catulin had the largest changes in magnitude induced by JAG1 in183 cells,
whereas AXL and LAMC2 were among the top twelve genes with greatest fold-change in
both cell lines.
We also confirmed the regulation of two downstream targets AXL and α-catulin
at the protein level. Although the gene expression array suggests that these molecules
may be regulated at the transcriptional level, we still need to explore the transcriptional
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binding sites of these effectors. AXL has three AP1 binding motifs and five sp binding
sites in its promoter regions (Mudduluru & Allgayer, 2008). Chu et al. have demonstrated
that the intracellular form of NOTCH1 (ICN1) can repress AP1 mediated transactivation
(Chu, Jeffries, Norton, Capobianco, & Bresnick, 2002). Thus, it is possible that NOTCH1
may transcriptionally regulate AXL, however, since AP1 transcriptional factors regulate
several other genes, it is difficult to attribute that the transcriptional modulation of AXL
is due to NOTCH1 alone. CTNNAL1 has five putative binding sites in the promoter
region that can recruit LEF-1, AP-2α and CREB (Xiang et al., 2012). Our future work
will aim at how NOTCH1 or its canonical downstream targets (HES and HEY family
members) modulate AXL and α-catulin.
Among the canonical downstream targets of the NOTCH pathway, we found that
HES2 and HES5 were upregulated by more than 3-fold in comparison with HES1, 3, 4
and HEY1. In hematopoietic malignancies, the expression of HES1 and HES5 has been
shown in several blood cell lineages including T-cells, B-cells and hematopoetic stem
cells (Yu et al., 2006). The expression of HES and HEY family members is modulated in
a cyclic fashion. We evaluated the expression of these genes 12h, 16h, 20h and 24h after
activation of the NOTCH signaling pathway since these are early response genes, and
observed maximum induction of HES2 and HES5 at the 20h time point, while other HES
and HEY members had no difference at each time point between culturing them on
Jagged1 versus Fc. It would be interesting to investigate the lack of induction of HES1, 2,
4 and HEY1 when NOTCH is activated. Epigenetic changes such as promoter
methylations may contribute to this effect. In neuroblastoma cell lines, Zage et al. have
shown moderate to heavy methylations in CpG islands of the promoter regions of HES2

151

and HES5 (Zage et al., 2012). In addition, frequent deletions in the regions of the 1p36
chromosome that harbors HES2, HES3, HES4 and HES5 is observed in neuroblastoma
(Maris & Matthay, 1999). Thus, it might be possible that in HNSCC, methylations or
deletions in such regions may modulate the expression levels of these genes.
TCGA analysis of NOTCH mutant head and neck cancer patient specimens
revealed a surprising modulation of genes involved in the maintenance of stem cells.
Alcolea and colleagues created an esophageal epithelial system in which they inhibited
NOTCH signaling using dominant negative mastermind (dnMAML1) in just one cell of
the basal cell population and monitored the expansion of these cells in vivo (Alcolea et
al., 2014). They found that a year after inhibiting NOTCH signaling in basal cells, the
population of differentiating cells drastically decreased selecting only for these
undifferentiated basal cells. Although they don’t claim these cells to be in a stem cell
state, it is possible that this population was enriched and might contribute to tumor
initiation. In our system, since we observe markers of stem cells from the TCGA patient
tumors that have an active NOTCH1 gene signature, there might be a population of cells
exhibiting stem cell characteristics after NOTCH activation. However, we did not
observe significant modulation of these genes in cell lines. Differences between cell lines
and tumors include intensity of NOTCH signaling, infiltrating muscle cells and tumor
purity, microenvironment regulation, and other genetic alterations in tumors (NUMB,
p63, etc.) may contribute to the discrepancies between genes regulated in cell lines versus
tumors.
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CHAPTER 7: INHIBITION OF AXL AND αCATULIN MODULATES CELL GROWTH
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Chapter 7: Inhibition of AXL and α-catulin modulates cell growth
Chapter 7.1: Knocking down AXL and α-catulin inhibits cell growth and tumor formation
Rationale: In chapter 5, we demonstrated that NOTCH inhibits cell growth and in
chapter 6, we elucidated that NOTCH1 is sufficient and necessary to decrease the
expression of AXL and α-catulin. AXL and α-catulin are proto-oncogenes that are
overexpressed in several cancers. Both proto-oncogenes have shown to be involved with
cell growth, proliferation, migration and metastasis (Cao et al., 2012; Graham,
DeRyckere, Davies, & Earp, 2014). Moreover, targeting AXL in HNSCC cell lines
increased their sensitivity to cetuximab and radiation (Brand et al., 2015). Fan et al.
showed that α-catulin promoted the growth of oral squamous cell carcinoma by inhibiting
senescence (Fan et al., 2011). Although there is evidence that AXL and α-catulin
suppress growth, the functional relevance of these proto-oncogenes in a NOTCH mutant
background hasn’t been fully explored. We first demonstrated that restoration of
NOTCH1 inhibits tumor growth, then we showed that NOTCH1 inhibits AXL and αcatulin. To evaluate AXL and α-catulin meditated modulation of cell and tumor growth,
we knocked down the expression of these proto-oncogenes using shRNA’s and
hypothesized that AXL and α-catulin might be necessary for tumor growth.
Results: We obtained four different lentiviral sort hairpin RNA’s that were GFP
tagged for each target gene, AXL and α-catulin, and stably transfected the mutant cell
lines HN31, and UMSCC22A and wild-type cell lines PJA34 and 183 with sh RNA’s
against AXL (shAXL) and α-catulin (shCAT) and purified them by flow cytometry. The
percentage and intensity of GFP positive cells were matched for each lentiviral shRNA
construct prior to transductions. After obtaining a pure population of cells expressing the
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shRNA’s, we cultured cells at low densities in a colony forming clonogenic assay for 10
days. Shown in Figure 47 and Figure 48 are western blots indicating that both AXL and
catulin have been knocked down by more than 70%. Knocking down AXL and α-catulin
significantly reduced cell growth in all cell lines (Figure 51). In all cell lines, we
observed at least 50% decline in cell growth after inhibition of AXL and α-catulin. Based
on our previous results, when NOTCH1 was activated in HN31 and PJA34, we observed
greater than 50% decline in cell growth. Moreover, we have also shown that NOTCH1 is
necessary and sufficient to inhibit AXL and α-catulin. Here we show that knocking down
AXL and α-catulin recapitulates the NOTCH induced growth inhibition.
Since we found that decreasing AXL and α-catulin expression is associated with
decreasedcell growth in vitro , we then investigated the role of modulation of expression
of these proto-oncogenes on tumor growth in vivo. After knocking down AXL and αcatulin using shRNA’s in HN31 mutant cells, the cells were purified for GFP by flow
cytometry and injected them into the tongue of mice in an orthotopic model of oral
cancer. We injected 50,000 cells per mouse and had 11 mice in each condition. As seen
in Figure 52, knocking down AXL and α-catulin led to significantly abrogated tumor
growth by more than 75% compared to the shEMPTY and parental control cells injected
mice at 17 days post injection (P<0.001). Tumors in the control groups (parental and
shEMPTY) were initiated 5 days post injection, while tumors in the AXL and CAT group
began to develop only at day 10. In the parental and empty vector control groups, all 11
mice developed tumors 17 days after injection but in the shAXL and shCAT groups, only
6 and 8 mice respectively developed tumors. The overall survival in mice that had
shAXL and shCAT cells injected was greater than the control groups (P<0.01). The
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median survival of mice in the parental and shEMPTY groups was 24 and 21 days
respectively, while the shAXL and ShCAT mice groups survived for more than 35 days.
The in vivo effect of AXL was slightly greater than α-catulin in that, tumor sizes in
shAXL groups were smaller than in the shCAT group and the former had a slightly
greater overall survival than the latter (although not significant). Comparing these results
to restoration of NFL1 in vivo, we observe a similar trend in tumor growth inhibition.
Restoration of NFL1 in HN31 cells lead to a 60-70% decline in tumor volumes at day 25
post injection, while knocking down AXL and α-catulin resulted in a similar decline
slightly earlier (day 18). Taken together, our results imply that knockdown of AXL and
α-catulin recapitulates the NOTCH induced phenotype in wild-type and mutant cells
suggesting that AXL and α-catulin might be involved with NOTCH mediated suppression
of tumor growth.
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Figure 47: Knockdown of AXL and α-catulin in wild-type cell lines 183 and PJA34 usign
shRNA’s
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Figure 48: Knockdown of AXL and α-catulin in mutant cell lines UM22A and HN31
using shRNA’s
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Figure 49: Quantitation of the western blots after knocking out AXL and catulin in wildtype cell lines 183 (above) and PJA 34 (below).
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Figure 50: Quantitation of the western blots after knocking out AXL and catulin in
mutant cell lines UM22A (above) and HN31 (below).
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Figure 51: Clonogenic assay in wild-type (PJA34 and 183) and mutant cell lines
(UM22A and HN31). Knocking down AXL (shAXL) and α-catulin (shCAT) inhibits cell
growth in a colony forming clonogenic assay
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Figure 52: AXL and α-catulin modulates in vivo tumor formation and overall survival.
Knocking down AXL and α-catulin using shRNA’s in a mutant cell line significantly
inhibits tumor growth and increases overall survival
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Chapter 7.2: HES2 and HES5 might be sufficient to inhibit cell growth
Rationale: We have previously shown that HES2 and HES5 are canonical
downstream targets of the NOTCH signaling pathway that is significantly up regulated in
HNSCC cell lines compared to other HES and HEY family members (Figure 40). In
addition, we have also shown that NOTCH1 is necessary and sufficient to inhibit cell
growth and protein expression levels of AXL and α-catulin which might be downstream
of NOTCH and are necessary for inducing the same phenotype. Furthermore, we have
shown that HES2 and HES5 might be sufficient to inhibit protein expression of AXL and
α-catulin. HES and HEY family are known canonical downstream transcriptional
modulators (mostly repressors) of the NOTCH signaling pathway. Since AXL and αcatulin were suppressed after NOTCH activation resulting in growth inhibition, we
wanted to investigate if these canonical targets are sufficient to modulate cell growth.
Results: Using HES2 and HES5 MigR1, GFP-tagged constructs, we
overexpressed these genes in the NOTCH1 mutant cell line HN31. Prior to sorting these
cells for pure population of GFP cells, viral titers were optimized such that each
overexpression condition (HES2, HES5 and MigR1) express similar intensity and
percentage of GFP positive cells. Since each virus may have varied efficacy after
infection, it was imperative that the titers be matched to each other to avoid confounding
variables that may be caused due to the infections process itself rather than the constructs.
After sorting for a pure population of GFP positive cells and confirming the expression of
these flag tagged constructs (Figure 41), we performed an in vitro colony forming
clonogenic assay in which we plated 1000 cells from each sorted cell conditions into 6well plates. HES2 and HES5 significantly inhibited growth compared to the parental and
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empty vector conditions (Figure 53). The number of colonies in the parental and MigR1
were similar, but HES2 and HES5 were sufficient to induce more than 75% suppression
in growth of HN31 cells (P<0.01). This result suggested that NOTCH activated HES2
and HES5 appear to be sufficient in modulating cell growth. In future studies, we will
examine the regulation of AXL and catulin by HES2 and HES5 in inhibiting cell growth.
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Figure 53: HES2 and HES5 are sufficient to inhibit cell growth
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Discussion
In chapter 7, we demonstrate the roles of AXL and α-catulin in modulating cell
growth in vitro and in vivo. We have shown that knocking down these proto-oncogenes
using shRNA’s significantly inhibits cell growth in a colony-forming assay. Previously,
in chapter 5, after restoration of the NOTCH signaling pathway in wild-type and mutant
cells, we show greater than a 50% decrease in cell growth. Then, in chapter 6, we
demonstarted that NOTCH activation in mutant and wild-type cell lines inhibits AXL and
α-catulin. Here, we observe that AXL and α-catulin might be necessary in modulating
cell growth. Using siRNA’s, Brand et al. demonstrated that cell lines expressing high
levels of AXL are sensitive to siRNA-mediated inhibition of AXL (Brand et al., 2015).
However, in their experiments, siRNA’s against AXL induced less than a 50% inhibition
in cell proliferation. Our results are more robust in that we performed stable transfections
with shRNA’s and assayed cell growth over a longer time period and observed more than
a 60% inhibition in cell growth. A caveat to this experiment is that the role of AXL and
α-catulin independent of NOTCH activation still remains unexplored. For this, we might
have to overexpress these proto-oncogenes in a background in which NOTCH has been
knocked out (for example in CRISPR-Cas9 knockout cells) before culturing these cells
on Jagged1 to prove that AXL and α-catulin are sufficient to modulate growth. Finally,
we show that HES2 and HES5 might be sufficient to modulate cell growth. We have
previously shown that activation of NOTCH signaling induces HES2 and HES5
expression. Furthermore, HES2 and HES5 can possibly down regulate AXL and αcatulin. HES2 and HES5 may be sufficient to inhibit growth by more than 60% a mutant
HNSCC cell line, HN31. In Acute Myelogenous Leukemia (AML), Zage et al. showed
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that HES1 was sufficient to induce more than a five-fold decrease in growth of AML
cells (Zage et al., 2012). At this point, we don’t have evidence demonstrating that HES2
and HES5 are required for inhibiting cell growth. To prove that these targets are required,
we are knocking down HES2 and HES5 in wild-type cell lines before culturing them on
Jagged1 to show that loss of these molecules upregulates AXL and α-catulin and relieves
NOTCH induced growth inhibition. The transcriptional targets of the HES and HEY
family have not been well studied. Genes like Achaete-scute-like 1 (ASCL/HASH1),
atonal homolog-1 (ATOH1) and neurogenin-1 have been reported before (Kageyama,
Ohtsuka, Hatakeyama, & Ohsawa, 2005). In the future, we aim to understand NOTCH
signaling at the transcriptional level and elucidate how NOTCH modulates AXL and αcatulin in regulating cell growth.
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CHAPTER 8: DISCUSSION AND FUTURE
DIRECTIONS
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Discussion and future directions
The main goal of my thesis is to understand the tumor suppressive role of NOTCH1 in
HNSCC. In 2011, our lab had published results from whole exome sequencing of 32
primary patient tumors in which frequent somatic mutations in NOTCH1 was identified
(Agrawal et al., 2011). Until then, TP53 was known to be mutated frequently, followed
by p16, PIK3CA, Hras and overexpression/amplifications in Cyclin D1 and EGFR. The
sequencing studies performed by Agarwal et al. (Agrawal et al., 2011) and Stransky et al.
(Stransky et al., 2011) identified for the first time frequent somatic mutations in
NOTCH1. More recently, the TCGA utilized a broader sequencing platform and
observed NOTCH1 mutations at a similar frequency as the other two studies ("TCGA
Releases Head and Neck Cancer Data," 2015). The role of NOTCH1 in cancers surfaced
from studies in T-ALL in which this receptor has activating mutations in the
transmembrane and PEST domains that results in constitutive activation of the pathway
rendering it an oncogene in this tumor type (Weng et al., 2004). In HNSCC, inactivating
mutations were primarily located at the extracellular domain of NOTCH1 and were
mostly missense and nonsense mutations. These mutations prevented the binding of the
NOTCH receptor with the ligand inactivating this pathway in a subset of HNSCC. Based
on sequencing studies, only a small fraction of HNSCC (15-19%) harbor inactivating
NOTCH1 mutations while the majority seems to express the wild-type NOTCH1
receptor. Although wild-type NOTCH1 is expressed in many tumors, these tumors
resemble the mutant subset. In such tumors, there might be other aberrations such as
overexpression of NUMB; a negative regulator of NOTCH activation, overexpression of
Jagged1; resulting in cis-inhibition or modulations in fringe glycosylation; that results in
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improper receptor-ligand binding. Indeed, we have seen the overexpression in NUMB in
some of our cell lines that are both wild-type and mutant for NOTCH1 (
Figure 54). In addition, cell lines that are both wild-type and mutant for NOTCH1
express Jagged1 (Figure 55) that can potentially lead to cis-inhibition (Figure 33). In this
dissertation, I hypothesized that the inactivating mutations observed in NOTCH1 in
HNSCC render it a tumor suppressor in this tumor type and the activation of a functional
NOTCH pathway would inhibit growth of these tumors.
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Figure 54: Basal NUMB expression in wild-type and mutant HNSCC cell line

Figure 55: Jagged1 expression in wild-type and mutant HNSCC cell lines
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Activation of NOTCH signaling inhibits growth
Based on sequencing data that showed frequent inactivating mutations in
NOTCH1 in this cancer type (Agrawal et al., 2011), for the first time, we demonstrate the
functional relevance of these inactivating mutations. Using the intracellular and fulllength NOTCH1 constructs (ICN1 and NFL1) in mutant cell lines, we observed a
decrease in the population of cells expressing NOTCH1. Cells expressing NOTCH1 were
selected against cells expressing the empty vector in a competitive cell proliferation
assay. In a similar assay, Kannan et al. have shown that ICN was sufficient to inhibit
AML cell growth (Kannan et al., 2013). Although, we do not completely understand what
causes growth inhibition, we did observe morphological changes after transducing cells
with ICN1 or NFL1 that might explain this observance.
NOTCH and senescence
Cellular senescence was a phenotype that accompanied growth inhibition in
mutant cell lines after transduction with ICN1 and NFL1 when cultured on Jagged1.
Senescence partially explains the flat, enlarged and pancake-like morphology that we
observe after NOTCH activation. Senescence serves as a fail-state mechanism to prevent
oncogene-induced aberrant proliferation. It has been shown that in esophageal
keratinocytes, ICN1 inhibited cell proliferation, induced expression of p21 and arrested
cells in the G1 phase of the cell cycle (Kagawa et al., 2015). We observed a similar
phenotype in that ICN1 did inhibit p21, and arrest cell in the G1 phase of the cell cycle.
Senescence, however, was observed only in a small fraction of cells and it is unclear what
inhibits growth in cells that do not undergo senescence. Mechanisms other than
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senescence governing growth inhibition such as cell death, or mitotic catastrophe still
need to be explored.
NOTCH and differentiation
The NOTCH pathway is known to regulate differentiation and it is possible that
NOTCH induced differentiation might inhibit cell growth. Studies performed in mice
keratinocytes with specific deletion of NOTCH1 in the epidermis abolished cell growth
and disrupted well-defined borders between the basal and upper differentiating layers
(Rangarajan et al., 2001). Induction of p21 is one of the earliest events underlying
differentiation induced growth arrest (Missero, Di Cunto, Kiyokawa, Koff, & Dotto,
1996) and we show here that ICN1 is sufficient to induce p21 in a NOTCH1 mutant cell
line. Furthermore, mice injected with the mutant cell line UM47 expressing NFL1
showed the formation of keratin pearls indicative of differentiation. Signaling between
NOTCH ligands, Jagged1 and Jagged2 and NOTCH receptors 1 and 2 increases in
differentiating keratinocytes in the suprabasal layers of the epidermis (Luo, Aster,
Hasserjian, Kuo, & Sklar, 1997). This suggests that they are part of a positive feedback
mechanism required for differentiation and epidermal border formation (Rangarajan et
al., 2001). Another line of evidence that NOTCH1 might induce differentiation is
modulation of p63, a p53 family member that is involved with cell fate determination and
stem cell maintenance (Mills et al., 1999; Yang et al., 1999). We observed a marked
suppression in protein levels of ΔNp63 after infecting a mutant cell line with ICN1
(Figure 56). In the murine system, p63 is likely to play a significant function in
preventing differentiation and maintenance of premature senescence (Keyes et al., 2005;
King et al., 2003). Elevated levels of ΔNp63 has been shown to be associated with a

173

variety of epithelial tumors, including squamous cell carcinomas in which NOTCH
expression is suppressed (Lefort et al., 2007; Parsa, Yang, McKeon, & Green, 1999;
Pellegrini et al., 2001). This suggests that NOTCH and ΔNp63 might be linked. Here, we
show that ICN1 might induce ΔNp63, thus promoting differentiation and contributing to
growth inhibition. NOTCH and ΔNp63 can have opposing effects. While NOTCH1
suppresses expression of ΔNp63, overexpression of ΔNp63 has been shown to inhibit
NOTCH activity and maintenance of immature keratinocytes (Okuyama et al., 2008). We
have not shown the expression levels of ΔNp63 in NOTCH1 wild-type cells, but it may
be possible that the activity of ΔNp63 might inhibit NOTCH activation although these
cells express a functional receptor. Taken together, we have independent evidences of
NOTCH inducing p21 and NOTCH inducing differentiation. Whether there is a link
between NOTCH, p21 and differentiation in HNSCC needs to be explored in the future.
Interestingly, although ICN1 causes cells to round up and appears to come off the
substrate, we did not observe the induction of apoptosis. Infection of mutant cells with
ICN1 arrested 15% of the cells in the sub G0 phase of the cell cycle indicative of cell
death. In B-ALL, one of the mechanisms of NOTCH induced apoptosis involves HES1
activating PARP1 leading to self and global PAR-ylation, reduction in NAD and ATP
levels, nuclear translocation of AIF and subsequent B-ALL apoptosis (Kannan et al.,
2011). However, when we performed a western blot for cleaved PARP and total PARP,
we did not observe induction of apoptosis after NOTCH activation. This rules out the
possibility of apoptotic cell death.
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Roles of NOTCH1 and NOTCH2
The majority of the data in my dissertation focuses on the role of NOTCH1 in
HNSCC. However, mutations in NOTCH2 are also observed in this tumor type. More
recently, a publication by Li et al. found deletions in NOTCH2 in primary tumors and
HNSCC cell lines (H. Li et al., 2014). Since NOTCH1 and NOTCH2 mutations are not
mutually exclusive, it is hard to predict if the mutations in one of the NOTCH members
can be overcome by another functional receptor. We observed that ICN1 and ICN2 are
sufficient to inhibit growth in a wild-type and mutant cell line. Furthermore, we have also
shown that both NOTCH1 and NOTCH2 are necessary to inhibit cell growth. The
functional difference between NOTCH1 and NOTCH2 lies in the intracellular region of
the receptor. Kraman and McCright performed a study in which they replaced the nonconserved region of ICN2 with the homologous region of ICN1 and created mice with
NOTCH1-NOTCH2 fusion protein (Kraman & McCright, 2005). Mice homozygous for
this fusion were phenotypically normal and organs that required NOTCH2 functionality
had developed normally with the fusion protein. They suggested that ICN1 can
functionally replace the corresponding region of ICN2. Since we used the intracellular
form of NOTCH1 and NOTCH2, our results are consistent with findings from Kraman
and McCright and also corroborates the study that demonstrates that ICN1 and ICN2
could activate transcription in vitro (Kurooka, Kuroda, & Honjo, 1998). Our results are
also consistent with another finding that elucidates that ICN1 and ICN2 could both
induce growth arrest and senescence in small cell lung cancer cells (Sriuranpong et al.,
2001). In our evaluation of NOTCH2 induced growth inhibition, we only overexpressed
the activated form of this protein. To gain a complete understanding of the role of
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NOTCH2 in HNSCC, we will clone the full length NOTCH2 receptor similar to NFL1
and perform similar functional studies.
Although we have shown that either ICN1 or ICN2 can inhibit cell growth, it
appears that knocking out both together is necessary to relieve growth inhibition. Using
the CRISPR-Cas9 technique to knock out NOTCH1 (NOTCH1 KO), NOTCH2
(NOTCH2 KO) or both (double KO) and then culturing the cells on Jagged1, we
observed that the dKO is required to relieve Jagged1 induced growth inhibition. It
appears that both NOTCH1 and NOTCH2 are able to signal through Jagged1. The other
compensates the loss of one of the NOTCH receptors. To circumvent the issue of which
particular NOTCH receptor contributes to tumorigenesis, we used a pan NOTCH
inhibitor, dnMAML1 to evaluate tumor formation. The dnMAML1 significantly
increased tumor growth in a weakly tumorigenic cell line but only 50% of the mice
injected formed tumors. This can possibly be attributed to the lack of nuclear localization
of dnMAML1 because of which its inhibitory effects on NOTCH signaling wasn’t
exerted. Mastermind- like 1 functions as a transcriptional co-activator in the nucleus
where it binds to ICN. To determine if NOTCH singling was indeed inhibited in 50% of
mice from the dnMAML1 group, we have to immunostain these tumors with HES or
HEY. Alternatively, in the other 50% dnMAML1 mice without tumors, nuclear
localization of dnMAML1 can be determined. It is possible that the lack of nuclear
localization of dnMAML1 after transduction in these wild-type cells might have caused
decreased inhibition of NOTCH activity. Another shortcoming to inhibiting the NOTCH
pathway using dnMAML1 is the difficulty in incorporating both copies of the construct
in mammalian cells after infection. We sorted cells after infection based on optimal GFP
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intensity and number of GFP infected cells. There is a possibility that some cells
incorporate only one copy of the gene that may not have an immediate effect in vitro, but
may decline in efficacy in vivo. Lastly, technical limitations while injecting these cells in
the tongue of mice might have also contributed to such aberrations.
Since our results from inhibiting NOTCH activity had these discrepancies, we
exploited the CRISPR-Cas9 technology to knockout NOTCH1 and NOTCH2 in the same
wild-type cell line; PJA34. Until now, loss-of-function studies using the CRISPR-Cas9
technology in HNSCC have not been performed. In other cancer types such as AML,
melanoma, colon, PDAC, NSCLC and liver cancer, this system has been used to knock
out genes such as p53, KRas, PIK3CA, APC and Smad4 (Castro et al., 2015; C. Chen et
al., 2014; S. Chen et al., 2015; Heckl et al., 2014; Shalem et al., 2014). Here, we show for
the first time that knocking out NOTCH1 and NOTCH2 relieves Jagged1 induced growth
inhibition in vitro. When NOTCH1 is knocked out in PJA34 cells and cultured on
Jagged1, there is some signaling through NOTCH2 which partially relieves growth
inhibition when compared to the parental cells cultured on Jagged1 (grey bar of parental
versus grey bar of NOTCH1 KO in Figure 27). Similarly, when NOTCH2 is knocked out,
signaling through NOTCH1 partially relieves growth suppression compared to parental
controls (grey bar of parental versus grey bar of NOTCH2 KO in Figure 27). This shows
that NOTCH1 or NOTCH2 is not sufficient to completely prevent the growth inhibitory
phenotype. Interestingly, knocking out NOTCH2 and NOTCH2 completely relieves
growth inhibition suggesting that both NOTCH1 and NOTCH2 are required for cell
growth suppression. It is intriguing that knocking out either NOTCH1 or NOTCH2
individually inhibits growth in the Fc controls compared to the parented cells cultured on
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Fc (black bar of parental cells versus black bars of NOTCH1 KO or NOTCH2 KO cells
in Figure 27). PJA34 cells express the ligand Jagged1. It might be possible that knocking
out one of the NOTCH receptors increases ligand sensitivity to the other NOTCH
receptor enhancing signaling activity. For example, NOTCH1 KO cells may have
enhanced sensitivity of the NOTCH2 receptor to the ligand and vice versa. In skin
keratinocytes, Demehri et al. have shown that conditional deletion of NOTCH2 in the
epidermis does not exacerbate carcinogen induced tumor initiation in the presence of
NOTCH1 as much as conditional deletion of NOTCH1 that generated spontaneous
tumors (Demehri et al., 2009), but progressive deletion of NOTCH1 and NOTCH2
enhanced epidermal hyperplasia. Our results are similar to this previously reported study
in that knocking out NOTCH1 or NOTCH2 separately could not relieve growth
suppression but knocking out both enhanced cell growth. In the previous study,
conditional deletion of NOTCH1 or NOTCH2 resulted in late tumor onset but conditional
deletion of both initiated early onset of tumors (Demehri et al., 2008). It might be
possible that NOTCH1 and NOTCH2 play roles in different stages of tumor
development. In cervical keratinocytes, loss of NOTCH1 with retention of NOTCH2
occurs in cells that are more aggressive and invasive implying that different NOTCH
receptors may participate in early and late stages of tumor progression (Talora, Sgroi,
Crum, & Dotto, 2002). Restoration of NFL1 in the dKO PJA34 cells rescues abrogation
of growth inhibition. This shows that NOTCH1 alone might be sufficient to mirror the
parental phenotype in the double knockout cell line. NOTCH2 might also result in a
similar phenotype, but at this point, we are unaware if NOTCH2 alone is sufficient to
rescue the dKO mediated growth.
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Identification of downstream effectors of the NOTCH signaling pathway
After we established a growth inhibitory phenotype after NOTCH activation in
wild type and mutant HNSCC cell lines, we evaluated the mechanism behind such an
effect. In our study, 1808 genes were differentially modulated after NOTCH activation.
We set a threshold of 1.4 fold, which filtered the 1808 genes to 120. Among these 120
genes, 50 were up regulated and 70 were down regulated. We report here that NOTCH
activation the significantly alters cell growth and proliferation pathways based on
“Ingenuity Pathway Analysis” of the differentially expressed genes. This finding
corroborates our earlier report of NOTCH activation inhibiting cell growth (Chapter 5).
In a study performed in laryngeal squamous cell carcinoma, in which NOTCH is
overexpressed, Dai et al. show that inhibiting NOTCH activity down regulates genes
associated with cell growth, proliferation, apoptosis, invasion and migration (Dai et al.,
2015). In our system, since NOTCH1 acts as a tumor suppressor, we found that NOTCH
activation down regulates genes associated with cell growth, proliferation and migration.
The oncogenic protein α-catulin found to be down regulated by NOTCH in our
experiments is overexpressed at the invasive front of human HNSCC tumors (Cao et al.,
2012). It is associated with poor clinical outcome in non-small cell lung cancer (NSCLC)
(Liang et al., 2013). Silencing α-catulin induces senescence in HNSCC (Fan et al., 2011),
and inhibits proliferation, migration, and invasion in both HNSCC and NSCLC cell lines.
Αlpha-catulin interacts with molecules regulating cell adhesion and the cytoskeleton,
functions as an activator of Rho GTPase and NF-κB signaling, and is a downstream
target of integrin-linked kinase (Fan et al., 2011). AXL, also downregulated by JAG1 in
our experiments, encodes a receptor tyrosine kinase frequently overexpressed in cancers,
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where it has been associated with poorer survival and increased metastasis (Paccez,
Vogelsang, Parker, & Zerbini, 2014), including in HNSCC (C. H. Lee et al., 2012).
Oncogenic properties of AXL have been attributed to proliferative and pro-survival
signaling, and inhibiting AXL reportedly blocks migration, invasion, and growth of
certain HNSCC cell lines (C. H. Lee et al., 2012). Integrins mediate attachment to
extracellular matrix proteins and are involved in proliferation, survival, migration and
invasion of tumor cells. Integrin α3, also downregulated by NOTCH signaling in our
experiments, is a major receptor for lamin-5; the principal component of the basement
membrane extracellular matrix (ECM) found in squamous epithelial of the skin and upper
aerodigestive tact. Loss of adhesion to ECM leads to apoptotic death known as anoikis,
and integrin α3 is necessary for survival of keratinocytes in culture (Manohar et al.,
2004). Overexpression of integrin α3 has been associated with lymph node metastasis in
HNSCC (Kurokawa et al., 2008; Nagata et al., 2013) while expression of integrin α5 has
been linked to increased metastasis and proliferation in laryngeal cancers (Lu, Sun,
Wang, Jin de, & Liu, 2009). We don’t know if NOTCH activation directly inhibits
integrins or there is a mediator downstream of NOTCH singling that facilitates this
modulation. P63 has previously been shown to inhibit integrins in the basal layer of
keratinocytes (Okuyama et al., 2008). We show that in one of the mutant cell lines ICN1
could significantly downregulate protein expression of ΔNP63 (Figure 56). However, in
wild-type cell lines, activation of NOTCH signaling using Jagged1 only modestly
suppressed ΔNp63 (Figure 57). Moreover, ΔNP63 was not significantly modulated after
NOTCH activation in the gene expression analysis. Mutations in NOTCH1 and TP63
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tend to be mutually exclusive (Figure 58). Thus, it is possible that in HNSCC, modulation
of integrins may be p63 independent.

181

HN31

ΔNp63

Actin

Figure 56: ICN1 inhibits p63 expression
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Figure 57: Activation of NOTCH signaling by Jagged1 slightly inhibits protein
expression of ΔNP63
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Figure 58: NOTCH1 and TP63 mutations tend to be mutually exclusive
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The gene expression analysis is based on mRNA levels of effectors altered after
NOTCH activation. We observed increased gene expression of potential tumor
suppressor genes and decreased levels of proto-oncogenes. Since we are interested in the
subset of patients that have inactive NOTCH signaling, we focused on proto-oncogenes
that had increased expression in the absence of NOTCH activation. We confirmed that
NOTCH indeed inhibited protein expression levels of AXL and α-catulin by inhibiting
NOTCH activity using the pan-NOTCH inhibitor dnMAML1. Blocking NOTCH activity
completely relieved NOTCH mediated inhibition of α-catulin and partially relieved AXL
inhibition. The dnMAML1 functions in the nucleus, suggesting that blocking of NOTCH
activity in the nucleus prevents inhibition of these proto-oncogenes. There are two
possible ways in which NOTCH activation could downregulate proto-oncogenes; by
directly binding to the promoter of these genes and impinging transcription (noncanonical NOTCH signaling) or by activating its canonical downstream targets (HES and
HEY), which then repress proto-oncogenes (canonical NOTCH signaling).
Non-canonical NOTCH signaling
Activated NOTCH by itself can regulate targets independent of HES and HEY.
For example, Rangarajan et al. have shown that expression of the activated form of
NOTCH1 caused a significant increase in p21 (Rangarajan et al., 2001) in keratinocytes.
Furthermore, they also showed that at the transcriptional level, p21 has an RBP-Jκ
binding site within close proximity to the TATA box to which ICN binds. In addition,
involcurin, a differentiation marker was found to be under transcriptional control of
NOTCH when keratinocytes differentiate at the basal layer. The promoter of involucrin
has two critical regions that contribute to its activation; sp1 and AP1 binding sites at the
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distal promoter region and a TATA box at the proximal region with a critical AP-1
binding site that overlaps with a motif for ets transcription factor binding sites (Efimova,
LaCelle, Welter, & Eckert, 1998). Rangarajan et al. have shown that intracellular
NOTCH binds to this promoter region independent of RBP-Jκ and upregulates expression
levels of involucrin. NF-κB is another target that is transcriptionally activated when ICN
binds to its promoter (Vilimas et al., 2007). NOTCH1 also directly interacts with the
transcription factor YY1 to drive c-myc transcription in human myelogenous leukemia
(Liao et al., 2007). In breast cancer, Lin et al. have shown that NOTCH activity
transcriptionally upregulates IL-6 that results in the activation of the JAK-STAT pathway
(Jin et al., 2013). We haven’t investigated if NOTCH activation transcriptionally
regulates AXL and α-catulin. Both these proto-oncogenes have AP1 and sp1 binding
sites. Chu et al. had demonstrated that ICN could inhibit the expression of AP-1
dependent genes. Overexpression of ICN in cells transfected with AP-1 component gene
strongly decreased AP1-mediate gene expression such as IL-8, MMP1 and IκBα (Chu et
al., 2002). It might be possible that in our system, activation of NOTCH signaling by
culturing cells on Jagged1 inhibits AP1 mediated transcriptional activation of AXL and
CTNNAL1. Transcriptional regulation of α-catulin is not completely explored. Xiang et
al. suggested that AP-2α and LEF-1 transcription factors regulate expression of
CTNNAL1 (Xiang et al., 2012). However, their evidence was limited to ozone-induced
stress activation of CTNNAL1.
Canonical transcriptional modulation of NOTCH targets
The canonical downstream targets of the NOTCH signaling pathway include
members of the HES and HEY family genes. We show here that restoration of NFL1 in a
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mutant cell line HN31 increased expression levels of HES2, HES5 and HEY2 by a least
two fold. Previously, we found at least 500-fold increase in HES5 after activating wildtype and mutant cell lines with ICN1. These levels however, are not physiological since
cells were transduced with high amounts of ICN1. Zage et al. have shown that in
neuroblastoma cell lines, ICN1 could induce more than 1000-fold increase in HES4 and
more than a 100,000-fold increase in HES5. When these cells were cultured on Jagged1,
they observed a 100-fold and 20-fold increase in HES4 and HES5 respectively (Zage et
al., 2012). Since HES and HEY family are known canonical repressors, we hypothesized
that HES2 and HES5 might transcriptionally suppress expression levels of AXL and
CTNNAL1. Thus, we overexpressed HES2 and HES5 in the mutant cell lines HN31 and
evaluated expression levels of AXL and CTNNAL1 by qRT-PCR. HES2 and HES5
didn’t seem to modulate mRNA expression levels of either proto-oncogenes (Figure 60).
HES and HEY transcriptionally modulate genes such as Achaete-scut-like 1
(ASCL1/HASH1), atonal homolog-1 (ATOH) and neurogenin (NGN1) have been
reported as targets of HES in neural tissues (Kageyama et al., 2005). Among the HES and
HEY1 family, the downstream effectors of HES1 and HEY1 have been well
characterized. Genes downregulated by HES1 included NEUROG3 (J. C. Lee et al.,
2001), GAA (Yan, Raben, & Plotz, 2002), CDKN1B (Murata et al., 2005), RCOR1, and
CFD and genes downregulated by HEY1 include GATA4 and GATA6 (Fischer et al.,
2005). Hes factors play critical roles in the development of many organs and expand
progenitor cell pools regulating cell fate decisions. HES1 and HES5 are regulated by
auto-negative feedback loops and function as effectors of NOTCH signaling coordinating
cell proliferation and differentiation via cell-cell interaction (Kobayashi & Kageyama,
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2014). Hey proteins are also basic helix- loop-helix (bHLH) transcription factors related
to the HES family. HEY proteins play critical roles in embryonic development,
differentiation and tissue homeostasis (Weber, Wiese, & Gessler, 2014).

Figure 59: Activated NOTCH1 increases gene expression of HES5
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Both HES and HEY proteins have a conserved bHLH domain that is essential for
DNA binding and homo and heterodimer formation. The N-terminal region defines the
specificity of binding to target DNA sequences which are N-box (CACNAG), E-box
(CANNTG) and class C site (CACG(C/A)G) (Sasai, Kageyama, Tagawa, Shigemoto, &
Nakanishi, 1992). It has been suggested that certain proline residues, which is conserved
in all HES factors, may be involved in target specificity, providing higher affinity for N box sites rather than E-box sites. On the contrary, the bHLH domain of HEY proteins
preferentially to E-box sites (Heisig et al., 2012). HES itself is regulated canonically after
ICN binds with RBP-Jκ upstream of the HES promoter (Katoh & Katoh, 2007). The
promoter sequences of AXL and CTNNAL1 did not harbor the N-box or E-box binding
motifs (Figure 61Figure 62) (Mudduluru & Allgayer, 2008; Xiang et al., 2012). At the
same time, non-canonical NOTCH signaling also upregulates HES proteins. These
pathways include bone morphogenetic protein (BMP), fibroblast growth factor (FGF),
leukemia inhibitory factor (LIF), NF-κB, sonic hedgehog (Shh) and Wnt signaling
pathways (Nakayama, Satoh, Igari, Kageyama, & Nishida, 2008).

189

NS
4

AXL
CTNNAL1

F o ld c h a n g e

3

2

1

0

H

N

31

P

ar

en

ta

l

H

N

31

M

R
ig

1

H

N

31

H

E

S

2

H

N

31

H

E

S

5

Figure 60: HES2 and HES5 don’t seem to transcriptionally modulate levels of AXL or
CTNNAL1.
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Figure 61: Promoter sequence of AXL lacks N-box or E-box motifs suggesting that HES
and HEY might not directly transcriptionally regulate AXL gene expression.
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Figure 62: Promoter sequence of CTNNAL1 lacking N-box and E-box binding sites.

192

Gene expression in TCGA HNSCC patient tumors
TCGA analysis of patient tumors using the 120-gene signature confirmed our
previous microarray analysis performed in cell lines. In addition, we also analyzed more
than 20,000 genes from the TCGA RNA-Seq data for differentially expressed genes at
two anatomical sites: Oral Cavity and Larynx/Hypopharynx. We found a few stem cell
markers among the top upregulated genes in patients harboring an active NOTCH
signature. These markers included Aldehyde Dehydrogenase ALDH1A1 and ALDH1A3,
which were not among the top modulated genes in cell lines. This finding is interesting
because it suggests that NOTCH activation might promote maintenance of stem cells,
which is contradictory to our hypothesis that NOTCH activation inhibits tumor growth.
Biologically, this is not surprising, since NOTCH signaling can promote stem cell
maintenance and suppress differentiation in certain lineages while promoting
differentiation in other lineages (Artavanis-Tsakonas, Rand, & Lake, 1999). NOTCH
activation is known to suppress growth of AML, however, there are reports that
activating mutations in β-catenin in osteoblasts stimulated Jagged1, which subsequently
activates NOTCH signaling in hematopoietic stem cells causing AML (Kode et al.,
2014). The hallmarks distinguishing normal stem cells from cancer stem cells is selfsufficiency in growth signals and insensitivity to anti-growth signals (L. Li & Neaves,
2006). The molecular pathways used by normal stem cells for homing to their niche may
be hijacked by cancer stem cells that promote invasion and metastasis. These results
suggest that activation of NOTCH signaling by ligands expressed by the supporting ECM
may contribute to a stem cell phenotype. We haven’t confirmed a cancer stem cell
phenotype in our panel of cell lines after NOTCH activation since we observed only two
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of the stem cell markers in patient samples. The most commonly used cancer stem cell
markers to date have been CD34, CD133, CD24, CD44, CD29 and CD31. Aldehyde
Dehydrogenase has only recently been propounded as a marker for HNSCC (Hoffmann,
Matthes, Stucker, Segerling, & Altmeyer, 1990). ALDH positive cells exhibit high selfrenewal capacity and radioresistance (Fabian, Barok, Vereb, & Szollosi, 2009). In
HNSCC cancer cell lines that have been evaluated previously, specifically- oral cavity,
pharynx, larynx, nasopharynx and hypopharynx, the most common cancer stem cell
markers include CD34 (Barth, Schenck zu Schweinsberg, Ramaswamy, & Moll, 2004),
CD117 (Tan, Selvaratnam, Kananathan, & Sam, 2006), CD44 (Kojc, Zidar, Vodopivec,
& Gale, 2005) and SCF (Pries, Witrkopf, Trenkle, Nitsch, & Wollenberg, 2008) .We did
not observe these markers in our cell lines and patient tumors. Stem cell proliferation is
regulated by nice signaling. Maintaing the balance between proliferation and antiproliferation is an important contributor or stem cell regulation. Any genetic mutation
that leads normal stem cells to become independent of growth control will cause them to
become cancer stem cells. Although the molecular markers of CSC’s may provide useful
information about the tumor pathogenicity, it is unclear whether every stem cell possess
some or all of these markers that enable a cancer cell to be stem cell like. Thus, the
stability of these CSC’s need to evaluate by sphere forming assays. It might be worth
considering an activated NOTCH1 inducible system in mutant cell lines and evaluating
sphere formations in 3-D cultures. Physiological and artefactual differences between cell
lines and patient tumors may also contribute to the differences in gene signatures we
observe in the two systems. The intensity of NOTCH activation varies from cell lines to
tumors. We are unaware of the physiological levels of NOTCH signaling needed to
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modulate these stem cell markers and this might confound our understanding of stem cell
regulation by NOTCH activation. Also, other genetic alterations in patient tumors such
as NUMB overexpression of p63 activation may also contribute to such a difference. The
microenvironment also plays an important role in stem cell regulation which we cannot
elucidate in a 2-D in vitro culture system. Alternatively, the modulation of stem cell
markers may not be specific to the tumor site due to infiltration of muscle or immune
cells in the tumor creating an artifact in our data. Lastly, two different techniques were
used to analyze differentially expressed genes in cell lines and TCGA patient tumors.
While we used the Affymetrix 2.0 microarray technique, TCGA analysis was performed
by RNA-Seq. Such differences in analysis may have confounded our results.
Inhibition of AXL and α-catulin modulates cell growth
In the last chapter, we show evidence that inhibition of AXL and α-catulin
modulates cell and tumor growth in mutant HNSCC cell lines. AXL is an attractive target
since it is overexpressed in several cancers including HNSCC where it is activated and
tightly correlated with cetuximab resistance (Brand et al., 2015). Here we show that
inhibition of AXL significantly inhibits cell and tumor growth. Brand et al. have recently
demonstrated that knocking down AXL using siRNA’s and a pharmacological inhibitor
R428 significantly inhibits growth. Our results corroborate with published data and
suggest that the AXL inhibitor can be effective in patients with inactivated NOTCH
signaling. We also observed that knocking down AXL in vivo is more effective than αcatulin. Clonogenic assays showed that knocking down α-catulin had the most significant
reduction in cell growth. It will be interesting to investigate the combined effect of
inhibiting both AXL and α-catulin in vivo. Since we observed significant suppression of
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growth when individually knocking down AXL or α-catulin, we assumed that combined
inhibition would produce a more aggressive suppressive effect. A limitation to our study
is that we haven’t proved NOTCH dependent modulation of AXL and α-catulin in vivo.
To show an in vivo effect, we will use the wild-type cell line PJA34 in which NOTCH1
and NOTCH2 have been knocked out using CRISPR-Cas9 and examine if they accelerate
tumor growth. Further, we will stain these tumors for AXL and α-catulin. It is possible
that the absence of NOTCH activation increases expression levels of these protooncogenes. This would give us a definitive correlation between NOTCH, AXL and αcatulin in a more physiological system. We will also evaluate the AXL inhibitor R428 on
tumorigenesis in comparison with mutant cells after NFL1 is restored. The restoration of
the NOTCH pathway could possibly provide a similar protective effect to the tumors as
those treated with R428. Although there is an inhibitor of AXL, currently there is no
pharmacological inhibitor of α-catulin. Recently Zheng et al. showed that overexpression
of α-catulin possibly plays an important role in malignant transformation of HNSCC by
inducing apoptotic resistance, promoting proliferation, cell cycle progression, migration,
and invasion. They also suggested that knockdown or silencing α-catulin might reverse
the aggressive phenotypes and EMT process (Z. Zhang et al., 2015). They demonstrate
that overexpression of α-catulin in a cell line that had low α-catulin mRNA expression
accelerated cell growth. Here, we show that knocking down α-catulin in a NOTCH1
mutant HNSCC cell line reverses cell growth and aggressive tumor formation and
prolongs overall survival. Besides cell growth, AXL and α-catulin are also involved with
cell migration and invasion. We haven’t demonstrated the effects of modulating AXL and
α-catulin on invasion since our primary focus was on NOTCH mediated growth
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suppression. Cell migration and invasion was the second most modulated pathway based
on IPA of our unbiased microarray. Thus, the role of NOTCH signaling in regulation cell
migration/invasion mediated by AXL and α-catulin can potentially be explored in the
future.
HES2 and HES5 inhibtis cell growth
After restoring NOTCH signaling in a mutant cell line HN31, we observed
elevated levels of HES2, HES5 and HEY2 about 20h after culturing these cells on
Jagged1. We did not observe a significant change in HES1, HES3, HES4 and HEY1. The
experiments were performed at 4 different time points after culturing cells on Jagged1.
While we did observe maximal upregulation of HES2, HES5 and HEY2 at 20h, other
time points (12h, 16h and 24h) also had higher expression, which was not seen in HES1,
HES3, HES4 and HEY1.
A critical aspect of HES regulation is its oscillatory nature on cell proliferation in
cultured cells. HES1 expression oscillates in many cell types including fibroblasts,
myoblasts and neuroblasts. The period of HES1 oscillation is about 2h in many murine
cell lines. After HES1 activation, the translated HES1 protein represses its own activity
by directly binding to the N-box sequence of its own promoter. HES1 gene products:
mRNA and protein are very unstable and have a half-life of about 20 min. Thus, they
disappear rapidly, indicating that auto repression is short and transient. HES1
autonomously initiates oscillatory expression with short periodicity. Several studies have
indicated HES1 oscillation and cell proliferation correlate with each other (Yoshiura et
al., 2007). While we do not observe modulations in HES1 levels, it might be possible that
in our system oscillations in HES2 and HES5 modulate cell growth and proliferation.
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HES1 can also repress cell cycle related genes such as E2F1, p27 and p57 (Castella,
Sawai, Nakao, Wagner, & Caudy, 2000; Georgia, Soliz, Li, Zhang, & Bhushan, 2006;
Hartman et al., 2004). We show that overexpression of HES2 and HES5 can suppress
AXL and α-catulin at the protein level. Whether HES2 and HES5 transcriptionally
modulates AXL and α-catulin in yet to be explored. AXL and α-catulin both lack N-box
or E-box motifs at their promoter sites. Thus, it might be possible that HES 2 or HES5
may not transcriptionally regulate AXL and α-catulin. Takata and Ishikawa have shown
that HES1 can repress target genes in a transcription- independent manner by recruiting
Sirt1, a homologue of silent information regulator 1 and class 3 histone deacetylase
through its bHLH domain, thereby suppressing target gene expression (Takata &
Ishikawa, 2003). HEY1 has been shown to directly interact with NcoR and Sin3a via its
bHLH domain. This forms part of the Sin3 corepressor complex which recruits histone
deacetylase-1 (HDAC1) (Gould, Harrison, Hewitt, & Whitehouse, 2009). Hey proteins
were also shown to bind to the androgen receptors and its co-activator Src1 to repress
transcription from promoters that depend on androgen (Belandia et al., 2005). In order to
address such non-transcriptional inhibition of AXL and α-catulin by HES2 and HES5, we
would have to perform a high-throughput screen to identify potential binding partners.
Techniques such as yeast 2-hybrid screens could be employed that would screen for a
library of potential interacting proteins.
Lastly, we show that overexpression of HES2 and HES5 inhibits growth that is
possibly mediated by AXL and α-catulin. First, we demonstrated that overexpression of
NOTCH1 inhibits cell and tumor growth. Next, we showed that NOTCH1 inhibits AXL
and α-catulin, which produces a similar growth inhibitory effect. Lastly, we prove that
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HES2 and HES5 may be sufficient to inhibit AXL and α-catulin. Taken together, these
results suggest that NOTCH mediated inhibition of cell growth might involve HES2,
HES5, AXL and α-catulin (Figure 54). Following NOTCH activation, the NOTCH-CBF1
complex binds to the HES promoter and activates transcription. In neural development,
Ohtsuka et al. have shown that HES1 and HES5 are required for mammalian neuronal
differentiation (Ohtsuka et al., 1999). In their model, overexpression of NOTCH1 in
HES1 or HES5 null mice inhibited cell differentiation and increased cell proliferation
suggesting that HES1 and HES5 may be required for NOTCH mediated inhibition of cell
proliferation and induction of differentiation. We haven’t completely evaluated the roles
of HES2 and HES5 in modulating AXL, α-catulin and cell growth. We have shown that
HES2 and HES5 may be sufficient to inhibit AXL and α-catulin in a cell line that has
inactivated NOTCH signaling. To prove that these canonical downstream targets are
necessary, we might have to overexpress NFL1 in cell lines that have HES2 and HES5
knocked out (by CRISPR-Cas9 system) and evaluate tumor formation, further staining
the tumors for AXL and α-catulin. This would indicate if HES2 and HES5 are necessary
for tumor growth and inhibition of AXL and α-catulin.
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Figure 63: Mechanistic model of NOTCH mediated growth suppression
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CHAPTER 9: CONCLUSIONS
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Conclusions
We were among the first group to identify frequent inactivating somatic mutations
in HNSCC (Agrawal et al., 2011). Recent TCGA data has shown that NOTCH is mutated
at a frequency of 15-19% in primary tumors ("TCGA Releases Head and Neck Cancer
Data," 2015), however the functionality of NOTCH in this cancer type was unknown. In
this thesis, we have shown evidence that NOTCH1 acts as a tumor suppressor in HNSCC.
For the first time, we cloned the full length NOTCH1 receptor and restored NOTCH
signaling in mutant cell lines and showed a growth inhibitor effect in vitro and in vivo.
Furthermore, we also evaluated the downstream effectors of the NOTCH signaling
pathway that mediate growth inhibition. We identified a novel link of two protooncogenes AXL and α-catulin in relation to the NOTCH signaling pathway. We propose
that NOTCH regulates these molecules at the protein expression level that might be
mediated by HES2 and HES; canonical downstream effectors of NOTCH signaling.

There are limitations to this study that need to be addressed. Firstly, how NOTCH
inhibits growth is not completely elucidated. We have shown partial evidence of
senescence and G1 growth arrest. However, the appearance of spherical ball like
structures after NOTCH is activated in a few cell lines like UM22A and HN31 are
reminiscent of stem cell morphology. In addition, stem cell markers ALDH3A1 and
ALDH1A1 were significantly upregulated in patients with an active NOTCH gene
signature. This necessitates the need to understand the balance between stem cell
maintenance and differentiation after NOTCH activation in our system. Secondly, we
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selected two proto-oncogenes AXL and α-catulin based on significance of modulation,
intensity of change and novelty to literature. There are several other molecules like
KRT13, KRT15, INTGA5 and INTGA3 that are involved with differentiation and
adhesion that were also upregulated after NOTCH activation. We couldn’t address
adhesion and cell migration/invasion in this study. Since cell migration/invasion was the
also one of significantly modulated pathways, it will be worth understand this aspect of
NOTCH signaling. Lastly, how NOTCH activation regulates AXL and α-catulin is
unknown. From our data, NOTCH might transcriptionally regulate AXL and α-catulin
but this might happened independent of HES2 and HES5. ChIP assays to evaluate
binding sites along the promoter regions of AXL and α-catulin will help address
transactional regulation of AXL and α-catulin by NOTCH signaling.

Besides these limitations, the identification of AXL being downstream of
NOTCH signaling has clinical relevance. Patients that are mutant for NOTCH1 have high
expression levels of AXL. Using the AXL inhibitor, it might be plausible to identify this
subset of patients for treatment with this inhibitor. Taken together, NOTCH1 acts as a
tumor suppressor in HNSCC, activates HES2 and HES5 and suppresses proto oncogenes
AXL and α-catulin which can potentially be exploited to treat patients harboring
inactivating NOTCH1 mutations.
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Appendix 1: Differentially expressed genes after activation of NOTCH signaling in
PJA34 and 183 cells. Green highlighted “Significance” cells show genes modulated
based on treatment, independent of cell lines. Orange highlighted “Significance” cells
show genes modulated based on treatment and cell lines

GENE
NETO2
ORC1
SVIL
HYOU1
SNX9
SDC4
LOC100131564
BUB1
PLEK2
LOXL2
TMEM55A
GLTP
EPHX1
TRAF6
MTA2
RBBP8
PFDN1
CCNE1
CHKA
EHD4
TMEM45B
PIGK
ACD
VPS13D
CAP1
KRT13
TRIM21
LAMC1
LOC100505648
NEK4
FKSG49
CDCA2
SPATA5
E2F7
LINC00305
PRODH
ALDH1B1

Test statistics
P-VALUE
1.31E-06
2.03E-06
2.19E-06
9.68E-06
1.06E-05
1.09E-05
1.48E-05
1.58E-05
1.86E-05
2.16E-05
2.32E-05
2.64E-05
3.02E-05
3.86E-05
4.28E-05
5.12E-05
5.39E-05
5.45E-05
5.90E-05
5.99E-05
6.02E-05
6.27E-05
7.57E-05
7.72E-05
8.26E-05
9.57E-05
9.63E-05
9.95E-05
0.000103862
0.000104204
0.000114433
0.000115175
0.000115519
0.000158426
0.000163931
0.00016933
0.000194034

Significance
SIGNIFICANCE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

Fold changes
PJA34 on Fc
183 on Fc
-1.786766469 -1.591373679
-1.293608993 -1.259996923
1.223653112
1.250670199
-1.495332483 -1.292542472
-1.262373825 -1.334064475
-1.368789079 -1.283115657
1.875013231
1.623158874
-1.226914977 -1.200692744
-1.786902142 -1.605018829
-2.494472424 -1.62763903
-1.478416916 -1.322108616
1.376199925
1.313716811
1.35263688
1.449610284
-1.152709899 -1.267995575
-1.12559422
-1.152395292
-1.258116005 -1.308456843
-1.219056404 -1.345029118
-1.474795156 -1.335716497
-1.234297491 -1.456601315
-1.487946593 -1.295572884
1.429789064
2.055369763
-1.175155846 -1.172503044
-1.157926571 -1.213096054
1.268872579
1.132285777
-1.229542907 -1.138716253
1.77026689
3.60191253
-1.179553244 -1.193941252
-1.319869362 -2.021028169
1.813266152
1.463558142
-1.130451774 -1.209764606
1.574041091
1.549512174
-1.219181131 -1.265979904
-1.19604649
-1.252998702
-1.289616457 -1.302467882
1.120782192
1.117798109
1.82869686
1.593180575
-1.414398822 -1.209027432
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C22orf32
VPRBP
BIN1
GRWD1
TOE1
GALT
FADS3
C16orf57
SQRDL
TWF2
SLAMF7
TP53BP2
CDCA8
H3F3B
MALAT1
HSPH1
CBL
CTNNBIP1
ABHD3
ZBTB25
ADAM15
FAM219A
TOMM40
NBR1
PCMTD1
NOL11
LSM2
WDR44
IGHG3
DPP7
CPD
SMURF2
LINC00511
LOC647012
SOX13
IL1R1
EIF2S2
UHRF1
FEN1
SPRED1
ZNF594
VKORC1L1
HSPA5
LOC100272216

0.000197178
0.000201273
0.000202017
0.000207466
0.000214969
0.00021556
0.000216641
0.000223521
0.000224705
0.000225339
0.000234851
0.000241564
0.000249332
0.00026069
0.000264194
0.000270567
0.000314101
0.000315766
0.000343651
0.000355473
0.000358385
0.000379691
0.000383483
0.000386537
0.000392268
0.000392324
0.000397076
0.000400631
0.000405287
0.000407105
0.000414971
0.000431243
0.000455291
0.000458961
0.000468285
0.0004875
0.00050376
0.000507888
0.000510527
0.00052766
0.000556438
0.000564705
0.000572539
0.000585628

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.160389924
-1.293232462
-1.322500096
-1.36700702
-1.336199744
1.297673436
-1.223837056
-1.346730387
-1.516282869
-1.37447999
-1.283074106
-1.179167952
-1.273954509
1.329345141
2.066669804
-1.160921812
-1.194529075
-1.393831987
-1.346209522
1.228214388
-1.224466846
-1.290578907
-1.29218039
1.260411621
1.231978882
-1.199564185
-1.11575537
-1.167975473
1.450297705
1.267265071
1.203387714
-1.239318784
1.202667989
-1.202200671
-1.166520205
1.289275026
-1.073577415
-1.30266581
-1.380328609
-1.339721849
1.410535469
-1.170939583
-1.147947658
1.738720093

1.199436895
-1.169661492
-1.514343369
-1.141186622
-1.326452408
1.185341207
-1.341600513
-1.32449736
-1.33368959
-1.176127818
-1.167099379
-1.316301924
-1.171928341
1.364899342
1.355450487
-1.224394234
-1.273433504
-1.347872954
-1.202183782
1.240702106
-1.235001168
-1.348998551
-1.135574829
1.175231438
1.345370524
-1.165537578
-1.257140018
-1.15586707
1.52644626
1.145468908
1.557163358
-2.068924561
1.443979779
-1.09464217
-1.364274341
1.938324922
-1.128741207
-1.202528743
-1.141452263
-1.392720777
1.276505876
-1.094360572
-1.203772664
1.514815069
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HSPA13
FAM157B
GPD2
FAM57A
OR8B3
FRK
PRORSD1P
MAP2K1
SLC9A1
VARS
ZBTB8A
GJC1
LOC100131434
MCM6
CD97
TTI1
CRYZL1
ESYT1
UAP1
PCYT2
EIF3F
THRAP3
FLJ45340
UFD1L
SMCR9
SLC16A1
NT5C2
RABGEF1
AMPD3
RAB26
IL20RA
PSMC3
TRBV5-1
TUBGCP4
MYSM1
CSE1L
LOC100288069
GSG2
PSMD12
NDST1
OCIAD2
KCTD9
CLK4
HNRNPU-AS1

0.000590424
0.000594079
0.000635699
0.000648745
0.000678339
0.000694778
0.000703802
0.000716848
0.000718803
0.000806383
0.000812592
0.000821452
0.000822597
0.000825588
0.000832563
0.000854126
0.000883016
0.00088412
0.000892989
0.000919649
0.00097262
0.000974314
0.000987726
0.000989381
0.001008265
0.00101877
0.001030223
0.001037365
0.001042321
0.001050574
0.001086824
0.001092144
0.00110443
0.001113621
0.001129062
0.001141472
0.001141889
0.001163901
0.001170838
0.001181211
0.001182903
0.001210061
0.001212289
0.00122636

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.054196479
1.909602286
-1.12685908
-1.328236535
-1.206940332
1.388054496
1.394405033
-1.394362066
-1.273198995
-1.314578851
-1.480987827
-1.156469072
1.683313028
-1.208127076
-1.287670548
-1.279442153
1.207725873
-1.595067548
-1.466897988
-1.207264975
1.159942667
-1.098936044
1.782429293
-1.166051339
-1.298573703
-1.154026654
1.119115853
-1.178031674
-1.265653826
1.222881856
1.318803561
-1.322784003
-1.327061294
-1.145609803
1.269770512
-1.152464387
1.765061556
-1.262337699
-1.285504432
-1.380693357
-1.556949385
-1.20445099
1.398852928
2.157469333

-1.150919628
1.387007581
-1.428244225
-1.251381626
-1.165626136
1.167870118
1.244419143
-1.110948043
-1.304208168
-1.141278214
-1.352056694
-1.447435154
1.482152043
-1.115939086
-1.363728948
-1.176280036
1.204011237
-1.149591818
-1.144797967
-1.363135773
1.086747285
-1.088246955
1.304067101
-1.097111777
-1.26293699
-1.451774579
1.337324108
-1.102004091
-1.422929114
1.216314483
2.148012943
-1.129624084
-1.21561504
-1.1032789
1.129472381
-1.083511616
1.328881943
-1.334676676
-1.122910038
-1.169410689
-1.122781668
-1.128654543
1.263704401
1.453534529
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PSMA1
SLC35E2
CLEC17A
TCTN1
EPHB4
TTK
CLK1
COX10
LOC100506479
LOC100132062
LOC100653348
CDH3
SNORD84
STK4
SFR1
FOXN2
CDC27
SNORD91B
ZNF35
FAM118B
LAMA3
ATL2
ODF3B
TPD52
CCNF
EIF3I
NCAPH
C1orf146
OCA2
IGFL4
DCAF8
PAN2
MRPS11
SH3BGRL3
TAF5
FAM122C
OR6B3
FAM46A
PSMA7
CTSA
GOLGA8C
POGK
GLT25D1
RASA4

0.001259243
0.001264955
0.001276609
0.0012788
0.001313916
0.001350236
0.001398848
0.001410188
0.001452983
0.001482583
0.001493134
0.001518356
0.001529692
0.001544275
0.001550509
0.001585853
0.001614763
0.001617171
0.001691019
0.001699061
0.001738458
0.001763792
0.001778024
0.001778274
0.001821216
0.001836842
0.001849109
0.001852168
0.001862792
0.001863598
0.001887869
0.001906978
0.001919266
0.001926675
0.001948789
0.001985931
0.002004681
0.002008932
0.002063621
0.002072446
0.002143645
0.002145979
0.002159086
0.002168785

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.196766829
1.200316252
-1.283001599
1.177566714
-1.117776332
-1.172201035
1.3904032
-1.104828409
1.918322565
1.810779445
1.871788981
-1.205714629
-1.108867356
-1.098528954
-1.326122306
-1.123577645
-1.182725124
1.130501138
-1.394711983
-1.21144686
-1.205982894
1.189065324
1.246758179
1.124090552
-1.266024078
-1.204890771
-1.183510252
-1.105574468
1.372399845
1.248627502
1.290723733
1.250390504
-1.310008296
-1.351744876
-1.141204504
1.151456395
-1.679502672
-1.479562317
-1.304162877
1.181721107
1.258968127
-1.195107669
-1.374305197
1.130235813

-1.095626295
1.126374789
-1.340105009
1.250927959
-1.296898448
-1.088664024
1.194132732
-1.173120573
1.306739336
1.300552223
1.32519271
-2.323396352
-1.133102691
-1.133062626
-1.274766477
-1.273755938
-1.085424244
1.257632747
-1.221597473
-1.143650655
-2.62113096
1.451325041
1.290313533
1.105773284
-1.182778925
-1.122326063
-1.105393594
-1.141910078
1.21903518
1.354082104
1.119782767
1.202139158
-1.10850888
-1.168113905
-1.243739076
1.282829205
-1.257620124
-1.216231584
-1.115425852
1.104804888
1.247813024
-1.210291568
-1.162192046
1.174806859

208

LOC100506636
AP3B2
TOMM34
RAD54B
ELOF1
TAF13
ARMC9
ZNF593
ABCA5
ADAT1
ABCA2
PCDHB18
SLC4A1AP
HSPA14
C9orf78
ASNA1
WDR36
OXNAD1
SPATA5L1
ROR1
MLLT11
LOC100653350
C3orf38
RDH11
DUX4L9
MCM3
LOC100133032
LYST-IT2
SNORA16B
PDCD1LG2
PBXIP1
ARHGDIA
CTCF
RNF207
PTPLAD1
DOLK
MLKL
BORA
MIR3689D1
SLC25A34
HHAT
USP48
LOC100506926
LDLRAD1

0.002182729
0.002185912
0.00222442
0.002234403
0.002236058
0.002248343
0.002268096
0.002272196
0.002275699
0.002293045
0.002317235
0.002327844
0.002372555
0.002380471
0.002406737
0.002442203
0.002462321
0.002467984
0.002489387
0.002546865
0.002551575
0.002557473
0.002584638
0.002611957
0.002635471
0.002635823
0.00263938
0.002648508
0.002660148
0.002668483
0.00269523
0.002736477
0.002762059
0.002783972
0.002844242
0.002894157
0.002901199
0.002920487
0.002946025
0.002980464
0.003022559
0.003022715
0.003039253
0.003041538

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.965580857
-1.139617117
-1.155041684
-1.198440837
-1.190819571
-1.301445786
-1.348939983
-1.221642777
1.446113105
-1.159905253
1.277503114
1.376796784
-1.15309246
-1.259227341
-1.151618977
-1.279293663
-1.140522857
-1.224988221
-1.40801875
-2.771381193
-1.551308408
-1.604746916
-1.180209063
-1.240587233
1.088351303
-1.123201497
1.133191665
1.409364984
1.432638092
-1.251598029
1.248909473
-1.388162796
-1.062049945
1.332365881
-1.175048628
-1.134445711
-1.204360821
-1.237885463
1.131992593
1.369878113
1.229899811
1.170695227
-1.157971455
1.211917067

1.298851484
-1.209679085
-1.413960853
-1.234573886
-1.071162823
-1.09392258
-1.220935505
-1.252188572
1.199999554
-1.266511687
1.143709909
1.114361557
-1.164520462
-1.245634752
-1.168343497
-1.101563842
-1.046372381
-1.156874243
-1.181282725
-1.334780243
-1.118740801
-1.380776818
-1.16586902
-1.082844886
1.426573737
-1.105011312
1.254169884
1.167814212
1.714984897
-3.302925645
1.191319012
-1.173613809
-1.114575891
1.278784301
-1.090491122
-1.243752331
-1.212046639
-1.177660205
1.476894034
1.141297974
1.208087909
1.094216952
-1.129393974
1.531508357

209

ZCCHC17
NOLC1
ANO1
APCDD1L
GPM6A
C17orf96
BOLA3
LOC654342
VASP
PLAC8L1
MIR4668
GOLGA8F
ANXA2P3
LRWD1
SCARNA21
LINC00514
THOP1
GRIK1-AS1
LOC729737
AMMECR1-IT1
ADPGK
TBC1D8
ADIPOR2
EPHA2
DBP
DNER
LOC554249
GPR65
IRF6
C9orf118
DNLZ
FAF1
LOC100287314
GBA
TRDJ2
NFYA
ZFAND2A
BMS1P5
ATP5S
MIR146B
SRD5A1P1
SNORD41
SELK
ITPA

0.003051979
0.003058899
0.003072006
0.00311888
0.003191475
0.003209697
0.003217741
0.003246446
0.003281192
0.003283025
0.003283186
0.003304404
0.003324505
0.003335295
0.003342125
0.003363033
0.003389264
0.003407719
0.003409182
0.003442353
0.003465772
0.003468426
0.003482462
0.003589923
0.003608038
0.003626329
0.003690705
0.003692228
0.00372726
0.003737204
0.003740105
0.003743002
0.003817511
0.003826381
0.003858077
0.003865274
0.003878197
0.003882601
0.003915878
0.003934832
0.003985077
0.003990502
0.00400774
0.004018787

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.302214406
-1.150051442
1.139045653
-2.026960024
-1.219558763
-1.099247753
-1.232781555
-1.523898262
-1.234048503
1.206297563
1.398813602
1.181782911
-1.523805742
-1.355611739
1.410408644
1.156422128
-1.304545151
1.301317831
2.103759441
1.139656571
-1.203901795
1.185818317
1.144721272
-1.485376135
1.175918938
-1.614963336
1.311408353
-1.256768361
1.063972323
-1.043415261
-1.388288522
1.094334874
-2.081614963
1.327467973
1.278546253
-1.148997031
-1.107301118
1.15825541
1.288044456
-1.712102686
1.216775526
1.314774035
-1.209650652
1.07017234

-1.118168788
-1.087622331
2.076667977
-1.143485905
-1.199435033
-1.41801
-1.159255018
-1.309840007
-1.334912987
1.236947949
1.572780922
1.126158306
-1.334015604
-1.190733455
1.137917443
1.168801951
-1.151971597
1.161168282
1.294475749
1.139566251
-1.156404935
2.313449352
1.081682242
-1.616781185
1.339803253
-1.235236778
1.31568982
-1.122144414
1.264426131
-1.181264887
-1.255445771
1.149666445
-1.211822115
1.281804471
1.168678249
-1.143601777
-1.249088208
1.154195964
1.11439769
-1.141662684
1.359809448
1.238238355
-1.258921629
1.114499093

210

PRMT7
BLM
CRISP1
PAFAH1B2
PIWIL4
UBE3A
RNU105C
FOSL1
MIR4742
AHNAK
TBC1D22A
SRA1
IARS
SNRPB
FUBP3
ND3
ARHGEF10
PSMD8
TMPRSS11BNL
GCFC1
CAV1
AXL
RAB40B
KRT15
VTCN1
C11orf54
EPHA4
FHL2
TP53INP1
SLPI
CMTM8
LOC645553
SERPINE1
ACSS1
PTRF
NAV3
LAMC2
MIR622
DRAM1
AFAP1L2
ANK3
LURAP1L
SUV39H1
PLD1

0.00404008
0.004068344
0.004206731
0.004213345
0.004224568
0.004312855
0.004339569
0.004399443
0.004420224
0.004497224
0.004514445
0.004609955
0.004613694
0.004633707
0.004675741
0.00478452
0.004812048
0.00484086
0.004849467
0.004863511
3.59E-09
6.41E-09
1.78E-08
2.22E-08
2.24E-08
3.57E-08
8.73E-08
1.15E-07
1.21E-07
1.58E-07
1.64E-07
1.78E-07
2.07E-07
2.27E-07
3.53E-07
4.33E-07
5.09E-07
5.60E-07
5.62E-07
6.00E-07
6.37E-07
7.13E-07
8.88E-07
8.95E-07

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.272695461
-1.136694174
-1.221353692
-1.231352047
-1.336913491
-1.089941778
-1.158404128
-2.537182189
1.448336912
1.188870686
1.056050372
-1.231012615
-1.067750282
-1.181061134
-1.100113723
1.149465184
-1.283419759
-1.198190776
-1.075984204
1.248138338
-1.879864475
-2.740535194
1.700767531
1.901707382
3.084901816
1.430378176
1.651338226
-1.793647944
2.990640742
1.435747632
-1.467111422
1.953409711
-2.737937127
1.330140299
-2.018511855
-2.015300831
-2.601950467
-1.713406578
-1.88475279
-1.48813128
1.38241757
1.743066142
-1.236273258
1.65776883

-1.077379596
-1.199473082
-1.105957874
-1.083086604
-1.311766301
-1.087460488
-1.120062761
-1.816340812
1.886408558
1.266188378
1.298516422
-1.117901999
-1.071573565
-1.103884557
-1.042948477
1.077011755
-1.244259404
-1.063805748
-1.159451655
1.114546701
-2.213279734
-3.550417429
1.981179136
1.686342124
2.960660781
1.436548543
1.937497399
-2.050525456
2.270578316
1.556415025
-1.621031591
1.785603835
-2.216887593
1.292522869
-2.160152521
-1.840096007
-4.660258605
-1.927822216
-2.08255253
-1.599475888
1.536904057
2.034945317
-1.256763713
2.024055226

211

SKA1
TJP1
ELK3
CXorf49
MICB
PDCD4
FUCA2
ME2
TMCC3
SEMA7A
ITGA5
HOMER3
ZBED2
TUBB
SYT16
SLC44A2
TINAGL1
MCM5
KIAA1147
PANX1
USP10
SLC16A2
TNFSF10
FGFBP1
FHOD1
GALNT2
TC2N
UTP20
PPAP2A
SKP2
ITCH
CTSC
P4HA1
ITGA3
PYGL
PXN
KRT18P10
MAP4K4
MBTD1
PKP2
GLTSCR2
CYP1A1
THSD4
NEDD4

1.29E-06
1.32E-06
1.50E-06
1.70E-06
1.78E-06
2.01E-06
2.13E-06
2.21E-06
2.29E-06
2.29E-06
2.34E-06
2.38E-06
2.55E-06
2.59E-06
2.68E-06
2.69E-06
2.94E-06
3.03E-06
3.24E-06
3.28E-06
3.30E-06
3.34E-06
3.47E-06
3.66E-06
3.75E-06
3.92E-06
4.16E-06
4.29E-06
4.43E-06
4.46E-06
4.79E-06
4.94E-06
4.95E-06
5.03E-06
5.22E-06
5.48E-06
5.51E-06
5.53E-06
5.65E-06
5.73E-06
6.21E-06
6.40E-06
6.42E-06
6.86E-06

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.430599512
-1.403405606
-1.25967842
-2.373220082
-1.386492784
1.722340546
-1.460606691
-1.21872262
-1.718795461
-1.57210976
-1.548089254
-1.605475502
-1.892263387
-1.130891546
-1.762607899
-1.285656293
-1.409760798
-1.26952641
1.467491511
-1.363988338
-1.115595875
-1.802144115
1.409020665
-1.843775565
-1.44140405
-1.352325102
1.424823062
-1.386989262
1.832492561
-1.26281721
-1.175851935
1.587310285
-1.419798997
-1.561938907
-1.275687899
-1.509970786
-1.655976362
-1.383645241
1.247070835
-1.509984202
1.334066127
1.652873806
-1.49717886
-1.139600153

-1.283475658
-1.258711109
-1.326464126
-1.770249814
-1.609662747
2.077520061
-1.34140004
-1.256448596
-1.879758243
-1.593661908
-1.66591199
-1.464097707
-1.69646004
-1.119801012
-1.621434495
-1.210443909
-1.386166566
-1.204929668
1.705353015
-1.260007079
-1.180940474
-2.572954157
1.626315216
-2.194481884
-1.467252458
-1.585801864
1.265983844
-1.250498328
3.047363185
-1.455441508
-1.137027189
1.366280459
-1.303381516
-1.882561378
-1.22819576
-1.831901732
-1.665664242
-1.265791535
1.220390928
-1.542301169
1.226318855
2.249775191
-1.54261147
-1.183365917

212

PBX1
NOP2
PNRC1
DFNA5
SLC12A2
WDHD1
ANLN
GCNT1
RCN3
SHMT1
RIPK4
E2F4
KIF14
ACPP
PLXDC2
HBP1
SPAG5
KLK6
FAM83D
HES5
ST6GALNAC2
LCN2
MCM8
SF3A3
FAM214A
SGSM2
CDCP1
DNAJC10
SOX15
ZWILCH
TUBB6
RNF138P1
INADL
ABCC3
LRFN4
RN5S496
GCLC
NMT1
CNKSR3
NF2
GATA6
YIPF1
CALB1
MOB3B

7.54E-06
7.91E-06
8.05E-06
8.18E-06
8.22E-06
8.32E-06
8.40E-06
8.44E-06
8.87E-06
9.17E-06
9.50E-06
9.52E-06
9.64E-06
9.76E-06
1.03E-05
1.07E-05
1.08E-05
1.11E-05
1.11E-05
1.15E-05
1.15E-05
1.19E-05
1.22E-05
1.26E-05
1.28E-05
1.28E-05
1.30E-05
1.33E-05
1.34E-05
1.36E-05
1.42E-05
1.42E-05
1.45E-05
1.46E-05
1.47E-05
1.52E-05
1.57E-05
1.59E-05
1.67E-05
1.91E-05
1.93E-05
1.94E-05
1.94E-05
1.94E-05

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.636231577
-1.272774869
1.337523493
-1.337065625
1.574053144
-1.205294668
-1.161794953
-1.317217456
1.165354094
-1.24460801
1.32600794
-1.318311614
-1.185854918
1.618462626
1.589624055
1.352290858
-1.207325799
-1.833552194
-1.221983101
1.455861404
1.456881687
1.507570226
-1.277139977
-1.152827264
1.40523228
1.376786204
-1.360600651
-1.215384665
-1.761679288
-1.198039909
-1.469844481
2.983802218
1.327631165
-1.397553493
-1.405695071
-3.410915511
1.774180387
-1.106073586
1.405179404
-1.247962622
-1.478216462
-1.272397024
1.427729205
-1.584894299

1.820221527
-1.198788856
1.422605915
-1.760828617
2.286239693
-1.217696276
-1.173841188
-1.333733481
1.272609596
-1.182589194
1.375810181
-1.361232757
-1.194170515
1.441360018
1.339970703
1.228506724
-1.193867684
-1.761434628
-1.136892115
1.640565012
1.566976092
1.373787535
-1.26620438
-1.179602843
1.46286467
1.333257908
-1.463711133
-1.279713107
-1.402531829
-1.267075109
-1.250822924
2.426622264
1.242823532
-1.761489599
-1.357507549
-1.917774556
1.412309223
-1.123937492
1.917444165
-1.216113273
-1.31407147
-1.329164765
1.339999325
-1.51973541

213

WNT7A
PCMTD2
CAP2
DNAJC2
CLSPN
KPNA2
PLAUR
MMP9
PRKX
MPV17L2
NPLOC4
DSP
FLII
RHOD
C20orf20
GPX8
TCF19
MFN2
NFE2L3
UPP1
FAM102B
CFLAR
UBE2T
LOXL4
SLC7A2
CYB5A
BRCA1
MCM7
TMEM27
GTF2IP1
DOCK5
CDS1
RAP2B
ANKRD2
BAG2
ISYNA1
MPPE1
P4HTM
WNK2
FANCD2
1-Mar
CCDC85C
ADD3
KRT18P54

1.97E-05
2.07E-05
2.08E-05
2.17E-05
2.22E-05
2.31E-05
2.35E-05
2.35E-05
2.37E-05
2.42E-05
2.46E-05
2.46E-05
2.47E-05
2.57E-05
2.57E-05
2.75E-05
2.78E-05
2.80E-05
2.80E-05
2.80E-05
2.85E-05
2.86E-05
2.91E-05
2.94E-05
3.00E-05
3.02E-05
3.03E-05
3.09E-05
3.16E-05
3.23E-05
3.38E-05
3.47E-05
3.50E-05
3.72E-05
3.76E-05
3.88E-05
3.90E-05
3.91E-05
3.92E-05
3.95E-05
4.02E-05
4.03E-05
4.08E-05
4.08E-05

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.332383813
1.409059196
-1.50968777
-1.29249164
-1.306358909
-1.136255138
-1.910431499
-1.598714895
1.562484797
-1.400850335
-1.18580229
1.467566441
-1.340949221
-1.412526842
-1.339681283
-1.204988833
-1.215235775
-1.181066435
-1.389423572
-1.432519049
1.660198946
1.220136259
-1.224744388
-3.122215928
-1.504287819
1.329640469
-1.135070532
-1.191800102
-1.63390962
1.260071836
-1.146817587
-1.471580804
-1.261172536
-1.665783348
-1.474943714
1.349583497
1.252157724
1.225615466
1.485789317
-1.116855619
-1.379733209
-1.333526241
1.358820282
-1.371958391

-1.683790922
1.481326956
-1.313624236
-1.24023538
-1.286925784
-1.080337381
-1.743558843
-2.528770321
1.660797133
-1.300737366
-1.157307387
1.651192413
-1.278247522
-1.297628171
-1.31992651
-1.370357629
-1.155721191
-1.12823715
-1.46206054
-1.548333718
1.408780083
1.283926877
-1.20240708
-1.797933225
-2.240838573
1.394810557
-1.116543091
-1.208786606
-1.484812487
1.195103599
-1.109710407
-1.365683477
-1.246133097
-1.563020181
-1.29861083
1.344983351
1.146987714
1.169545978
1.350053332
-1.120172785
-1.209994276
-1.213183336
1.410445919
-1.604895302

214

FAM116A
CIRH1A
ARHGDIB
DARS2
AP2B1
PEA15
TPMT
PLOD3
FAM21A
LOC439990
SH3TC2
MANSC1
H3F3A
SMS
INTS7
SOX2
SLC25A13
LY6K
CD3EAP
CDC25A
GOLGA8B
FERMT2
SDF2L1
SFSWAP
ANKRA2
ZC3H14
MCM10
PRIM2
JAG2
GEMIN5
PSMB1
CASD1
LSR
SRP68
CACNG4
ORC6
DLL1
FXYD5
BFAR
TBC1D3G
CRIM1
LEPREL1
SERINC2
DDX56

4.14E-05
4.17E-05
4.24E-05
4.26E-05
4.28E-05
4.30E-05
4.37E-05
4.40E-05
4.44E-05
4.50E-05
4.54E-05
4.58E-05
4.58E-05
4.58E-05
4.62E-05
4.62E-05
4.62E-05
4.62E-05
4.64E-05
4.70E-05
4.87E-05
4.92E-05
4.92E-05
5.00E-05
5.03E-05
5.04E-05
5.06E-05
5.45E-05
5.48E-05
5.48E-05
5.52E-05
5.69E-05
5.82E-05
5.86E-05
5.87E-05
5.91E-05
5.92E-05
5.93E-05
6.02E-05
6.07E-05
6.27E-05
6.37E-05
6.53E-05
6.53E-05

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.205069728
-1.397767207
-1.96602048
-1.199047349
-1.431655239
-1.509446711
-1.601193275
-1.36954968
1.163310643
-1.97086006
1.288006009
1.562403784
1.185208302
-1.215885914
-1.182604393
1.439008166
-1.168402185
-1.510338848
-1.533856284
-1.453085166
1.755164941
-1.525847841
-1.377527908
-1.126488176
1.342585244
-1.100060431
-1.335189746
-1.231896516
-1.213845854
-1.271575948
-1.283745597
1.198303744
-1.160269975
-1.125162221
-1.267468044
-1.467914621
-1.338208803
-1.175943928
-1.207693857
1.196220852
-1.198495189
-1.629279347
-1.618478241
-1.239628019

1.195905164
-1.232822721
-1.391176075
-1.131005693
-2.222986212
-1.253661547
-1.303637071
-1.976501665
1.141073698
-1.581887867
1.280236117
1.730101187
1.149451876
-1.182905969
-1.26712887
1.375236492
-1.210186803
-1.267068197
-1.314359608
-1.316096195
1.430585282
-1.310791219
-1.269674802
-1.116264512
1.275819028
-1.071990957
-1.163231602
-1.221243314
-1.392949812
-1.188542557
-1.121026262
1.138690168
-1.216788602
-1.112908479
-1.32472122
-1.222637654
-1.646450978
-1.384971547
-1.132621484
1.274581238
-1.397970117
-1.505439876
-1.376283612
-1.140127332

215

SLC39A14
GOLGB1
GLUL
PPAP2C
WDR19
PDIA4
MELK
LETMD1
FAF2
DNMT1
SLC3A2
CANT1
TPR
PKD1P1
YARS2
STAC
RHOV
EIF2C4
GOLGA8A
B4GALNT1
CUL1
TMEM59
CD55
THSD1
KHNYN
NUP88
C1QBP
GCH1
KPNA3
CHRNA5
MTM1
HEG1
SCRN1
SERPINE2
ZAK
OLFML3
HLTF
WDR60
SLC11A2
CENPN
SLC25A6
TIMP1
TYMS
PI4K2A

6.56E-05
6.57E-05
6.63E-05
6.79E-05
6.82E-05
6.94E-05
7.00E-05
7.01E-05
7.04E-05
7.09E-05
7.27E-05
7.28E-05
7.30E-05
7.33E-05
7.38E-05
7.54E-05
7.68E-05
7.76E-05
7.85E-05
7.86E-05
7.92E-05
8.35E-05
8.36E-05
8.37E-05
8.44E-05
8.56E-05
8.56E-05
8.60E-05
8.62E-05
8.64E-05
8.69E-05
8.76E-05
8.84E-05
8.89E-05
9.32E-05
9.39E-05
9.39E-05
9.44E-05
9.48E-05
9.55E-05
9.55E-05
9.57E-05
9.60E-05
9.68E-05

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.460453143
1.324327257
1.671557955
1.16900111
1.308874626
-1.249534891
-1.296728801
1.289321084
-1.167500406
-1.15081456
-1.229056493
-1.263101153
1.155543982
1.381327638
-1.335294464
-1.724328789
1.309605705
1.316108752
1.696759181
-1.313654459
-1.22546041
1.37694188
-1.42095849
-1.701477442
1.194914334
-1.132512485
-1.169364152
-1.364705711
-1.157837018
-1.253404087
-1.11230361
-1.489284699
-1.156697525
-1.369715324
-1.240993049
-1.376356582
1.222382931
1.243347578
1.168255724
-1.274710571
1.126789546
-1.18153691
-1.241345088
-1.4942046

-2.261275184
1.267323124
1.434873429
1.385468694
1.250091094
-1.217454913
-1.19070894
1.296732181
-1.195980278
-1.211846273
-1.193028566
-1.325381965
1.165324222
1.22173835
-1.21395653
-1.368932259
1.615115896
1.282118598
1.403030571
-1.657225633
-1.15876126
1.228639864
-1.72847595
-1.310144595
1.148038266
-1.137218206
-1.135026527
-1.666349608
-1.139180939
-1.222216732
-1.228309266
-1.867101731
-1.313001516
-1.598968503
-1.397499274
-1.285810891
1.487774907
1.262711226
1.282132254
-1.240757009
1.119678886
-1.356171271
-1.153860772
-1.400038662

216

STAM
EXO1
NOMO3
PKP1
IPO9
FST
CLOCK
NPIP
KLHL24
DLAT
DIAPH3
PELI2
LPAR1
ACO1
MAL2
CDC6
ZNF658B
NXPE3
VEGFC
CXCL16
ETV4
NEK3
ETHE1
CPPED1
MICAL3
CLIC1
PLXNA2
HSP90B1
RAB3D
GBP2
TJP2
EMC1
ZDHHC16
PVR
SIRPA
TXNIP
STXBP1
TTC13
RFWD3
KIRREL
MAML2
CERS6
NOMO2
VGLL3

9.74E-05
9.78E-05
9.80E-05
9.86E-05
0.000100404
0.00010061
0.0001013
0.000103775
0.00010392
0.000104889
0.000105834
0.000106871
0.000107489
0.000107568
0.000107997
0.000109142
0.000109385
0.000109425
0.000109475
0.000110021
0.000110256
0.000110287
0.000110842
0.000113126
0.00011452
0.000115447
0.000116539
0.000117002
0.000118126
0.000119409
0.000119862
0.000120037
0.000120428
0.000120639
0.000121239
0.000124053
0.000124291
0.000125826
0.000125975
0.000126131
0.000126779
0.000126906
0.000127704
0.000128607

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.387963716
-1.23873618
-1.195281414
1.232903721
-1.188523973
-1.985150282
-1.24239604
1.351216977
1.741500364
-1.180222797
-1.304281888
1.486457442
-1.336840129
-1.77471041
-1.219185367
-1.239669677
1.390951125
-1.520349076
-2.014026443
-1.422118031
-1.260040685
-1.393380197
-1.454724904
-1.307208579
-1.324226219
-1.225052491
-1.298680192
-1.131376806
1.311233188
1.360413598
-1.194202233
-1.174426978
-1.264630158
-1.468257426
-1.798870851
2.626598723
-1.316633091
-1.283584096
-1.161337313
-1.770394052
1.200555625
1.253810849
-1.197527939
-1.151060371

-1.312774585
-1.247638667
-1.101620962
1.360957134
-1.172573525
-5.3153921
-1.147297409
1.23180045
1.545723369
-1.150167221
-1.252877818
1.258656044
-1.407432313
-1.293598741
-1.175573379
-1.287635628
1.209824992
-1.690504953
-1.497205405
-1.395273239
-1.33407348
-1.536496255
-1.25989776
-1.397153705
-1.243332578
-1.15332439
-1.372448664
-1.178549854
1.294328322
1.640683921
-1.14433086
-1.167427417
-1.104047711
-1.186739576
-1.416787658
1.665566548
-1.298607274
-1.197292853
-1.237966391
-1.455777418
1.26831129
1.273062251
-1.095538934
-1.295448274
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RBL2
PIM1
OLR1
PSMD2
VPS36
TXNDC12
MPHOSPH6
NEBL
SEH1L
CYB5B
ZCCHC2
ACOT9
HSF4
FKBP14
STAMBPL1
ANXA3
DBNL
MYH14
RPS27
CTSB
BMP2K
TCOF1
FAM21C
LOC401561
TK1
NLRP2
KIAA0040
DPP4
AKAP9
GABARAP
CYR61
MGEA5
MIR4640
MRPL39
C8orf46
RRAS
PTAFR
MCMBP
OAT
JMJD6
DIAPH1
DCLRE1B
CHML
FAM21B

0.000128657
0.000130393
0.00013061
0.000131133
0.00013134
0.000131498
0.00013259
0.000134046
0.000135952
0.000136916
0.000136977
0.000137038
0.000137223
0.000137232
0.000138956
0.000139997
0.000140159
0.000141238
0.00014398
0.000145272
0.000145427
0.000145856
0.000146041
0.000148086
0.000149338
0.000149947
0.000150652
0.000152024
0.000153399
0.000154087
0.000154488
0.000154813
0.000155638
0.000156396
0.000157188
0.00015826
0.000158438
0.000158533
0.000160086
0.000162102
0.000163211
0.000166884
0.000167976
0.000168372

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.148332559
-1.338092789
-6.593014033
-1.241205525
1.291499687
-1.085144955
-1.292402445
1.286885398
-1.125631789
-1.129290092
-1.173435814
-1.351231814
1.148093441
-1.436561452
-1.306682129
-1.583029242
1.146970395
1.572475683
1.055957332
1.185355928
-1.330493071
-1.41542631
1.270631874
1.649211391
-1.331678598
-1.232331092
-1.55138277
-1.303076488
1.209742836
1.160762625
-1.917068636
1.260700811
1.177069801
-1.21625183
-1.248317153
-1.28076513
-1.353423693
-1.170769472
-1.285508001
-1.324361315
-1.215219668
-1.36373508
-1.597081385
1.146016411

1.18979772
-1.287994761
-2.079015688
-1.162526183
1.129650201
-1.083696684
-1.214202508
1.643426513
-1.130986249
-1.228622902
-1.298030922
-1.2684911
1.175934745
-1.173360801
-1.43335589
-1.349604018
1.191510937
1.730454879
1.086223937
1.231324654
-1.552107745
-1.266377001
1.199604992
1.470136681
-1.321397108
-1.32647322
-1.461947231
-1.183726898
1.24546084
1.162612807
-1.697498787
1.229362711
1.215226637
-1.126594416
-1.251454368
-1.183682416
-1.804724925
-1.159160244
-1.607076323
-1.151635456
-1.250376819
-1.192861699
-1.279224973
1.155356286

218

CCNA2
NKX1-2
ZC3HAV1
PRKCDBP
LASP1
KARS
VLDLR
SORL1
HEATR1
TEAD4
RALGAPA2
ABCC5
PRPF4
ADAM9
ATP11C
FAM53A
SLC30A6
FOXN3
FZD6
ITGB6
ARID3B
ATP2C1
SYF2
LAMB1
SKA3
FAM84A
KLF5
RAB32
TMEM30A
SAMD4A
SPR
PTBP1
ERV3-1
C6orf165
MOCOS
PALLD
FAM63B
SLC7A5
TMEM179B
HAS3
TCHH
RUSC2
LHFP
DOCK10

0.000174051
0.000177005
0.000177802
0.000179403
0.000181513
0.00018201
0.00018433
0.000184793
0.000185163
0.000185529
0.000186118
0.000186165
0.000186629
0.000187849
0.000188532
0.000188586
0.000189679
0.000189923
0.000190746
0.000193008
0.000194849
0.000197257
0.000198774
0.000201107
0.000201989
0.000207119
0.000208562
0.000209603
0.000210213
0.000217179
0.000217473
0.000218831
0.000219413
0.000223184
0.000226977
0.000228332
0.000230183
0.000230817
0.0002314
0.000231477
0.00023262
0.000233435
0.00023378
0.000234026

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.174797098
-1.492677011
-1.192226982
-1.664242664
-1.252079602
-1.179188418
-1.582824968
1.229216004
-1.17483543
-1.205489319
1.244111383
1.633557517
-1.260510032
-1.183954662
-1.343794796
-1.211837916
-1.222344786
1.281457321
1.229515086
-1.334627181
-1.376856696
1.272914338
1.186657176
-1.208656242
-1.256462495
1.320521161
1.1617269
-1.479021293
1.263619983
-1.377379174
-1.184735714
-1.173585682
1.375311101
1.381043681
-1.423209418
-1.414526972
-1.284453124
-1.248829373
1.260924525
-1.578672124
1.579845583
-1.306457967
-1.723069618
-1.296767806

-1.091181929
-1.335451615
-1.286243346
-1.218909765
-1.29549853
-1.088139507
-2.03474913
1.45642516
-1.098202489
-1.200823774
1.37276222
1.347721622
-1.177526575
-1.092258817
-1.299415373
-1.331239224
-1.119678722
1.303567232
1.148164809
-1.340142473
-1.823429638
1.193186263
1.159074472
-1.520539289
-1.269966115
1.22475819
1.213677895
-1.801964392
1.113659747
-1.128595584
-1.246897802
-1.137846803
2.052480665
1.170540974
-1.21834116
-1.222083655
-1.190846517
-1.149629545
1.172412358
-1.302197181
1.348696719
-1.437612054
-1.220986856
-1.929596045

219

NAT10
IMPDH1
TBC1D3B
ATIC
ACTN1
UBLCP1
NUDC
EHD1
UGGT1
LOC100506642
GALNT5
CENPO
CUL7
RAD51
MIR525
FOXD1
ESCO2
TIPARP
TCF25
WDR27
LRBA
TMEM205
QSOX1
TIMP4
PLAU
KRT4
LIMK1
SNORD59B
PPP1R3E
CDV3
PTPN1
PLEKHG1
TARS
GALNTL4
BCAT1
TGFBRAP1
RRP12
FAM49B
METTL7A
ZNF84
UBE2Q2P3
STIL
OGT
PCDH1

0.000234149
0.000234618
0.000237602
0.00023766
0.000238037
0.000239024
0.000239859
0.000241775
0.000242424
0.000242446
0.000246347
0.000247984
0.000248577
0.000251478
0.000252032
0.000252063
0.000253454
0.000254503
0.000254555
0.000254571
0.000255492
0.000258499
0.000260581
0.000261133
0.000263114
0.000263173
0.000264328
0.000265121
0.000265159
0.00026529
0.000265926
0.000269287
0.000273428
0.000275503
0.000276784
0.000277133
0.000277682
0.000279676
0.00027996
0.000280049
0.000281714
0.000283325
0.000283938
0.000286697

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.168857975
-1.235753742
1.264148035
-1.20604795
-1.210219655
-1.253229939
-1.276227195
-1.236428606
-1.156504447
1.283913602
-1.217249433
-1.211149201
1.400573398
-1.43068189
-1.266632404
-1.222640877
-1.269443153
-1.449674808
1.15803223
1.250768761
1.228653437
1.252828633
-1.805719258
-1.404216098
-1.647117974
2.00019907
-1.428165077
1.510727321
1.152240112
-1.122606238
-1.158598226
1.315911808
-1.11458299
-1.525054857
-1.283464515
-1.237017388
-1.438354478
-1.187853366
2.169741035
1.344416222
1.315607567
-1.209125943
1.239065213
-1.960020009

-1.103733029
-1.368780499
1.212473727
-1.13518368
-1.2533989
-1.231617332
-1.130574209
-1.130977491
-1.122268492
1.283086491
-1.163914074
-1.186898785
1.215672681
-1.243320085
-1.264326579
-1.332116549
-1.216026834
-1.27682851
1.131243501
1.283727916
1.090909674
1.359534642
-1.307023989
-1.460939361
-1.319414987
7.953067935
-1.210252291
1.232666676
1.134403823
-1.115015548
-1.144637111
1.363640669
-1.098573674
-1.207628203
-1.871113366
-1.315893799
-1.230514184
-1.397427958
1.335303208
1.364854842
1.185772599
-1.174571755
1.180666549
-1.355610088

220

FAM98A
RNASEH2A
ORC3
RPL31
FOXO4
CTSS
PLXDC1
FLOT1
LOC100506935
ABCG2
PLEKHM3
TRIP13
CDC7
SRI
ASNS
ALS2CR8
JMY
ACER3
DONSON
PLCE1
MRP63
HSPA4
RAB7L1
RPN1
GLA
ADAM8
TXNL1
DPYD
OAZ1
SERPINH1
ECH1
MRM1
ZNF250
DLX5
IKZF2
ZNF22
VPS13C
TMEM184C
C2orf18
RN5S402
LOC100130476
ARHGEF12
U2AF2
DNM1P41

0.000287065
0.000290059
0.000291348
0.000293117
0.000293421
0.000295009
0.000298272
0.000300376
0.000302553
0.000307053
0.000310256
0.000310665
0.000310739
0.000312296
0.000312816
0.00031319
0.000315048
0.000316994
0.00031732
0.000318331
0.000320155
0.00032145
0.0003233
0.000324194
0.000324335
0.000325857
0.000325906
0.000328209
0.000328364
0.000329939
0.00033046
0.000331348
0.000331756
0.000332635
0.00033363
0.000335975
0.000339616
0.000342295
0.000345685
0.00034665
0.00034892
0.000349716
0.000350018
0.000352588

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.442439238
-1.207746271
-1.194760527
1.25640145
1.557674534
1.129789489
1.141517911
1.100666417
1.430678231
-1.840993127
1.283268195
-1.353190978
-1.10572237
1.175916012
-1.149648453
1.631122823
1.456572275
-1.551363012
-1.22742729
1.540953497
-1.174698757
-1.130127173
-1.329652548
-1.117483298
-1.549920116
-1.24321647
-1.14475063
1.975114736
-1.121996324
-1.2716395
1.199772041
-1.368464778
1.165688967
1.773681707
1.409508975
-1.326502968
1.335101102
-1.168528379
-1.279155646
-2.094243389
-1.502695813
1.147202384
-1.184107597
1.483164879

-1.156892608
-1.117177962
-1.140101193
1.145365005
1.250727071
1.217655031
1.139270165
1.088624747
1.424488892
-6.595932251
1.227954822
-1.145040559
-1.241761546
1.217541175
-1.226739845
1.319786257
1.272182613
-1.243252732
-1.128293933
1.199927888
-1.100974838
-1.146876655
-1.192857565
-1.085571681
-1.221684458
-1.227970694
-1.110377152
1.29580529
-1.12764447
-1.964693633
1.140797118
-1.160283049
1.094164499
1.643323949
1.446120059
-1.298118361
1.187367721
-1.137299011
-1.222216226
-1.82277049
-1.503344309
1.076751774
-1.125368369
1.275378048

221

DGKE
GPRC5A
NUP93
PRMT5
KRT18P49
TES
PMS2L2
PMS2P5
GSTA4
C6orf211
AKT1S1
CDK8
DBT
CASK
NLN
STK10
PGLYRP4
FAM101B
RNF219
MYBL2
USP39
SLC41A1
PPT1
GUSBP9
RNF19B
MYO1B
MIR3118-4
ARNTL2
EBP
NDST2
RPN2
ERLIN1
XPO5
ISG15
GINS2
SH3BP4
ABLIM1
RAD51C
GLIPR1
ARFGEF1
PERP
SLC25A44
PIR-FIGF
SH2B2

0.000353441
0.00035589
0.000356243
0.00035667
0.000357895
0.000357904
0.000359986
0.000359986
0.000361327
0.000364231
0.000364962
0.000365801
0.000367342
0.000370181
0.000370875
0.000371016
0.000373443
0.000374899
0.000378321
0.000379107
0.000379132
0.000380477
0.000380835
0.000383478
0.000384782
0.000385759
0.000386184
0.00038825
0.000391217
0.000392231
0.000392231
0.000394002
0.000394361
0.000394798
0.000396571
0.000397478
0.000398989
0.000399977
0.000400231
0.000400335
0.000410611
0.000410707
0.000411148
0.000412761

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.260957911
-1.311761982
-1.271206327
-1.165549375
-1.292834105
-1.160941069
1.439119651
1.439119651
1.590912499
-1.17348653
-1.1100692
-1.228256127
1.086812505
1.138163985
-1.177901578
-1.189543578
1.435101296
-2.277261896
-1.147913364
-1.314265138
-1.080629468
-1.199676563
-1.093386609
1.521824158
-1.371650258
-1.248379215
1.498860631
-1.193232673
-1.263148341
1.254525871
-1.13038129
-1.148578165
-1.210434815
-1.182644619
-1.376554814
-1.193214817
1.298356204
-1.252490529
-1.905034225
1.252426728
1.214338733
-1.362905828
1.239320758
1.267326869

-1.337517938
-1.327476756
-1.107937094
-1.168698641
-1.605403809
-1.110593195
1.212335364
1.212335364
1.274311438
-1.225366797
-1.13104742
-1.276149129
1.180747621
1.46202143
-1.146674214
-1.618581834
2.226299786
-1.450537858
-1.192659235
-1.173781215
-1.182676322
-1.452884206
-1.097100531
1.326504944
-1.183815139
-1.648823193
1.256512862
-1.522893129
-1.132080357
1.201595683
-1.05901345
-1.164722288
-1.117951235
-1.264439744
-1.141047609
-1.579219229
1.238585109
-1.288075293
-1.248103139
1.106949583
1.167502082
-1.25459698
1.25333293
1.371170765

222

TMEM222
MEA1
QARS
RFC2
HAUS2
LOC647979
TIPIN
HPRT1
UTP15
MUC16
LOC100506290
PSMD1
TRIM2
SBF1P1
ALOX12
HK2
MPP5
RPAP3
ZDHHC7
ABCD3
PDLIM1
MFAP5
STS
RARRES1
NOL10
CDK4
NT5E
TGFA
TMC7
NCS1
COL17A1
SAT1
RANBP3
MICA
LENG8
MIR3676
GOLGA8G
FAM129A
STARD13
GOT2
SNAI2
RHOF
LMBRD1
ZNF117

0.000418161
0.000420433
0.000426096
0.000426119
0.000426211
0.000427466
0.00042835
0.000428437
0.000430994
0.000431455
0.000432292
0.000434354
0.000436444
0.000437353
0.000442432
0.000450298
0.000451158
0.000451444
0.000453953
0.000454202
0.000454591
0.000455964
0.000460998
0.000461643
0.000461765
0.000463178
0.000464717
0.000468305
0.00047177
0.000478377
0.000479488
0.000480785
0.000482191
0.000483363
0.000483747
0.000487013
0.000490984
0.000492087
0.000492427
0.000493577
0.000495325
0.000504387
0.000505787
0.000509494

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.132163406
-1.19018474
1.129330411
-1.21783339
-1.318649401
1.240307358
-1.219811799
-1.17903191
-1.37843241
2.026128216
1.670214782
-1.394527668
1.375156749
-1.214372994
-1.162794445
-1.550770824
-1.116850495
-1.146979965
-1.106400032
-1.219134
-1.095258272
-1.478819118
-1.340771707
1.226912609
-1.251842777
-1.194554413
-1.480174664
-1.418222296
-1.284458373
-1.533531795
-1.430252434
1.398732593
-1.198483587
-1.198544144
1.368191747
-1.843221848
1.202486305
-1.303456156
-1.221427498
-1.187586043
-1.232970827
-1.132011235
1.272861006
1.626818393

-1.181137478
-1.187661609
1.144844025
-1.10985627
-1.170033909
1.247846774
-1.302642991
-1.196121536
-1.245847317
1.468663634
1.554751672
-1.126170689
1.394340441
-1.159817018
-1.240116603
-1.241913665
-1.162400946
-1.216548346
-1.092583846
-1.174268814
-1.337934288
-3.139033811
-1.265197302
1.465701522
-1.101358409
-1.087780014
-2.337974947
-1.313560883
-1.907917739
-1.251854445
-3.369209972
1.21063313
-1.23327753
-1.651612814
1.263895588
-1.323379118
1.178326662
-2.062373963
-1.265248543
-1.094510737
-1.452932665
-1.406164656
1.143712271
2.632758366

223

MIR604
ATP6V1B1
DSG3
DUSP11
COTL1
GLT8D2
PXDC1
R3HDM2
RNF115
COL16A1
C11orf92
LOC100507246
TPBG
GJB3
WDR54
PDLIM7
PSMB4
AKR1C3
C3
CAV2
RAPGEF1
ECI2
APEX2
DDX27
HAUS8
POP1
MRPL3
GUSBP3
POC5
GTF2I
MLL3
ADHFE1
CX3CL1
SRPK2
GRAMD2
ELF4
CPA4
SLFN11
USP9X
TMOD3
FHL3
PFN1
SEMA3C
OXSR1

0.00051253
0.000513896
0.000515293
0.00051542
0.000518556
0.000519097
0.000521503
0.000522297
0.000523985
0.000526458
0.000526987
0.000527199
0.000529801
0.000531072
0.000531552
0.000538951
0.000541015
0.00054151
0.00054209
0.000544092
0.000544619
0.000546006
0.000546729
0.000547319
0.00054765
0.000553031
0.000556298
0.000559537
0.000564986
0.000567686
0.000570346
0.000570583
0.000573927
0.000574199
0.000574281
0.00058007
0.000582963
0.000584503
0.000585833
0.000589855
0.000590076
0.000596219
0.00059906
0.000599963

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.373334152
1.345765004
1.152599008
-1.142985362
-2.038697352
-1.637172733
-1.544102236
1.448574992
-1.130255846
-1.13954184
1.766385454
1.081239626
-1.134853603
-1.645448784
-1.155332006
-1.324166234
-1.20102979
1.52382786
1.403875859
-1.196683459
-1.203831512
-1.243921845
-1.402186037
-1.157790264
-1.32905615
-1.312847662
-1.204463552
1.499782294
-1.358779735
1.191963145
1.276481595
1.18943858
1.392881848
-1.104144483
-1.298022503
-1.417224458
-1.452735428
-1.208243553
1.290694487
-1.133693413
-1.497665466
-1.188416809
-1.217572308
-1.081237746

1.548266438
1.678777376
1.563168816
-1.161218734
-1.250166583
-1.333282501
-1.215308425
1.20282285
-1.201886197
-1.149237932
1.255404344
1.114368834
-1.128199138
-1.300553429
-1.173694769
-1.327565362
-1.199348861
1.760795703
1.171946658
-1.168171517
-1.383980847
-1.197036583
-1.203790916
-1.133284579
-1.277787951
-1.132281077
-1.157523394
1.459929138
-1.205240311
1.276633066
1.224283141
1.30070258
2.146916292
-1.152969708
-1.487095197
-1.332432954
-1.555289209
-1.675638131
1.172403498
-1.210097482
-1.291103098
-1.178498982
-1.841082541
-1.1748069

224

KIAA1524
PMS1
MATN2
MFSD6
CENPI
EPPK1
TACO1
EFEMP1
RBM28
NUP205
ADRM1
VAV2
NEIL3
KIF3C
GPR126
SMCR8
DDAH1
IFNAR2
TTL
FAM96B
HIST1H1B
TMPRSS11E
PSMC4
GSN
TRIM6-TRIM34
TMEM168
SGCB
GNPTAB
CRIPAK
PTP4A1
TSPAN6
PRIM1
PZP
DEPDC1B
PON2
SERPINB8
SIDT1
FOXM1
EMP3
ACTN4
RAMP1
PARS2
RPP30
HDAC5

0.000600491
0.000601916
0.000607162
0.000612958
0.000614203
0.000614982
0.000619082
0.000625158
0.000627341
0.000630118
0.000631168
0.000635237
0.000638708
0.000641728
0.00064457
0.000646064
0.00064659
0.000646843
0.000647001
0.000647143
0.000649139
0.000652038
0.000654542
0.000662043
0.000667451
0.00066816
0.00066888
0.000670713
0.000674297
0.000674702
0.000675882
0.000676564
0.00067711
0.000677189
0.000677898
0.000683735
0.00068595
0.000687367
0.000688038
0.000690755
0.000696378
0.000699299
0.000699974
0.000703172

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.161790468
-1.196767418
-1.131501159
1.154980046
-1.19362436
1.357365752
-1.235714167
-1.068481485
-1.245365292
-1.159102832
-1.254267956
-1.247269079
-1.190166654
-1.270073417
1.172385976
-1.194083482
-1.612827728
-1.176321531
-1.390035739
-1.315690673
-1.238476216
-1.575440077
-1.245044655
1.43268062
-1.302742315
1.203686861
-1.299292514
-1.262080244
1.147877381
-1.172085151
1.267655651
-1.169707264
1.135515437
-1.220824114
1.140415914
-1.572617062
1.249483044
-1.143699705
-2.13164752
-1.108242299
-1.232846735
-1.187451354
-1.198628194
1.265584926

-1.211277624
-1.161239175
-1.314854132
1.123077081
-1.341475072
1.550650431
-1.126352335
-1.242841909
-1.176991541
-1.085691289
-1.212769425
-2.150572863
-1.132852287
-1.501714934
1.538376925
-1.155493075
-1.290432962
-1.176280562
-1.292778826
-1.164691432
-1.101216363
-1.150112353
-1.13838766
1.300659931
-1.295112938
1.115470967
-1.236033406
-1.118202952
1.419845249
-1.271938886
1.113359649
-1.185184813
1.144630519
-1.205779355
1.460477642
-1.169322031
1.326082932
-1.186810517
-1.533763012
-1.083746207
-1.636862421
-1.281943012
-1.13928284
1.686525798

225

SYMPK
IPMK
IL27RA
CYP2E1
PCM1
IGFBP7
RAD18
OGFOD1
ING4
BRCA2
SDR42E1
BNC1
MRPS12
TNFRSF4
UTP11L
SBF2
DDX21
LY6G6C
CKS2
SDAD1
AGR2
SMYD2
KCTD12
ZNF12
MFAP2
NUAK2
NUP107
CMTM4
ABCG1
GPR39
RALGPS1
INF2
XPO6
DDX47
CDK19
PTGS2
SLC5A6
CENPP
WDR75
COL4A2
DTL
OSBPL11
MRPL11
IL4R

0.000705142
0.000706133
0.000707473
0.000710732
0.000710742
0.00071841
0.000718892
0.0007229
0.00072356
0.00072591
0.000727985
0.000730132
0.000734108
0.000742016
0.000745753
0.000748578
0.000754224
0.000757731
0.000758207
0.000760505
0.000760828
0.000760963
0.00076218
0.000775308
0.000779268
0.000780394
0.000782383
0.000784435
0.00078468
0.000790115
0.000790922
0.00080018
0.000803822
0.000808368
0.000809867
0.000810904
0.000823949
0.000825169
0.000829648
0.000830712
0.000831615
0.000834721
0.000836706
0.000844586

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.194820892
1.139967642
-1.762852686
-1.184018094
1.129808309
-1.201820747
-1.202941018
-1.399891803
1.373876609
-1.206593226
-1.266016649
-1.391265953
-1.282189999
1.272879369
-1.244012792
1.239079636
-1.187994768
-1.14179877
-1.206545999
-1.181120772
1.570548479
-1.233490616
-1.305265428
1.164404702
1.308821679
-1.279698412
-1.230140632
1.190056553
1.319185818
-1.299924627
1.431086128
-1.205505186
-1.27585122
-1.100556232
1.337778649
1.313527574
-1.350732224
-1.16026611
-1.138632674
-1.335384404
-1.175425313
-1.091437979
-1.15753979
-1.265541503

-1.105386936
1.372578269
-1.364678351
-1.254291737
1.071666752
-1.889165242
-1.264784061
-1.167897024
1.256140318
-1.288603607
-1.276865668
-1.804120297
-1.164266633
1.147809916
-1.158951889
1.125902342
-1.099063769
-1.50388925
-1.167190834
-1.120854822
1.184839389
-1.322790227
-1.543834715
1.121825476
1.377890923
-2.015706524
-1.14539431
1.124137908
1.319885066
-1.776531126
1.213487846
-1.294277323
-1.204310554
-1.16212792
1.103699299
1.664072431
-1.198367857
-1.113769723
-1.211119358
-1.134269488
-1.241206589
-1.194842683
-1.17193492
-1.358132448

226

ILF3
TUBG1
ABCC2
HAT1
CKAP2L
C10orf57
BDNF-AS
ARG2
TTC27
KLHL5
IL13RA1
NSFL1C
RQCD1
RRM2
EEF2
DUSP14
ASAP2
CD24
GMPS
SCARNA17
CXorf26
EMC8
PPP1R18
NTN4
RN5S141
FLJ38717
VPS13B
ARGLU1
CDH1
PHTF1
PTGS1
C1orf116
PARP4
CYLD
AAED1
PLEKHA7
ZCCHC10
ZNF608
SFN
GUSBP2
POLA1
CACYBP
EPHA1
ACAD10

0.000844973
0.000850654
0.000851326
0.000853277
0.000859114
0.000874993
0.000879984
0.000880077
0.000880758
0.000881204
0.000881814
0.000882103
0.000884378
0.000888959
0.000891413
0.000895603
0.000896129
0.000904049
0.000904791
0.00090611
0.000910121
0.000910899
0.00091436
0.000914917
0.000915637
0.00091743
0.000921359
0.000923889
0.00092567
0.000929853
0.000932815
0.000932931
0.000933158
0.000935093
0.00093778
0.000938517
0.000938548
0.000939121
0.000939983
0.000941458
0.000947849
0.000948221
0.000950274
0.000950563

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.121739257
-1.233498731
-1.190850677
-1.116941957
-1.386751006
1.183573898
1.243420102
-1.222868307
-1.145647674
1.106142661
-1.103225969
-1.23124561
-1.153499595
-1.200327209
1.056604702
-1.210354566
-1.132627535
-1.218456986
-1.120059474
1.469796093
-1.364148411
-1.275316153
-1.211788233
1.473587882
-1.621217205
1.575567637
1.24827577
1.23818442
-1.091796841
-1.293587747
-2.352679179
-1.445451554
1.091828536
1.130257723
-1.48094638
1.096132261
-1.205033556
1.234019542
-1.609135183
1.398116632
-1.13507446
-1.18556201
-1.19533359
1.386545331

-1.09659805
-1.176974014
-1.48445276
-1.14741
-1.110742856
1.321097418
1.121108378
-1.258138711
-1.231327079
1.38037741
-1.152708679
-1.126874773
-1.142083281
-1.066997389
1.061013909
-1.287170303
-1.397973834
-1.171777607
-1.171919008
1.67313633
-1.24963176
-1.126519202
-1.151363923
1.122463003
-2.128259883
1.298999224
1.144901959
1.176963458
-1.178500458
-1.191933219
-1.292299307
-1.167236979
1.153117476
1.384883899
-1.255276215
1.255650101
-1.244907763
1.770837086
-1.163326399
1.681486061
-1.228171987
-1.157731116
-1.166914062
1.225719954

227

ICMT
ABLIM3
RMND5A
FLJ42969
SYNE2
SYK
RRM1
POMGNT1
SLC25A30
SEMA3A
POLR2J4
SNORD89
PHF10
EMP1
GPNMB
CTNNAL1
MTHFD1
NYNRIN
LOC100506394
UBE2I
ZNF142
TNFAIP1
PLEKHJ1
OGFRL1
MEIS1
APBB2
ALDH3B2
CALCOCO1
SERINC5
XRN1
MCOLN2
ZNHIT6
KIF20B
10-Sep
PDPN
DEGS1
NOTCH3
KRT80
COBL
PSME3
C12orf52
NBPF9
MIR554
CLMP

0.000952607
0.00095293
0.000957436
0.000959406
0.000959855
0.000964668
0.000972796
0.000973227
0.000974159
0.000975056
0.000980301
0.00098063
0.000981202
0.00098153
0.000981954
0.0009852
0.000987164
0.000994242
0.000994914
0.000994964
0.000996292
0.00100187
0.001002547
0.001008465
0.001020179
0.001027845
0.001033554
0.001034386
0.001035734
0.001038287
0.001040274
0.001040426
0.001042811
0.001047817
0.001053677
0.001065155
0.001065657
0.001067682
0.001070467
0.001071623
0.0010766
0.001079741
0.001080725
0.001080808

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.162943999
-1.234230909
1.110575416
-1.260569561
1.78113032
-1.177421271
-1.076512083
-1.140911679
-1.447048358
-1.882510187
1.479629678
1.318861215
1.167819638
-1.171674389
1.48014167
-2.1214858
-1.076583605
1.536353114
-1.329984927
-1.130555975
-1.113324395
-1.248208544
-1.283739269
1.199222376
1.368418649
-1.293902126
1.704218782
1.260380629
1.178625735
1.116664415
-1.173969397
-1.198937576
-1.133560114
1.196196205
-1.265802281
-1.286993708
1.370106227
-2.492491213
-1.264742265
-1.152352813
-1.216881728
1.403796627
1.362702231
-2.253807061

-1.077875997
-1.956271505
1.244916254
-1.137984484
1.210340979
-1.471814497
-1.112546198
-1.42278981
-1.250804223
-1.199523659
1.358347929
1.140530145
1.37985371
-1.113216819
1.309320424
-24.8561035
-1.138626508
1.236500873
-1.288546039
-1.097049356
-1.15118056
-1.201887735
-1.092581987
1.105500785
1.179074824
-1.578561538
1.271750792
1.437899244
1.468007583
1.08812908
-1.146565398
-1.285648331
-1.109959442
1.11100309
-1.494904294
-1.205410308
1.710864492
-1.287124069
-1.156731987
-1.180757177
-1.207517135
1.202039762
1.597081576
-1.321050289

228

GRB2
LONP2
LRP12
UBE2Q2
NUP153
HCCS
RRP36
TCP11L2
RMI1
PRNP
ESRP1
EIF3L
NUDCD1
HNRNPF
CCDC41
LYAR
ANXA7
ISG20L2
HIF1A
FSCN1
TBC1D3H
DUOX1
CXorf1
DCTPP1
TMEM123
RNF41
TOR1A
ITPRIPL2
EDEM2
MYO5A
XGPY2
SLC39A11
GSTA1
MIR21
CCT4
AUP1
TIMP3
SPDYE1
CD276
PXMP4
ZW10
GTF2F1
F2RL1
PCGF3

0.001103725
0.001107504
0.001111252
0.001114725
0.001114848
0.001115016
0.001118257
0.001120543
0.001121308
0.001123621
0.001128
0.001129478
0.00113594
0.001137028
0.001145757
0.001148631
0.001151527
0.00115211
0.001153776
0.001162646
0.001163475
0.001166187
0.001166442
0.001169036
0.001169914
0.00117257
0.001178727
0.001181298
0.001184432
0.001185833
0.001186003
0.001187415
0.001190598
0.001191982
0.001201646
0.001204002
0.001204042
0.001205404
0.001209768
0.001211502
0.001213644
0.001215589
0.001218105
0.001222003

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.146271929
1.450078588
-1.477680992
-1.180200009
-1.277902877
-1.205638121
-1.224368754
1.276431961
-1.138795518
-1.169093629
1.087027442
1.167946855
-1.337414797
-1.109532511
-1.19969162
-1.655435064
-1.101708845
-1.371536389
1.155249778
-1.453754223
1.14149564
1.230226047
-1.222916324
-1.314334006
1.198501196
-1.189564188
-1.173399842
1.160803361
1.305955459
-1.1382975
-1.253044767
1.326893172
2.046465982
1.402867727
-1.223712629
-1.159905891
-1.535393281
1.37727744
-1.133457612
1.184284753
-1.330751406
-1.128889767
1.14258099
-1.07418608

-1.167525031
1.41392497
-1.228810374
-1.185070249
-1.18501199
-1.172626097
-1.101229487
2.70759893
-1.245052125
-1.247101301
1.10706682
1.068528314
-1.194440988
-1.127922669
-1.160625013
-1.222563388
-1.101959531
-1.123069287
1.086477386
-1.191782033
1.316820649
1.271301736
-1.222808101
-1.122237651
1.218780078
-1.12559562
-1.125277622
1.196214415
1.27038979
-1.390018502
-1.444222901
1.178954266
1.328055528
1.71199778
-1.078968048
-1.05730467
-1.407362715
1.151626391
-1.389832655
1.502300451
-1.118262471
-1.085278368
1.232083625
-1.144362927

229

PLCD3
SPATS2
IL36RN
FAM65A
RAPGEF5
LOC100130171
GAD1
NFKBIZ
PSMB2
IKBKAP
RNU12
VANGL1
ITGA1
PDSS1
ST6GALNAC1
CDH13
NOC4L
NSDHL
SH3D19
BCL11A
CCL22
CWC22
NUP188
CNTNAP3B
CDK2
FJX1
TP53
ERBB3
PTPLA
CHAF1B
DHRS3
SLC46A3
NAA15
SSBP2
PHF19
AVPI1
TM7SF2
ABCF2
RERE
BUB1B
GRB14
FADS2
ABCB7
ITGB8

0.00122295
0.00122521
0.001227352
0.001227516
0.001229062
0.001245601
0.001246999
0.001254104
0.001257414
0.001262905
0.001269223
0.001269286
0.001269749
0.001270522
0.00127404
0.001276195
0.001277621
0.001281565
0.001286112
0.00129014
0.001290235
0.001296268
0.001302387
0.001303376
0.001308565
0.001309318
0.001329223
0.001333768
0.00133508
0.001335356
0.001337919
0.0013397
0.001340886
0.001345234
0.001347785
0.00134918
0.001350825
0.001351503
0.001354473
0.001355748
0.001359199
0.00135952
0.001361836
0.001381044

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.223228996
-1.269512824
-1.519358394
-1.180200472
1.593934756
-1.579934549
1.226049648
1.340959627
-1.235256785
-1.111470244
-1.255494977
-1.204117527
-1.251228127
-1.261479372
1.293984271
-1.614135001
-1.306206527
-1.187281305
-1.117426667
1.477987883
1.133301254
-1.169882832
-1.174814169
1.314725495
-1.178840228
-1.699628722
1.161568959
1.203510441
-1.183297545
-1.434941192
1.190412238
1.319384912
-1.228657283
1.789325193
-1.254595002
-1.266114165
1.365953495
-1.206556532
1.156347965
-1.093631037
-1.232016477
-1.197218216
1.137172633
1.218925139

-1.542141136
-1.210292566
-1.32328596
-1.48176942
1.187385291
-1.276187074
1.219059775
1.124132784
-1.069332385
-1.148359671
-1.375663431
-1.073931496
-1.333835705
-1.303877898
2.574589481
-1.446680393
-1.1995611
-1.234055201
-1.295806422
1.174073775
1.339513612
-1.108304725
-1.097677622
1.327010122
-1.093650308
-1.240860842
1.38633366
1.109930721
-1.506405162
-1.151303398
1.98806535
1.710798254
-1.094936649
1.186165227
-1.185347131
-1.064712166
1.141461865
-1.08445368
1.130032467
-1.089008767
-1.317410636
-1.286840355
1.171729623
1.114313148

230

CEL
GJB2
TNFRSF12A
HSPA8
DBF4B
FPGS
TAF3
DPP3
SENP5
TGFBR2
ZNFX1
TIMM50
C19orf33
IFNGR1
TMPRSS11A
CCDC86
RPF1
MB21D1
MBOAT7
NAB1
FAM46B
AMD1
TUFT1
KIAA1109
GLTPD1
GABPB1
DUOXA1
LYRM1
FTSJ3
IL20RB
RAPGEFL1
MSN
TUBA1B
ILK
MFSD4
SSX2IP
E2F8
PHLDA1
RAB38
FTSJ1
CHMP1B
SCARNA9
ATG16L1
AIM2

0.001388198
0.001392775
0.001396515
0.001404473
0.001404895
0.001405808
0.001407922
0.00141076
0.001414698
0.001417222
0.001418503
0.001421477
0.00143348
0.001436703
0.001444316
0.001446269
0.001450566
0.001451706
0.001452158
0.001460516
0.001472671
0.001476467
0.001477703
0.001481974
0.001486466
0.001487898
0.001489659
0.001497446
0.001498784
0.001503662
0.001508814
0.001522687
0.001527054
0.001527135
0.001534739
0.001534995
0.00154308
0.001544646
0.001547491
0.001548145
0.001551715
0.001560804
0.001561655
0.001562325

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.340804126
-1.550273551
-2.341633739
-1.166754211
-1.232766185
-1.208388841
-1.202313036
-1.092294726
-1.096285358
-1.183852733
-1.112638278
-1.31894106
-1.342742384
1.226814535
1.466246047
-1.311432264
-1.133087226
-1.339010707
-1.269807925
1.185582643
-1.414795759
-1.251899882
1.140963355
1.245692252
-1.177801124
-1.216401676
1.151324789
-1.269402804
-1.20521071
-1.184112697
1.237370564
-1.23313557
-1.505878133
-1.336420855
1.643016039
-1.207673933
-1.262078211
-1.2224323
-1.280250989
-1.317200679
1.111469325
2.159395854
-1.103690792
-1.176411052

1.372356893
-1.186006894
-1.233750779
-1.11439866
-1.101196728
-1.142723125
-1.135742577
-1.216525353
-1.1546162
-1.123351494
-1.150952746
-1.091943231
-1.143809224
1.498257433
1.273259802
-1.122974073
-1.161898333
-1.241961728
-1.277562324
1.28151164
-1.649355142
-1.214332406
1.137466277
1.092931675
-1.21321892
-1.140353284
1.156810917
-1.418898328
-1.169594844
-1.762295872
1.586575314
-1.419859376
-1.309378629
-1.091769677
1.231230696
-1.346228866
-1.161808004
-1.138535969
-1.140434634
-1.097254255
1.240296725
1.530425976
-1.23444781
-1.633801341

231

UBL4B
DHX37
FLJ14186
C1RL
GPX2
TM4SF1
ZC3H6
NKX3-1
TRAM2
ZBTB2
POMP
GSPT1
HIST1H2BC
ECD
PHF15
PCNT
NUFIP1
PSMA2
SNRPD2
MTUS1
ECHDC2
CHD3
PPP3CA
SEPW1
SMG1P1
CAMLG
ABCE1
TRIM24
MXRA5
LYRM4
THRA
TMEM141
PSMB9
CASP2
GTF3C1
NRG1
ACAA2
HEXB
CBFA2T2
HIST1H3J
SF3B4
MRTO4
TRIM32
TMED4

0.001564197
0.001564566
0.001564729
0.001566619
0.001572546
0.001579043
0.001586275
0.001594272
0.001595858
0.001600866
0.001601396
0.001606404
0.001608078
0.001608965
0.001610779
0.001611838
0.001619404
0.00162153
0.001623559
0.001634375
0.001635451
0.001638785
0.001639156
0.001640865
0.001642851
0.001643155
0.001645522
0.0016482
0.001651249
0.0016521
0.001656766
0.001659966
0.001660134
0.001663229
0.001664223
0.001664435
0.001679736
0.001680107
0.00168061
0.001682296
0.001685292
0.00169116
0.001691549
0.001694386

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.100648817
-1.34013498
1.80047719
1.381145527
1.287491544
1.327555262
1.323810527
-1.421848291
-1.235538085
-1.274403875
-1.292431582
-1.223006456
-1.255272041
-1.172017589
-1.288074551
1.115459949
-1.220619176
-1.28741315
-1.189800056
1.249070825
1.179462392
1.458033792
-1.10324315
-1.519620583
1.378948163
1.162277848
-1.276707136
1.184551446
-2.155046346
-1.191505186
1.179557849
1.226407223
-1.104367265
-1.199424619
-1.166259268
-1.746382495
1.122078567
-1.127682645
1.475096054
-1.333463136
-1.207630189
-1.363927364
-1.196023348
1.102334908

1.159740464
-1.179388567
1.317123866
1.147127438
1.146209418
1.469193589
1.369627583
-1.099355435
-2.701319124
-1.280707866
-1.115094405
-1.077711489
-1.287529045
-1.127102234
-1.195964193
1.1496592
-1.265636262
-1.116562835
-1.07051603
1.219192877
1.359621033
1.102622393
-1.101903138
-1.1050454
1.284892531
1.186139956
-1.170774229
1.287662421
-1.212587055
-1.255715303
1.38595627
1.129469963
-1.362472407
-1.189035551
-1.074307839
-1.203422955
1.511711127
-1.229744367
1.115874886
-1.177663691
-1.329891045
-1.185285641
-1.257436376
1.158585429

232

GOLGA6L9
CSTF2
MCM2
RFC1
TANC2
TBC1D3F
SS18
BACE1-AS
LOC100506178
KLF11
DDR1
SEZ6L2
CAMK1D
VPS13A
LPIN2
RICTOR
ASUN
POLR2J2
DDX18
NAIP
MAK16
RBM22
BCAR1
ARSI
YDJC
HERC6
RPF2
FAM19A3
ECM2
CENPL
NGF
FAM168A
PIGW
ENTPD6
DEFB109P1
CD59
SELT
SRD5A3
CDY2A
HLA-DRA
RAB31
MGAT2
NR2C2AP
REL

0.001694958
0.001696428
0.001697398
0.001699054
0.001703977
0.001704152
0.001705882
0.001711884
0.001714927
0.001726258
0.001727243
0.00173243
0.001733158
0.001737815
0.001740617
0.001742831
0.001743114
0.001744418
0.00174642
0.001754661
0.001780911
0.001782112
0.001785618
0.001787443
0.001791405
0.001794875
0.001803664
0.001806276
0.001808656
0.001816082
0.001819218
0.001832311
0.00183746
0.001838015
0.001842684
0.001855089
0.001860183
0.001861031
0.001863158
0.001875278
0.00187611
0.001877608
0.001878535
0.001879293

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.475971347
-1.451104436
-1.171806758
-1.143029942
-1.307225034
1.17226144
-1.072729504
1.381616901
-1.165856211
-1.454282236
1.10983549
1.137640807
1.490012241
1.280915662
-1.194713542
1.126294017
-1.210143274
1.168729181
-1.180665036
1.519860443
-1.332179163
-1.114030193
-1.252161402
-1.971970524
-1.233558229
-1.214584305
-1.229345839
-1.507746138
-1.317618682
-1.283186906
-1.857263836
1.409268783
-1.23160181
-1.095562629
-1.166430883
1.206591282
-1.183195816
1.087791906
-1.509110178
3.392956715
-1.123412358
-1.163717111
-1.273546491
1.122486639

1.179278772
-1.162140154
-1.187694795
-1.105130838
-1.197072427
1.243354088
-1.076871499
1.245603539
-1.367922067
-1.17097328
1.244166998
1.131144143
1.198314832
1.199477
-1.592150915
1.084626589
-1.095927995
1.51187421
-1.083950627
1.263967574
-1.145527748
-1.177584253
-1.494904572
-1.26329965
-1.126383896
-1.293875966
-1.105119582
-1.230062895
-1.207004547
-1.281818182
-1.189445563
1.142975315
-1.285592524
-1.139383141
-1.101038234
1.160892118
-1.073168366
1.349127008
-1.386819522
1.502073608
-1.117950864
-1.138087572
-1.288206742
1.247730276

233

FTH1
AMIGO2
PDGFB
PCYT1B
KIF13B
IL6ST
PHLDB2
TTI2
LOC100505769
LOC554223
ACSL4
DENND4A
MED12
LOC440434
CHTF8
ITPR2
NXT1
EIF4E3
SLC44A1
LANCL1
GTF2H1
C12orf59
CREB3L2
ZWINT
AP2S1
SPIRE2
RBBP9
FARSB
GOT1
RPUSD1
BCAS1
THRB
STRN3
SAMD7
NRAS
C10orf47
WDR12
BOK
CEP76
MARVELD2
LOC344887
FAM222A
SCARNA9L
ZNF750

0.001887898
0.0018889
0.001895263
0.001895392
0.001904202
0.001909535
0.001912044
0.001915738
0.001920731
0.001928648
0.001932316
0.001937241
0.001940255
0.001944679
0.001944822
0.001947595
0.001948121
0.001950195
0.001953701
0.00196403
0.001967902
0.001973807
0.00199343
0.001995665
0.001996914
0.001998905
0.002000119
0.002003137
0.002005937
0.00201212
0.002016284
0.002017064
0.002021722
0.002024152
0.002025715
0.002026082
0.002029242
0.002033838
0.002038679
0.002038922
0.002041176
0.002044775
0.00205073
0.002051615

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.515797787
-1.370059748
-1.30514377
-1.687008186
1.154246125
-1.097519898
-1.52103877
-1.192488871
1.216849037
-1.244880047
-1.196418266
1.22788202
1.175610128
1.417685291
-1.159554928
-1.267331222
-1.3153281
1.24483531
1.091772711
1.126603435
-1.077663498
-4.462578882
1.177117834
-1.079439671
-1.215380118
1.179102772
-1.146073802
-1.205994364
-1.128530028
-1.333890094
1.21686995
1.28056743
-1.086980717
-1.146964707
-1.155318164
-1.183113047
-1.166794406
-1.245632077
-1.176622723
-1.310658671
1.496098538
-1.167014202
1.217027797
1.254607421

1.183563924
-2.654541156
-1.145577838
-1.319150183
1.275083274
-1.49688535
-1.187214728
-1.150062302
1.793648665
-1.104705254
-1.566722851
1.074825569
1.189952731
1.538107228
-1.10619544
-1.201172766
-1.268249653
1.354018173
1.40607191
1.24952106
-1.165380412
-1.351332975
1.340860052
-1.158654893
-1.105028331
1.342107252
-1.196902189
-1.100465177
-1.198985205
-1.23427085
2.281925522
1.137884719
-1.264304572
-1.194701411
-1.066594519
-1.277951478
-1.093704268
-1.183243098
-1.173187332
-1.147250866
1.173339399
-1.207788541
1.320618211
1.563344097

234

DNAJC11
DHX9
PGAM1
RAD23B
CDK5RAP3
C6orf48
BDKRB2
IL6R
SPAG16
HIST1H3I
ANKHD1EIF4EBP3
MUT
GCNT4
PHF5A
ZNF846
DNA2
NOC3L
SGK196
KCNN4
MBOAT2
CCDC127
GIPC1
NRG4
SLC46A1
HMOX2
TNFRSF9
FAM203A
BCL7B
MRPL18
DICER1
DDX60
LOC100499467
CYP4F3
DCDC1
CDR2
AGFG1
CAMSAP2
DDX52
MAMLD1
PDIA5
PFKP
KIF18A
IFT57

0.002052131
0.00205335
0.00205944
0.00206069
0.002062668
0.002064983
0.002070944
0.002073781
0.00207774
0.002085524
0.002086012

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.142415932
-1.067735008
-1.402702428
-1.052766468
1.158793292
1.349574988
-1.839552791
-1.613502897
1.15167729
-1.101093387
1.169884293

-1.138009672
-1.155838053
-1.145015809
-1.144559637
1.127149198
1.115607203
-1.168585584
-1.631757591
1.49652797
-1.040258483
1.058190366

0.002094237
0.002100862
0.002101862
0.002101903
0.002110724
0.002122419
0.002124806
0.00212935
0.002130308
0.002130445
0.002132464
0.002144277
0.002145612
0.002149694
0.002151461
0.002158012
0.002184737
0.002191749
0.002194187
0.002199101
0.002201694
0.002215465
0.002218499
0.002221049
0.002221564
0.002223147
0.00222489
0.002232412
0.00224384
0.002244232
0.002245181
0.002245986

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.117245853
-1.361015306
-1.329219151
1.302815936
-1.10717826
-1.344916592
-1.143762307
-1.165088533
-1.527001782
1.102536654
-1.265939656
-1.806812138
-1.234678001
-1.209511061
-3.696606898
-1.134403819
-1.313308379
-1.198455694
1.087241442
-1.249212937
1.19716327
1.377293367
1.552188768
-1.624659354
-1.185567425
-1.063866289
-1.197720554
-1.118988164
-1.226478628
-1.134523211
-1.085760013
-1.192021015

1.178885859
-1.463133484
-1.128645948
1.09906791
-1.243066418
-1.255595288
-1.055077789
-1.470899749
-1.099922551
1.265324461
-1.100917231
-1.229129855
-2.055444891
-1.245151881
-1.348722585
-1.076893547
-1.087795697
-1.15546227
1.056457945
-1.121971114
2.258450783
2.068479422
1.239102932
-1.122050251
-1.090608332
-1.110574929
-1.087266256
-1.311351969
-1.195226001
-1.209129111
-1.17937557
-1.170468386

235

SART1
RN5S104
IGFBP6
NBPF24
ITGA11
ZFP42
PRKAR1B
LMNB2
SOX21-AS1
GMNN
LOC100506258
GPRC5B
FZD2
AMOTL2
CDCA5
HK1
KLK5
PPAT
CRNDE
ZNF238
CELA1
ARHGEF3
UTRN
PSMB7
CLCF1
MAP3K14
GYS1
SCARA3
GET4
GIT1
ZMYM2-IT1
ARMCX5GPRASP2
ERP27
ATAD2
DDX24
GCNT2
PPIP5K1
CHMP7
TPD52L2
SLC25A19
TSTD1
DBN1
FAM111B

0.002249354
0.002254274
0.002255934
0.002257625
0.002263489
0.002265391
0.002265725
0.002266644
0.002272671
0.002277658
0.002281291
0.002291121
0.002291203
0.002291759
0.002292976
0.002308038
0.002310367
0.002310672
0.002312384
0.002312966
0.0023271
0.002338956
0.00234781
0.002356647
0.002366559
0.002369572
0.002373173
0.002380121
0.002382259
0.002383078
0.002383632
0.002389738

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.078145098
-1.118190375
-2.151902836
1.40727203
1.129921048
-1.144515741
-1.297097788
-1.145498067
1.516658148
-1.394830351
1.124551789
-1.48442547
-1.173954957
-1.31322146
-1.139114704
1.104431342
-3.44621433
-1.210088781
1.339592474
1.126829959
1.241493414
-1.405865502
1.143030417
-1.215839245
-1.387492113
-1.20011968
-1.407726583
-1.161514245
-1.089864812
-1.147907731
1.382656396
-1.170102188

-1.103160366
-1.124513105
-1.14926457
1.181699558
1.191949199
-1.401934812
-1.251690115
-1.122192012
1.161536697
-1.2178873
1.217540745
-1.15520556
-1.983459379
-1.129505047
-1.27207661
1.112554287
-1.269083517
-1.179118187
1.436760647
1.363241735
1.099401734
-1.109517764
1.192591832
-1.180231502
-1.211882572
-1.252290466
-1.201935672
-1.490131153
-1.119664475
-1.16428397
1.516026909
-1.221563328

0.002390417
0.002390747
0.002390752
0.002392403
0.002412119
0.00242197
0.002430858
0.002431575
0.002431678
0.002433027
0.002433605

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.340553883
-1.100247633
-1.13489437
1.203843067
1.201660985
-1.108268488
-1.362425014
-1.642664601
1.177143875
-1.1149707
-1.170432276

-1.619644007
-1.116193715
-1.122124321
1.186978527
1.100468453
-1.17284439
-1.079315593
-1.162905665
1.188517442
-1.402299193
-1.203789251

236

PAICS
CDIPT
NRARP
PLS3
CIRBP
DDX60L
ARPP19
FBN2
TNKS
LRRC37A2
ALDH1L1
FAR2
FZD10
LOC728606
NABP2
NPIPL3
RNF168
KISS1
MON2
SPHK1
SCAPER
VGLL1
TSPAN31
LOC257396
CELSR2
CD27-AS1
MYO5B
TAP2
DLGAP5
ZFC3H1
GPT2
GARS
PAK1
ULBP3
FLJ35390
SERPINF1
PSMD11
HBEGF
ABCA4
UBR7
SUPT5H
ICAM1
SARNP
BSG

0.002437675
0.002437713
0.00245383
0.002463006
0.002465042
0.002466361
0.00246997
0.002475414
0.002485846
0.002487235
0.002496596
0.002498042
0.002504277
0.002517025
0.002517175
0.00252144
0.002523641
0.00252521
0.002526281
0.00252676
0.002538495
0.002539538
0.002547524
0.002549042
0.002564932
0.002569054
0.002570386
0.002572939
0.002573185
0.002585062
0.002588037
0.002593585
0.00259737
0.002613593
0.002614073
0.002616824
0.002619152
0.002619748
0.002642477
0.002643359
0.002647834
0.002648618
0.002654577
0.002665114

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.267139331
1.199036694
1.176614385
-1.10673588
1.345853159
-1.116488356
-1.082051199
-1.920316276
1.765935041
1.370565188
1.138416575
-1.419959775
1.206910044
-1.22416332
-1.383018175
1.395706503
1.114028918
-1.170128188
1.148741317
-1.206943679
1.246713199
-1.855396271
1.399464065
-1.233191072
1.098233224
1.192694228
1.217441455
-1.230357542
-1.107102838
1.143696459
-1.144757003
-1.070619878
1.174139241
-1.351813499
1.241784326
1.728826262
-1.343163299
-1.441997294
1.095567231
-1.238384454
-1.185310729
-1.851094079
-1.12116317
-1.076064213

-1.069742931
1.125028368
2.57566935
-1.102785943
1.148189191
-1.649649911
-1.092981974
-1.193015985
1.413357389
1.169556702
1.201907399
-1.152290665
1.349591423
-1.175778607
-1.131442787
1.270364901
1.070066232
-2.49035286
1.181160259
-1.145342787
1.209605425
-1.15455075
1.139060721
-1.164321232
1.510270021
1.22525111
1.302003298
-1.161281066
-1.103633439
1.147895022
-1.214038067
-1.090106976
1.282416819
-1.278702364
1.1604831
1.198599959
-1.102540213
-1.722791715
1.270634246
-1.148189901
-1.092536255
-1.180240815
-1.127744752
-1.122722406

237

PI15
SLC9A2
BCL6
PCNA-AS1
GSN-AS1
PTGFRN
EIF1AD
IL15RA
POLA2
PKM
ANKRD18A
DHCR7
CARD6
PFN2
CDC123
GTF2E1
LOC100289019
BIVM-ERCC5
ATP8B2
CCNB1
ACOT2
CCT3
CXCL1
RN7SK
SGTA
NACC1
LOC100652992
SUDS3
SCARNA27
GCFC2
SNRNP40
GLS2
FRY-AS1
SNX7
EIF2AK4
MYT1L
DNAJC4
NAGS
VAMP2
APPL2
LAMB2
SRPX
ANKRD10-IT1
CTNNBL1

0.002695354
0.002696376
0.002698801
0.00269972
0.002706553
0.002708448
0.002714002
0.002723342
0.0027234
0.002729077
0.002730139
0.002732832
0.002735661
0.002735971
0.00273916
0.002741587
0.002746406
0.002748825
0.002760932
0.002765899
0.002768714
0.002772158
0.002784748
0.002785229
0.00279075
0.002794968
0.002797113
0.002799459
0.002805637
0.00280636
0.002817561
0.002820875
0.00282321
0.002831562
0.002832392
0.002835832
0.002847734
0.002855775
0.002856759
0.002860204
0.002871771
0.002876775
0.002882154
0.002889617

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.342300272
-1.262401045
1.612769819
-1.310258938
1.190654083
-1.099257007
-1.424563852
-1.246606873
-1.120640471
-1.242955761
1.447504023
-1.352562039
-1.405273853
-1.108852942
-1.112343497
-1.249261636
1.687012677
1.086643622
-1.429907169
-1.122703287
-1.189366492
-1.157293809
1.193737939
1.275156378
-1.244558614
-1.386096742
1.421005768
1.227098702
1.239233805
-1.155049168
-1.115553739
1.243205439
1.43902438
-1.312775495
-1.162871454
1.165928009
1.383735782
-1.116907005
1.183496157
1.112933131
1.472150566
-1.578515077
2.190458821
-1.1930241

1.12681082
-1.294304766
1.492786603
-1.101888765
1.296110839
-1.304834208
-1.15988229
-1.207906555
-1.130819211
-1.095233742
1.205503467
-1.099655764
-1.106023004
-1.324108867
-1.091116752
-1.10088464
1.126432613
1.193060427
-1.160025975
-1.13803194
-1.629533525
-1.071512655
2.078109947
1.126100474
-1.069019178
-1.224529986
1.212574119
1.118632693
1.319997957
-1.146660982
-1.151854133
1.222093362
1.089422301
-1.362793439
-1.234870388
1.1098912
1.19224049
-1.202224476
1.096094383
1.146374826
1.173650715
-1.149005227
1.346461716
-1.105663299

238

LOC643837
LIMCH1
CXorf23
SLC27A2
FASN
C17orf28
MAP2K6
GALNT3
DSCC1
RNPEP
WDFY1
EZH1
PSMC2
TPX2
GOLM1
SLC35B4
UNC5B
STAG2
IFT81
C12orf57
MBNL2
SAP30BP
PINX1
POP4
BARD1
AP3D1
FAM203B
CCP110
BTG1
OPN3
MRPS23
SPRR2E
LOC100288160
SPPL2B
UXS1
KIAA0226
ANKRD5
RIT1
TNFRSF10D
LOC100190986
MAP3K7
ZNF619
EREG
DDB2

0.002890426
0.002909008
0.002910325
0.002928456
0.002929361
0.002935067
0.002937166
0.002939096
0.00294281
0.002956789
0.00296533
0.002967625
0.002971222
0.002973191
0.002978609
0.002994509
0.002999856
0.003009528
0.003015101
0.00303509
0.003036181
0.003042976
0.003048383
0.003049721
0.003049879
0.0030509
0.003052782
0.003066282
0.00307616
0.003091637
0.003092511
0.003107085
0.003138126
0.003141676
0.003144896
0.003144912
0.003145151
0.003147678
0.003151111
0.003169444
0.003171607
0.003173685
0.003182918
0.003185302

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.225685934
1.114587654
1.216649276
1.382945581
-1.323272797
1.387421459
1.484045831
-1.154176915
-1.39931163
-1.073997946
1.05833967
1.458264596
-1.254788
-1.209193054
-1.257087057
-1.287738815
1.402450814
1.068595927
1.108790228
1.170580763
-1.238289448
-1.17661259
-1.421303662
-1.191528888
-1.154652812
-1.162894145
-1.110156315
-1.120106405
1.084299393
-1.378527457
-1.300815737
1.098568851
-1.14559791
1.325435916
-1.068649301
-1.158831682
-1.200251027
1.208134711
-1.539228053
1.660177527
-1.082181618
-1.180786096
-1.931121423
-1.12304318

-1.140920259
1.735944258
1.110283963
1.107595642
-1.149428352
1.13643974
1.218326397
-1.222822213
-1.173490177
-1.066248838
1.119753887
1.158284663
-1.093191446
-1.06619505
-1.149576236
-1.175406287
1.186394749
1.082226979
1.311488189
1.162838655
-1.063536153
-1.092405533
-1.172331129
-1.097556366
-1.112292012
-1.074088895
-1.087277278
-1.095360432
1.298566002
-1.187582613
-1.10542628
1.143803489
-1.12753567
1.281562095
-1.170440854
-1.120836558
-1.16101368
1.14476044
-1.275111909
1.724934623
-1.045339693
-1.168204128
-1.461798475
-1.325501907

239

FAM169A
NRF1
EIF4G3
GNG12
CYB5R4
HMGA1P4
ACLY
ZNF689
NBPF11
CEBPA
ATP6V1B2
XRCC6BP1
PLS1
FER
RPL13AP20
SNAPIN
MRPL15
CNDP2
PROS1
LOC415056
LOC100133669
KPNB1
PTHLH
LOC100507199
PION
AURKA
AKAP13
GSK3B
CDKN2AIPNL
TLR4
ZNF740
DKC1
GDF11
ANKRD27
PSMB3
NIPSNAP1
PSMB5
KPNA4
BCAR3
LOC100506804
APOD
CA11
CLDN7
C20orf72

0.003195057
0.003201971
0.003202984
0.003203886
0.003210069
0.003215476
0.003221855
0.003222958
0.003223878
0.003243341
0.003243559
0.003244666
0.003253141
0.003261466
0.003272268
0.003274536
0.003279463
0.003289038
0.003289229
0.003306014
0.003314445
0.003331162
0.003333005
0.003336311
0.003336927
0.003337368
0.003370835
0.003379306
0.003380381
0.003386971
0.003397391
0.003406962
0.003425076
0.003442147
0.003445408
0.00344725
0.003449801
0.003458955
0.003462363
0.003463584
0.003476295
0.003479881
0.003483401
0.00348514

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.17217684
-1.098196536
1.106385013
-1.106649321
-1.212716969
1.406157001
-1.287566089
-1.265275331
1.336698773
1.310685413
-1.161813572
-1.074312058
-1.241215571
-1.071336909
1.192903444
-1.159368136
-1.086250246
-1.365562389
-1.285737913
1.159801921
-1.178793239
-1.071652363
-2.3633521
1.322883461
1.333610517
-1.354457355
1.087849728
-1.106976598
-1.248592737
-1.106566678
1.164516484
-1.202241275
-1.134603411
-1.276613363
-1.244923217
1.097781127
-1.172084358
-1.170024011
-1.255888709
1.202009396
1.367718163
1.289543166
-1.190980605
-1.116330284

-2.995086784
-1.154305657
1.065194481
-1.24716913
-1.104555573
1.272746004
-1.041224964
-1.479481504
1.171242874
1.218178143
-1.044054719
-1.105370208
-1.210463275
-1.337982093
1.125402977
-1.140680064
-1.232302451
-1.132041221
-1.30550612
1.122750371
-2.018987125
-1.160201966
-1.184768222
1.115190706
1.266179329
-1.110315613
1.506385185
-1.873139921
-1.248643063
-1.520068773
1.175504417
-1.114876953
-1.231346233
-1.069970688
-1.062206844
1.284449757
-1.075886941
-1.208324225
-1.297509566
1.168048552
1.472172658
1.177581642
-1.054353195
-1.14895433
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THUMPD3
CLDN1
TMEM48
S100A8
FKBP5
C1orf21
TTF2
ZNF563
RBBP7
SCN8A
PIP4K2C
CYTH1
RAB8A
MAPK6
PACSIN3
C17orf53
FLG-AS1
CLINT1
CD9
RORB
CCL5
TRIM4
UBR3
EFNB2
MYCBP2
PDIA6
VDR
BOLA2
BCL10
LAPTM4A
VAMP5
STIP1
CBLB
C18orf25
DOCK9
AIFM2
MED8
MIG7
SIPA1L2
ITGB1
CHAMP1
MGC2752
LOC100506136
FAM63A

0.003490639
0.003503503
0.003504059
0.003513288
0.00351514
0.003515416
0.003519936
0.003522237
0.003529097
0.003530101
0.003543426
0.003551255
0.003555313
0.003560525
0.003564382
0.00357018
0.00357038
0.003574341
0.003579104
0.003581996
0.003586256
0.00358752
0.003600691
0.003609829
0.00361039
0.003611713
0.003612768
0.003616414
0.003617988
0.003623557
0.003636687
0.00363671
0.003636926
0.003640532
0.003656273
0.003657111
0.003664012
0.00366875
0.003689658
0.003690357
0.003701113
0.003705642
0.003712409
0.003715406

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.130637291
1.106736677
-1.213399131
1.292746638
-1.378728917
-1.203666892
-1.122876679
-1.303223629
1.119974572
1.308399796
-1.20226338
1.283807985
-1.133348787
-1.297845976
-1.209624035
-1.254742787
1.218543112
1.201878826
1.291114621
2.305520197
-1.138367565
1.256453563
1.074661666
-1.887020609
1.10358465
-1.077698433
-1.480292037
-1.359190005
-1.097934199
1.079062036
-1.14357966
-1.097230887
1.444981564
-1.093637814
1.286139874
-1.236242592
-1.360762755
-1.279347539
1.88251308
-1.172624678
-1.134070527
-1.155335628
-1.316972579
1.202699844

-1.120661977
1.79761982
-1.085692405
1.751789617
-1.140475381
-1.470173521
-1.218695481
-1.309231386
1.080114075
1.208781854
-1.152433726
1.090690449
-1.066929524
-1.077482136
-1.260059526
-1.172815706
2.096552226
1.093476115
1.095622778
1.156790204
-1.244396278
1.176156361
1.088516128
-1.212295967
1.17444841
-1.188663018
-1.197292697
-1.107851369
-1.268327415
1.142991613
-1.170539614
-1.114602272
1.239025545
-1.225321085
1.091243829
-1.157700853
-1.120778643
-4.405221919
1.133681836
-1.145337663
-1.339542844
-1.05803155
-1.213485438
1.197762985
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MICAL2
SNX29P2
ARAP3
GBE1
FGFR1OP
TBP
UBL4A
HECW1
AJUBA
MAOB
HIST1H1A
LOC440944
FAM13B
MAP3K5
GUF1
IGLJ5
TMEM209
PNP
RHOBTB3
QRSL1
ZMPSTE24
KRT18
OSGIN1
ZBTB44
AOX1
EHHADH
FAM171B
C11orf82
C3orf26
HIST1H2BB
USP6NL
HUS1
ENTPD7
PNPT1
RNF26
INPP5F
3-Sep
GPR132
C12orf75
MRPL40
NLRP6
ZNF695
LMAN2
AP1M1

0.003716035
0.003723391
0.003725809
0.00374762
0.003771042
0.003772004
0.003788764
0.003788943
0.003794642
0.003800504
0.003803799
0.003804632
0.003806342
0.003809359
0.003815355
0.003817595
0.003834483
0.003852553
0.003858956
0.003859864
0.00387697
0.003886966
0.003892182
0.00389521
0.003901165
0.003902219
0.003902872
0.00390619
0.003907069
0.003911526
0.003919954
0.003926221
0.003932098
0.003933864
0.003934775
0.003935839
0.003940891
0.003957742
0.003970048
0.003979484
0.003980402
0.003981614
0.003998222
0.004029601

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.170288627
1.751767962
-1.173884988
-1.270623414
-1.228498117
-1.207969848
-1.373996656
-1.185810207
-1.095946407
-2.459902328
-1.39855425
1.149577821
1.100594453
1.544726089
-1.164865929
1.428029229
-1.137301411
-1.347254186
1.215926571
-1.138259386
-1.223495418
-1.117948851
1.201611666
1.135579315
-1.611822784
1.140698062
1.143958219
-1.370248264
-1.13438655
-1.505613308
-1.084426821
-1.151164774
-1.428519867
-1.185267731
-1.320173515
-1.134769168
-1.182771003
1.400114335
-1.086323232
-1.255231168
-1.221828347
-1.293683596
-1.080632128
-1.363355121

-1.283499311
1.683325307
-1.094235587
-1.25934132
-1.093366926
-1.151420835
-1.080844233
-1.107417142
-1.97432583
-1.177104216
-1.143097135
1.103192592
1.153880883
1.11024421
-1.126860662
1.637252849
-1.12152051
-1.078097371
1.397818569
-1.132257384
-1.07050938
-1.292367582
1.132394157
1.204476297
-1.10504109
1.229721705
1.560654613
-1.109295697
-1.114804842
-1.329101468
-1.291945527
-1.135031706
-1.087591361
-1.174778542
-1.203379748
-1.254914581
-1.200939826
1.234411717
-1.190054464
-1.08716925
-1.304519361
-1.23745659
-1.087144156
-1.100194177
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LOC100128281
NCOA5
C1orf106
DDX10
EFNB1
AFAP1-AS1
SCYL3
TMEM170A
RPS6KC1
PDDC1
C19orf53
PUS7
LOC100131541
KITLG
MYCL1
MSX1
MIR548AL
IL23A
B4GALT1
ZNF101
FAM43A
METTL5
SAMM50
TRIM52
CAMK2N1
TMEM194A
PCDH20
PPFIBP2
NDRG2
EDC3
GABRP
AKIRIN2
HAGH
NBPF10
MRPS34
SEC23B
IL1RAP
BZW1
KIAA1217
ARRDC4
LOC440149
PLEKHA5
VTRNA1-3
FEZ2

0.00403143
0.004032154
0.004038427
0.0040408
0.004041008
0.004041949
0.004050677
0.004053174
0.00405863
0.004061403
0.004081333
0.004081597
0.004083052
0.004087722
0.004096679
0.004108082
0.004110371
0.004118789
0.004119083
0.004119494
0.004119688
0.004123839
0.004126289
0.004128557
0.004152479
0.004154253
0.004173266
0.004177304
0.004178598
0.00419786
0.004203632
0.004204103
0.004208016
0.004211205
0.004224818
0.004233923
0.004236118
0.00424065
0.00424126
0.004248674
0.004249805
0.004255251
0.004264186
0.004269765

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.242251371
-1.082084766
-1.08549052
-1.113859545
-1.616562135
-1.286392993
1.176236419
-1.160372899
-1.095497802
1.143999932
-1.25015655
-1.259396921
1.147725622
1.164992545
1.178075883
-1.208747162
1.339608071
-1.146075704
-1.107250234
-1.17114352
1.264085829
-1.159113814
-1.158837606
1.490052902
-1.293968882
-1.298127409
1.159817835
1.237825081
1.091359315
1.086870931
2.02207947
-1.260933636
1.148645506
1.404516994
-1.322273042
-1.100206141
1.193526574
-1.25824909
1.154905573
1.311793217
-1.2207115
1.379652685
-2.691442655
1.2090904

1.650789252
-1.124284531
-1.06583896
-1.153509504
-1.19028385
-1.054473916
1.161588912
-1.18251556
-1.195345157
1.125551116
-1.062390496
-1.084624549
1.854010116
1.329053537
1.642415235
-1.217716168
1.92724487
-1.465917073
-1.839768256
-1.271362587
1.50038922
-1.14879745
-1.075291039
1.199511002
-1.087356902
-1.133182897
1.098041328
1.116166451
1.419668742
1.22488415
1.111175515
-1.086567092
1.292064291
1.179842423
-1.050062031
-1.060205693
1.502868998
-1.191338958
1.180003245
1.434698824
-1.166280647
1.070696468
-1.404992161
1.090259907
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CALR
SLC20A1
NRP2
C9orf64
TCEANC
KIF5B
OMA1
SLC45A3
IQSEC2
ATG4A
LOH12CR1
YPEL3
DKFZP434I0714
SHCBP1
GIGYF1
BCL2L1
ACSL3
NFKBIB
ZHX2
RBM27
RAP1GDS1
WISP2
RECQL4
COL6A5
RNF185
CHKB-CPT1B
LOC100130691
PLD6
EZR
DDAH2
TTC3P1
JOSD1
SLMAP
XYLT2
EBNA1BP2
C1orf135
FANCI
CHD6
CMTM1
MIR27B
ILF2
TBC1D3
KLRAP1
HSD11B2

0.004274298
0.004285127
0.004288149
0.004290423
0.00429656
0.004300333
0.004308375
0.004310858
0.004313657
0.00431996
0.004324276
0.004326632
0.004330564
0.004332587
0.004342846
0.004343814
0.004353056
0.004355086
0.004365018
0.004375577
0.004390651
0.00439078
0.004392177
0.004399322
0.004406729
0.004410121
0.004410603
0.004427323
0.004431593
0.004454441
0.004454853
0.004455513
0.004473647
0.004475296
0.004481313
0.004481411
0.004490913
0.004495298
0.004502117
0.004502838
0.004504118
0.004505459
0.004522846
0.004523267

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.036209647
-1.658305212
-1.078444916
-1.195049481
1.243734509
-1.036819922
1.176422581
-1.213001219
1.157784395
-1.402823052
1.300008831
1.189489686
1.14384037
-1.275325063
1.376004176
-1.184137972
-1.165582627
-1.269397039
-1.093884074
-1.083589628
-1.339744051
1.123830228
-1.104963093
1.119740619
-1.233341435
1.315946345
1.229944632
-1.194057386
-1.155397527
-1.127709588
1.153668744
-1.105060033
-1.083532819
-1.088270218
-1.316743421
-1.177852784
-1.172429925
1.42458742
-1.076498425
2.670782417
-1.140385878
1.113248061
1.12535877
-1.261739246

-1.173903819
-1.17930484
-1.365922441
-1.164332532
1.217387746
-1.065551353
1.137270104
-1.643509122
1.173756915
-1.047225577
1.159797241
1.350877956
1.169318974
-1.057083158
1.088944141
-1.32827688
-1.223124442
-1.104230169
-1.210641632
-1.136797624
-1.119818895
1.110013828
-1.223264795
1.124218203
-1.141333983
1.153855919
1.152289363
-1.477129885
-1.079645239
-1.135148666
1.240291044
-1.174153892
-1.079570575
-1.226456577
-1.062543118
-1.458163002
-1.164778746
1.088147242
-1.28792458
1.365566985
-1.043763047
1.248940488
1.226925478
-1.188009278
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CXXC1
MUC20
WNT2B
KBTBD8
EXT2
HNRNPAB
ETS2
SYNJ2
SEC22C
CWF19L1
ANXA5
TIMM10
C18orf62
LOC100289488
C21orf59
ICK
ATP5D
PBK
IL31RA
C10orf55
MEIS2
ELOVL5
ORC2
SERPINB4
EFTUD2
PDGFA
CITED4
RALGDS
SCD
BYSL
CENPE
ZNF652
FXR2
FAM135A
PTPRG
KREMEN2
BRWD1
LOC100507431
NCAPD3
TNC
TPM4
DPAGT1
B4GALT6
MAPRE2

0.004531646
0.004537564
0.004538284
0.004545545
0.004545622
0.004550528
0.004552425
0.004552862
0.004563696
0.004565285
0.00457023
0.004574681
0.004586677
0.004590148
0.004596453
0.004614763
0.004618436
0.004621447
0.004632518
0.004635059
0.004636792
0.004656555
0.004657139
0.004666116
0.004667626
0.004670081
0.004670944
0.004676469
0.004678316
0.004682591
0.004691311
0.00469199
0.004708679
0.004717198
0.004718958
0.004721884
0.004728881
0.004729159
0.004737876
0.004741788
0.004743035
0.004747405
0.004750404
0.004759408

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

-1.287278235
1.231221954
1.251165848
-1.535118546
-1.30540718
-1.115828718
-1.059699545
-1.291958383
-1.20404925
-1.212187418
-1.091983605
-1.340203967
-1.271028807
1.126349835
-1.16881241
1.461220094
1.084637415
-1.343428961
-1.334591948
-1.588741751
1.303565578
-1.113404365
-1.098404106
-1.91972371
-1.151727994
-1.126481472
1.167312628
1.081375279
-1.940549062
-1.304399026
-1.232118565
1.152234876
-1.357534561
1.245677615
-1.114649335
-1.397514352
1.12386667
-1.21609888
-1.226685884
-6.6766172
-1.306180835
-1.241776712
-1.461606731
-1.407919846

-1.132789803
1.184016722
1.099220242
-1.14084761
-1.082640676
-1.076557718
-1.231031698
-1.0921503
-1.140364763
-1.07267011
-1.213170894
-1.11379973
-1.131889082
1.355924183
-1.093295821
1.099171058
1.129080916
-1.126106391
-1.177130315
-1.263536559
1.155966099
-1.146743145
-1.124633289
-1.188959179
-1.054101369
-1.895154465
1.175944667
1.178787196
-1.106325896
-1.242852341
-1.089289318
1.166833979
-1.109798205
1.089870396
-1.566001932
-1.134617164
1.124005633
-1.214917183
-1.076695166
-1.240216628
-1.061591712
-1.162593768
-1.497859073
-1.309954402
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CD164
EXOC4
CST5
SIAH2
TRMT1
TMED1
PRKCH
BEND3
PAIP2B
GCC2
LOC100170939
CLK2
POLR1A

0.004764811
0.004769298
0.004772751
0.004776657
0.004780995
0.004784666
0.004790524
0.004793051
0.004793439
0.004812118
0.004834272
0.004849416
0.004854934

TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE
TRUE

1.216611369
1.139572044
-1.217518515
-1.153068428
-1.245092095
-1.171662031
1.174798921
-1.261956531
1.384374543
1.100738747
1.81936338
1.223342836
-1.096706765

1.073062693
1.055550076
-1.425639003
-1.144330104
-1.123824371
-1.100043077
1.049270173
-1.213828255
1.261033303
1.197230534
1.344978625
1.118383522
-1.069029034
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Appendix 2: Correlation heat-map in the Oral Cavity group
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Appendix 3:Histogram of p-values testing Cluster 1 versus Cluster 2 in the Oral Cavity
group
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Appendix 4: Ingenuity Pathway Analysis of significantly modulated pathways after
NOTCH activation by Jagged1 in cell lines
Functions

P-value
4.79E-13
9.92E-13
2.72E-12
6.64E-11
6.65E-11
1.63E-10

# Molecules
48
30
27
47
24
42
27

4.48E-10
2.26E-09
6.04E-09

11
13
15

6.87E-09
2.66E-08
4.13E-08
1.12E-07
1.45E-07
4.80E-07
1.71E-06
2.28E-06
2.47E-06
3.81E-06
4.70E-06
5.22E-06
6.30E-06
7.09E-06
8.92E-06

11
9
11
9
18
17
16
9
9
6
9
15
20
10
15

1.24E-05
1.33E-05
2.26E-05

5
6
5

2.81E-05
4.66E-05
5.76E-05
7.25E-05
8.89E-05
8.90E-05

6
17
12
3
3
5

Cellular Movement
cell movement of tumor cell lines
migration of tumor cell lines
cell movement
invasion of tumor cell lines
migration of cells
invasion of cells
cell movement of brain cancer cell
lines
migration of tumor cells
migration of endothelial cells
cell movement of fibroblast cell
lines
migration of brain cancer cell lines
migration of cancer cells
migration of fibroblast cell lines
homing
homing of cells
chemotaxis
invasion of tumor cells
cell movement of tumor cells
migration of sarcoma cell lines
invasion of carcinoma cell lines
chemotaxis of cells
leukocyte migration
invasion of breast cancer cell lines
cell movement of phagocytes
invasion of squamous cell
carcinoma cell lines
migration of endothelial cell lines
dissemination of cells
invasion of prostate cancer cell
lines
cell movement of leukocytes
cellular infiltration
dissemination of tumor cells
migration of skin cancer cell lines
migration of keratinocytes
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invasion of ovarian cancer cell
lines
invasion of glioma cells
cell movement of myeloid cells
migration of connective tissue
cells
recruitment of neutrophils
invasion of brain cancer cell lines
movement of endometrial stromal
cells
migration of breast cancer cell
lines
recruitment of phagocytes
cell movement of pancreatic
cancer cell lines
migration of kidney cell lines
cell movement of neuroglia
migration of mesenchymal stem
cells
cell movement of cancer cells
cell movement of epithelial cells
migration of smooth muscle cells
cellular infiltration by leukocytes
transmigration of myeloid cells
migration of phagocytes
migration of myeloid cells
migration of cervical cancer cell
lines
migration of neuroglia
migration of bone cancer cell lines
cell movement of embryonic cells
cell movement of granulocytes
transmigration of phagocytes
intravasation of cells
migration of embryonic cell lines
cell movement of bladder cancer
cell lines
invasion of endothelial cells

1.13E-04
1.29E-04
1.30E-04

4
3
13

1.41E-04
1.69E-04
1.80E-04

7
7
5

1.83E-04

2

2.09E-04
2.14E-04

8
8

2.15E-04
2.19E-04
2.64E-04

4
5
5

2.73E-04
2.83E-04
2.83E-04
2.93E-04
3.55E-04
3.94E-04
4.89E-04
5.76E-04

3
6
6
6
10
4
8
6

7.73E-04
7.73E-04
8.09E-04
9.18E-04
1.03E-03
1.04E-03
1.08E-03
1.19E-03

4
4
3
5
9
4
2
4

1.23E-03
1.23E-03

3
3

3.95E-11
1.02E-10
5.32E-10

64
62
20
36

Cellular Growth and
Proliferation
proliferation of cells
proliferation of tumor cells
proliferation of tumor cell lines
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proliferation of cancer cells
proliferation of epithelial cells
proliferation of connective tissue
cells
proliferation of ovarian cancer cell
lines
proliferation of muscle cells
proliferation of smooth muscle
cells
proliferation of blood cells
proliferation of immune cells
proliferation of endothelial cells
formation of connective tissue
cells
proliferation of lymphocytes
colony formation
inhibition of cells
proliferation of prostate cancer cell
lines
proliferation of mammary tumor
cells
proliferation of lung cancer cell
lines
expansion of neutrophils
proliferation of carcinoma cell
lines
formation of cells
proliferation of fibroblasts
proliferation of brain cancer cell
lines
proliferation of neuronal cells
proliferation of keratinocytes
growth of neurites
formation of colony forming unit
osteoblasts
colony formation of tumor cell
lines
inhibition of mononuclear
leukocytes
colony formation of cells
proliferation of fibroblast cell lines
formation of osteoclasts
outgrowth of cells
Cell Death and Survival

2.03E-07
3.96E-07

14
16

1.21E-06

17

1.51E-06
1.62E-06

8
13

3.21E-06
3.65E-06
5.35E-06
8.11E-06

11
20
19
11

8.46E-06
2.26E-05
2.93E-05
3.70E-05

9
17
14
7

3.90E-05

10

6.16E-05

5

7.39E-05
9.16E-05

9
2

1.23E-04
1.26E-04
1.53E-04

11
19
10

2.45E-04
2.60E-04
3.56E-04
4.20E-04

7
13
6
11

4.53E-04

2

4.89E-04

8

5.93E-04
7.46E-04
7.64E-04
8.01E-04
9.31E-04

4
11
10
5
10
59
251

cell viability
cell survival
necrosis
cell viability of tumor cell lines
cell death
cell death of tumor cell lines
apoptosis
necrosis of epithelial tissue
cell viability of endothelial cells
apoptosis of pericytes
apoptosis of tumor cell lines
cell death of tumor
cell death of muscle cells
apoptosis of muscle cell lines
apoptosis of heart cell lines
repopulation of fibroblasts
cell death of tumor cells
anoikis
apoptosis of tumor cells
apoptosis of endothelial cells
apoptosis of hepatic stellate cells
cell death of epithelial cells
anoikis of tumor cell lines
cell viability of carcinoma cell
lines
apoptosis of muscle cells
cell viability of prostate cancer
cell lines
permeability of endothelial cell
lines
cell death of lymphatic system
cells
cell viability of leukemia cell lines
killing of lung cancer cell lines
apoptosis of mammary tumor cells
cell viability of kidney cell lines
cell death of immune cells

7.12E-11
1.10E-10
7.22E-10
5.06E-08
7.44E-08
2.68E-07
5.44E-07
1.09E-06
1.49E-06
1.05E-05
1.07E-05
1.30E-05
1.78E-05
2.64E-05
2.89E-05
3.06E-05
5.09E-05
5.39E-05
1.23E-04
1.59E-04
2.07E-04
2.15E-04
2.15E-04

34
35
48
22
52
31
43
17
6
4
24
12
11
5
4
2
11
6
9
7
3
12
4

2.39E-04
3.21E-04

6
8

4.19E-04

4

4.44E-04

3

5.58E-04
5.93E-04
6.32E-04
7.38E-04
8.13E-04
1.04E-03

proliferation of tumor cells
proliferation of tumor cell lines
differentiation of cells
endothelial cell development

1.02E-10
5.32E-10
1.42E-08
1.34E-07

5
4
2
3
4
13
62
20
36
42
14

Cellular Development

252

proliferation of cancer cells
proliferation of ovarian cancer cell
lines
proliferation of muscle cells
proliferation of smooth muscle
cells
proliferation of blood cells
proliferation of immune cells
tubulation of endothelial cells
proliferation of endothelial cells
proliferation of lymphocytes
tubulation of endothelial
progenitor cells
differentiation of epithelial tissue
proliferation of prostate cancer cell
lines
differentiation of epithelial cells
proliferation of mammary tumor
cells
differentiation of tumor cell lines
proliferation of lung cancer cell
lines
expansion of neutrophils
development of connective tissue
cells
proliferation of carcinoma cell
lines
proliferation of fibroblasts
differentiation of connective tissue
cells
proliferation of brain cancer cell
lines
proliferation of neuronal cells
differentiation of connective tissue
proliferation of keratinocytes
growth of neurites
hematopoiesis of bone marrow
cells
formation of colony forming unit
osteoblasts
differentiation of osteoblasts
differentiation of bone cells
proliferation of fibroblast cell lines
formation of osteoclasts

2.03E-07

14

1.51E-06
1.62E-06

8
13

3.21E-06
3.65E-06
5.35E-06
6.01E-06
8.11E-06
2.26E-05

11
20
19
7
11
17

3.55E-05
3.62E-05

3
11

3.90E-05
5.11E-05

10
10

6.16E-05
6.17E-05

5
11

7.39E-05
9.16E-05

9
2

9.57E-05

8

1.23E-04
1.53E-04

11
10

2.38E-04

14

2.45E-04
2.60E-04
2.94E-04
3.56E-04
4.20E-04

7
13
15
6
11

4.44E-04

3

4.53E-04
5.29E-04
5.43E-04
7.64E-04
8.01E-04

2
8
10
10
5
253

onset of differentiation of cells
differentiation of skin

8.39E-04
9.61E-04

2
6

8.05E-10
1.01E-06
3.11E-06
3.11E-06
4.32E-06
7.29E-06
7.63E-06
1.36E-05
3.06E-05
3.29E-05
3.29E-05
3.69E-05
5.00E-05
5.78E-05
5.83E-05
7.83E-05

41
15
10
5
22
7
14
5
5
2
17
6
4
16
4
11
4

9.16E-05
1.67E-04
1.69E-04
1.78E-04
1.78E-04

2
6
7
10
3

1.83E-04
2.14E-04
3.03E-04
4.08E-04
4.41E-04

2
8
2
11
8

4.53E-04
5.50E-04
5.61E-04
6.32E-04

2
3
4
2

6.32E-04
8.83E-04
9.62E-04
1.13E-03

2
3
3
3

Cell-To-Cell Signaling and
Interaction
adhesion of tumor cell lines
cell-cell adhesion
attachment of tumor cell lines
activation of cells
adhesion of epithelial cells
binding of cells
adhesion of kidney cell lines
adhesion of embryonic cells
adhesion of mesothelial cells
activation of blood cells
binding of endothelial cells
adhesion of embryonic cell lines
activation of leukocytes
adhesion of melanoma cell lines
adhesion of blood cells
adhesion of epithelial cell lines
cell-cell adhesion of embryonic
cell lines
attachment of cells
recruitment of neutrophils
activation of T lymphocytes
adhesion of muscle cells
cell-cell adhesion of epithelial cell
lines
recruitment of phagocytes
aggregation of myoblasts
activation of lymphocytes
phagocytosis of cells
cell-cell adhesion of kidney cell
lines
cell-cell adhesion of leukocytes
activation of endothelial cells
adhesion of fibrosarcoma cell lines
adhesion of stomach cancer cell
lines
phagocytosis of leukemia cell lines
adhesion of endothelial cell lines
adhesion of carcinoma cell lines
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